var title_f40_47_41712="Parastomal hernia";
var content_f40_47_41712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Parastomal hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) An anterior view of a large paracolostomy hernia. Note the skin breakdown in the peristomal area where the appliance would be placed. This commonly occurs due to the pressure required to maintain the appliance in place against a large parastomal hernia.",
"    <br>",
"     B) A lateral view of a large paracolostomy hernia.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Robert Cima, MD",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41712=[""].join("\n");
var outline_f40_47_41712=null;
var title_f40_47_41713="Gynecomastia (breast enlargement in men)";
var content_f40_47_41713=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/47/41713/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41713/contributors\" id=\"au1052\">",
"       Glenn D Braunstein, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/47/41713/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41713/contributors\" id=\"se6363\">",
"       Alvin M Matsumoto, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/47/41713/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41713/contributors\" id=\"de5123\">",
"       Kathryn A Martin, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41713/contributors\" id=\"de2799\">",
"       Constanza Villalba, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/47/41713?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      GYNECOMASTIA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Gynecomastia is a condition in which the breasts become enlarged in boys or men, sometimes causing discomfort or nipple tenderness. It is usually the result of a hormonal imbalance and typically occurs during infancy, adolescence, or mid- to late-life. The condition often goes away on its own, but treatments are available for severe or persistent cases. When gynecomastia is the result of an underlying health problem, treatment of that problem usually improves the gynecomastia as well.",
"    </p>",
"    <p>",
"     Up to 70 percent of boys in early to mid-puberty experience gynecomastia because of the normal hormonal changes that occur during puberty. Gynecomastia is also common among middle-aged and elderly men. In this population, up to 65 percent of men are affected.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      COMMON CAUSES OF GYNECOMASTIA",
"     </span>",
"    </p>",
"    <p>",
"     Although people tend to think of androgens as \"male hormones\" and estrogens as \"female hormones,\" people of both sexes produce both types of hormones. In males, androgens are by far the predominant hormone, but small amounts of estrogen are also present. Gynecomastia can happen when the balance shifts, with an increase in estrogen or decrease in androgens. This can occur because of expected hormonal changes during puberty or aging, or because of the use of certain drugs or herbal products.",
"    </p>",
"    <p>",
"     The most common causes of gynecomastia in adult men include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pubertal gynecomastia that does not resolve &mdash; 25 percent",
"      </li>",
"      <li>",
"       Drugs &mdash; 10 to 25 percent",
"      </li>",
"      <li>",
"       Unknown causes (idiopathic) &mdash; 25 percent",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Puberty",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gynecomastia that occurs during puberty usually resolves without treatment within six months to two years. The condition sometimes develops between ages 10 and 12 years, and most commonly occurs between ages 13 and 14. It is uncommon for the condition to persist beyond age 17.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many drugs have been associated with gynecomastia, including:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Spironolactone (Aldactone&reg;), a drug used to treat heart failure, high blood pressure, and several other conditions.",
"      </li>",
"      <li>",
"       Nifedipine (Adalat&reg;, Nifedical&reg;, Procardia&reg;) and related drugs called calcium channel blockers. These drugs are used to treat high blood pressure.",
"      </li>",
"      <li>",
"       Cimetidine (Tagamet&reg;), ranitidine (Zantac&reg;) and related drugs called H2-receptor blockers. These drugs are used to treat stomach ulcers and severe heartburn.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If gynecomastia is caused by one of the drugs you take, your healthcare provider may recommend that you stop using the drug or replace it with another drug that is less likely to cause the condition.",
"    </p>",
"    <p>",
"     Gynecomastia occurs in up to 75 percent of men who take drugs called antiandrogens to treat prostate cancer. While these men may not be able to stop or substitute their prostate cancer treatment, they may be able to take steps to prevent gynecomastia (see",
"     <a class=\"local\" href=\"#H13\">",
"      'Prostate cancer patients'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Herbal products",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gynecomastia in children has been associated with regular use of skin care products (lotions, soaps, and shampoos) containing tea tree oil and lavender oil&nbsp;[",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/47/41713/abstract/1\">",
"      1",
"     </a>",
"     ]. These oils contain plant estrogens and can affect the body's hormone balance. Gynecomastia usually resolves completely after stopping the products. Soy products, such as soy milk, do not usually cause gynecomastia unless a large quantity is consumed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Treatment for HIV/AIDS (HAART)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Men taking combination treatment for",
"     <span class=\"nowrap\">",
"      HIV/AIDS,",
"     </span>",
"     called highly active antiretroviral therapy (HAART), sometimes develop enlarged breasts. In most cases, this breast enlargement is due to fat redistribution, which is a side effect of the treatment. In some cases, though, true gynecomastia has been associated with HAART.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Unknown causes (idiopathic)",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is not always clear what causes gynecomastia during mid- to late-life. Still, as men age, blood testosterone levels decline and the hormone balance changes, favoring an increased level of estrogen. These factors probably conspire to account for most cases of \"idiopathic\" gynecomastia.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      GYNECOMASTIA EVALUATION",
"     </span>",
"    </p>",
"    <p>",
"     Gynecomastia should not be confused with pseudogynecomastia, which occurs in overweight men whose breasts enlarge because of fat deposits.",
"    </p>",
"    <p>",
"     If you are a man or boy with enlarged or tender breasts, your healthcare provider will perform an examination to determine whether the tissue in your breasts is fatty or glandular. Glandular tissue is designed to secrete substances, such as milk or hormones, and usually has a network of ducts that can be felt.",
"    </p>",
"    <p>",
"     If the provider has difficulty determining whether you have gynecomastia, he or she may recommend that you have a mammogram, a specialized x-ray of the breast.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Laboratory tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;In certain situations, blood tests may be ordered to measure the level of hormones. Blood tests are not usually needed if the cause of the gynecomastia (eg, puberty, drugs) is known.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      GYNECOMASTIA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The best treatment for gynecomastia depends upon its cause, duration, and severity, and whether it causes pain or discomfort.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Adolescents",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because pubertal gynecomastia usually goes away on its own, treatment is not usually recommended initially. Instead, the provider will keep close tabs on the condition for several months. In most cases, pubertal gynecomastia resolves during that time.",
"    </p>",
"    <p>",
"     For boys with severe gynecomastia that is causing substantial tenderness or embarrassment, a short course of a drug called tamoxifen (Nolvadex&reg;) or raloxifene (Evista&reg;) may be recommended. These drugs block the effects of estrogen in the body, and can reduce the size of the breasts somewhat. However, neither of these drugs is approved in the United States for the treatment of gynecomastia. Drugs may be prescribed without FDA approval, although the risks and benefits have not been studied completely.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Adult men",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment is also usually delayed in adult men whose gynecomastia is likely to be caused by an underlying health problem or by drugs. In these men, treating the underlying condition or suspending the problematic drug usually allows the gynecomastia to resolve.",
"    </p>",
"    <p>",
"     For men with idiopathic gynecomastia that causes discomfort and lasts more than three months, a short course of tamoxifen or raloxifene may be recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Prostate cancer patients",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gynecomastia is a known complication of a treatment for prostate cancer (called antiandrogen monotherapy). Approximately 75 percent of men who use this treatment develop gynecomastia. However, there are several treatment options available to prevent the development of gynecomastia, including tamoxifen and radiation therapy. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=see_link\">",
"      \"Patient information: Treatment for advanced prostate cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Tamoxifen",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tamoxifen can be taken along with the anti-cancer (antiandrogen) treatment. Tamoxifen must be taken every day for the duration of antiandrogen treatment. In one study, only 8 percent of men who took tamoxifen plus an antiandrogen developed gynecomastia (compared with 68 percent of men who took the antiandrogen alone) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/47/41713/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Tamoxifen may also be given to men who develop gynecomastia while taking antiandrogens.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Radiation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treating the breasts with radiation before antiandrogen treatment begins can prevent gynecomastia. Radiation treatment (RT) is usually delivered in one to three sessions (similar to having an x-ray). In the study above, 34 percent of men who had RT before antiandrogen therapy developed gynecomastia [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/47/41713/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Gynecomastia that has already developed can be treated with higher radiation doses and may improve pain. However, when given after breasts have already developed, radiation is not very effective at reducing breast size.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Radiation therapy versus tamoxifen",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although tamoxifen may be more effective than radiation for men who take antiandrogen monotherapy, tamoxifen needs to be taken for the duration of antiandrogen therapy. For some men, taking another medication every day is less convenient than to have three sessions of radiation therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although tamoxifen and raloxifene are effective for men and boys who have had enlarged breasts for a few months, the drug is not effective in men who have had the condition for one to two years or more. For these men, surgery is an option to reduce the size of the breasts. For adolescents, surgery is generally not recommended until puberty is completed; there may be regrowth of the breast tissue if the surgery is performed before puberty is completed.",
"    </p>",
"    <p>",
"     The extent of surgery depends upon the severity of the breast enlargement and whether there is also excess fatty tissue. Many men are treated with a combination of surgical removal of the glandular tissue and liposuction.",
"    </p>",
"    <p>",
"     More extensive cosmetic surgery, including partial surgical removal of the breast skin, is required for men with more severe breast enlargement or those who have excessive sagging of the breast tissue, which may occur after weight loss.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Gynecomastia in adolescent boys is usually caused by puberty-related hormonal changes and typically resolves on its own. In extreme or painful cases, a brief course of tamoxifen may be recommended.",
"      </li>",
"      <li>",
"       Gynecomastia in adult men is usually caused by another underlying health problem or by the use of a drug. In such cases, treating the underlying condition or suspending the drug usually allows gynecomastia to resolve. When the cause of gynecomastia cannot be identified, brief use of tamoxifen may be recommended.",
"      </li>",
"      <li>",
"       Men who have had gynecomastia for more than one year do not typically benefit from the use of tamoxifen. For them, surgery to reduce the size of the breasts is an option.",
"      </li>",
"      <li>",
"       Men with prostate cancer who undergo certain types of hormone treatment (eg, antiandrogen monotherapy) are at risk for developing gynecomastia. Pre-treatment with radiation or taking a medication (tamoxifen) along with the antiandrogen are two options for preventing breast growth.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1785059845\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H255564\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/30/44513?source=see_link\">",
"      Patient information: When men develop breasts (gynecomastia) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/45/36562?source=see_link\">",
"      Patient information: Androgen replacement in men (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H255557\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=see_link\">",
"      Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27384?source=see_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/9/6294?source=see_link\">",
"      Epidemiology and pathogenesis of gynecomastia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/760?source=see_link\">",
"      Management of gynecomastia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/MEDLINEPLUS/ency/article/003165.htm\">",
"      www.nlm.nih.gov/MEDLINEPLUS/ency/article/003165.htm",
"     </a>",
"     , also available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mayo Clinic",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.mayoclinic.com/health/gynecomastia/DS00850\">",
"      www.mayoclinic.com/health/gynecomastia/DS00850",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Plastic Surgeons",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.plasticsurgery.org/cosmetic-procedures/breast-reduction-for-men.html\">",
"      www.plasticsurgery.org/cosmetic-procedures/breast-reduction-for-men.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/resources/upload/gynecomastia-bilingual-web.pdf\">",
"      www.hormone.org/Resources/upload/Gynecomastia-Bilingual-WEB.pdf",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/47/41713/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/47/41713?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41713/abstract/1\">",
"      Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007; 356:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41713/abstract/2\">",
"      Di Lorenzo G, Perdon&agrave; S, De Placido S, et al. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol 2005; 174:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41713/abstract/3\">",
"      Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr 2004; 145:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41713/abstract/4\">",
"      Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357:1229.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f40_47_41713=[""].join("\n");
var outline_f40_47_41713=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           GYNECOMASTIA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           COMMON CAUSES OF GYNECOMASTIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           GYNECOMASTIA EVALUATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           GYNECOMASTIA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f40_47_41714="Patient information: Varicose veins and other vein disease in the legs (The Basics)";
var content_f40_47_41714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15729\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/27/43440\">",
"         Putting on compression stockings",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/48/26368\">",
"          Heel-pocket-out method to put on compression stockings",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/10/16559\">",
"           Telangiectasias (spider veins) on the lower leg",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/14/39150\">",
"            Severe varicose veins",
"           </a>",
"           <li>",
"            <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/43/16050\">",
"             Pitting edema",
"            </a>",
"            <li>",
"             <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/29/12764\">",
"              Tips for using compression stockings",
"             </a>",
"            </li>",
"           </li>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/3/1075\">",
"         Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/34/30242\">",
"         Patient information: Doppler ultrasound (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/16/21762\">",
"         Patient information: Superficial phlebitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/42/21155\">",
"         Patient information: Swelling (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/32/30210\">",
"         Patient information: Vein ablation (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/17/35091\">",
"         Patient information: Chronic venous disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/44/12998\">",
"         Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Varicose veins and other vein disease in the legs (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/varicose-veins-and-other-vein-disease-in-the-legs-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1478272777\">",
"      <span class=\"h1\">",
"       What is vein disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vein disease is a condition that can affect the veins in the legs. It can cause leg pain, varicose veins, swollen legs, or open sores. Varicose veins are swollen and twisted veins.",
"     </p>",
"     <p>",
"      Vein disease happens when the veins in the legs do not work the right way. Normally, the veins in the legs carry blood from the legs back to the heart. The veins have tiny valves inside them to help keep blood moving in only one direction (toward the heart). The valves open to let blood flow to the heart, and close to keep it from flowing back down the leg. Vein disease can happen when the valves are damaged or do not work well. This causes blood to collect in the legs. Blood is especially likely to collect in the legs when people sit or stand for a long time without walking.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478272784\">",
"      <span class=\"h1\">",
"       What conditions can cause vein disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vein disease can be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A blood clot in a leg vein",
"       </li>",
"       <li>",
"        Leg injury",
"       </li>",
"       <li>",
"        Being pregnant more than once &ndash; This causes a change in hormone levels that can weaken vein walls.",
"       </li>",
"       <li>",
"        Weight gain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Vein disease can also run in families.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478272791\">",
"      <span class=\"h1\">",
"       What are the symptoms of vein disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with vein disease can have symptoms that include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Leg pain, or the leg feeling tired or heavy",
"       </li>",
"       <li>",
"        Swollen veins &ndash; &ldquo;Spider veins&rdquo; are small leg veins that are swollen (",
"        <a class=\"graphic graphic_picture graphicRef54276 \" href=\"mobipreview.htm?16/10/16559\">",
"         picture 1",
"        </a>",
"        ). &ldquo;Varicose veins&rdquo; are larger leg veins that are swollen and twisted (",
"        <a class=\"graphic graphic_picture graphicRef71564 \" href=\"mobipreview.htm?38/14/39150\">",
"         picture 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Swelling in the lower legs or ankles (",
"        <a class=\"graphic graphic_picture graphicRef61706 \" href=\"mobipreview.htm?15/43/16050\">",
"         picture 3",
"        </a>",
"        ) &ndash; People can have swelling at the end of the day or all the time.",
"       </li>",
"       <li>",
"        Skin color changes &ndash; The skin can turn red or red-brown. Skin color changes often happen first around the ankle.",
"       </li>",
"       <li>",
"        Open sores, also called &ldquo;venous ulcers&rdquo; &ndash; These are usually at the ankle and can be painful and ooze.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478272798\">",
"      <span class=\"h1\">",
"       Is there a test for vein disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam to look at your legs. He or she might also do a test called an ultrasound. An ultrasound can check how well the valves in the legs work. It can also see if any of the veins in the legs are blocked.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478272805\">",
"      <span class=\"h1\">",
"       What can I do to reduce my symptoms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To reduce swelling, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Walk around, and try not to sit or stand in one place for a long time",
"       </li>",
"       <li>",
"        Raise your legs up 3 or 4 times a day, for 30 minutes each time",
"       </li>",
"       <li>",
"        Do exercises to point your toes and feet down and up a few times each day",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To treat dry or itchy skin, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Use an unscented moisturizing cream. Ask your doctor or nurse before using any other type of cream or ointment, because some creams and ointments can cause a rash.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478272812\">",
"      <span class=\"h1\">",
"       How is vein disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can use different treatments to treat symptoms and reduce swelling. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Special socks, bandages, or devices:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        &ldquo;Compression stockings&rdquo; are special socks that fit tightly over the ankle and leg. If your doctor or nurse recommends that you wear them, he or she will tell you which type to wear and how to put them on (",
"        <a class=\"graphic graphic_figure graphicRef81922 \" href=\"mobipreview.htm?42/27/43440\">",
"         figure 1",
"        </a>",
"        and",
"        <a class=\"graphic graphic_figure graphicRef53659 \" href=\"mobipreview.htm?25/48/26368\">",
"         figure 2",
"        </a>",
"        and",
"        <a class=\"graphic graphic_table graphicRef57705 \" href=\"mobipreview.htm?12/29/12764\">",
"         table 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        &ldquo;Compression bandages&rdquo; are layers of bandages that wrap around a person&rsquo;s leg.",
"       </li>",
"       <li>",
"        A &ldquo;compression pump&rdquo; is a device that fits around the leg and squeezes the leg every few minutes.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Special coverings that are put on an open sore to help it heal",
"       </li>",
"       <li>",
"        Medicines &ndash; Doctors can use different types of medicines to treat different symptoms. For example, people with a skin infection might need antibiotics. People with itchy skin might need a prescription cream or ointment.",
"       </li>",
"       <li>",
"        Procedures &ndash; Doctors can do procedures if other treatments do not work. A doctor can remove or destroy damaged veins so they can no longer fill with blood.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1478272819\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21155?source=see_link\">",
"       Patient information: Swelling (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/3/1075?source=see_link\">",
"       Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30242?source=see_link\">",
"       Patient information: Doppler ultrasound (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/32/30210?source=see_link\">",
"       Patient information: Vein ablation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/16/21762?source=see_link\">",
"       Patient information: Superficial phlebitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/17/35091?source=see_link\">",
"       Patient information: Chronic venous disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"       Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/47/41714?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15729 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41714=[""].join("\n");
var outline_f40_47_41714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478272777\">",
"      What is vein disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478272784\">",
"      What conditions can cause vein disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478272791\">",
"      What are the symptoms of vein disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478272798\">",
"      Is there a test for vein disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478272805\">",
"      What can I do to reduce my symptoms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478272812\">",
"      How is vein disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1478272819\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15729\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/27/43440\">",
"      Putting on compression stockings",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/48/26368\">",
"       Heel-pocket-out method to put on compression stockings",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/10/16559\">",
"        Telangiectasias (spider veins) on the lower leg",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/14/39150\">",
"         Severe varicose veins",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/43/16050\">",
"          Pitting edema",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/29/12764\">",
"           Tips for using compression stockings",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/17/35091?source=related_link\">",
"      Patient information: Chronic venous disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30242?source=related_link\">",
"      Patient information: Doppler ultrasound (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/16/21762?source=related_link\">",
"      Patient information: Superficial phlebitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21155?source=related_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/32/30210?source=related_link\">",
"      Patient information: Vein ablation (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_47_41715="Leptin pathway in hypertension development in obesity";
var content_f40_47_41715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F86697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F86697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 638px\">",
"   <div class=\"ttl\">",
"    Leptin pathway in hypertension development in obesity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 618px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Selective leptin resistance help explain how high levels of circulating leptin in obesity may contribute to hypertension and sympathetic overdrive despite resistance to metabolic effects of this hormone. Long-term renal sympathetic stimulation caused by high leptin levels could raise renal sympathetic tone leading to hypertension while loss of leptin's ability to decrease food intake and increase thermogenesis promote obesity by increasing adiposity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rohmouni K. Obesity, sympathetic overdrive, and hypertension: The leptin connection. Hypertension 2010; 55:844. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41715=[""].join("\n");
var outline_f40_47_41715=null;
var title_f40_47_41716="Sleeper stretch for shoulder";
var content_f40_47_41716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/86081/Sleeper_stretch_sh_video.mp4?title=Sleeper+stretch+for+shoulder\" style=\"width:496px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sleeper stretch for shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sleeper stretch is included among the flexibility exercises performed throughout the rehabilitation of shoulder impingement syndromes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41716=[""].join("\n");
var outline_f40_47_41716=null;
var title_f40_47_41717="Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy";
var content_f40_47_41717=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41717/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41717/contributors\">",
"     Alain Meyrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41717/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41717/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41717/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41717/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41717/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/47/41717/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to minimal change disease (MCD), three other disorders usually present with the nephrotic syndrome and may also show only minor changes on light microscopy: idiopathic mesangial proliferative glomerulonephritis; IgM nephropathy; and C1q nephropathy. These disorders may represent variants of minimal change disease or focal-segmental glomerulosclerosis (FSG), but some clinicians and pathologists believe that they are separate conditions.",
"   </p>",
"   <p>",
"    The nosology of IgM and C1q nephropathy is particularly unsettled. However, clinicopathologic findings suggest forms of idiopathic nephrotic syndrome that, in terms of prognosis and treatment options, are closer to FSG than to MCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDIOPATHIC MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal (involving less than 50 percent of glomeruli on light microscopy) or diffuse mesangial cell proliferation (involving more than 50 percent of glomeruli on light microscopy) is a relatively nonspecific response to glomerular injury. This pattern can be seen in a variety of diseases including lupus nephritis, IgA nephropathy, and mild postinfectious glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, there is a seemingly idiopathic form in which there are either no immune deposits (in contrast to the IgA or IgG deposits in the above disorders) or focal or diffuse IgM-containing deposits in the mesangial areas. Patients with this glomerulopathy tend to present in one of two ways: with hematuria; or, more commonly, with proteinuria that is often in the nephrotic range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Most publications dealing with the latter involve childhood idiopathic nephrotic syndrome with FSG on renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with mesangial proliferative glomerulonephritis present with episodes of gross hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/5\">",
"     5",
"    </a>",
"    ] or with microscopic hematuria that may be detected on a routine examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These findings may follow a nonstreptococcal upper respiratory infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/6\">",
"     6",
"    </a>",
"    ], a pattern that resembles that of IgA nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link&amp;anchor=H14578038#H14578038\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Hematuria following upper respiratory infection'",
"    </a>",
"    .) The hematuria often resolves spontaneously, although persistent microscopic hematuria may be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/2\">",
"     2",
"    </a>",
"    ]. The renal prognosis in these patients is almost always excellent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 3 to 5 percent of patients with idiopathic nephrotic syndrome have mild diffuse mesangial cell proliferation but not FSG on light microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ]. Electron microscopy usually demonstrates relatively diffuse foot process fusion, suggesting that this disorder may be part of the minimal change disease-FSG spectrum. The observations that more than one-half of patients respond initially to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and that nonresponders at eight weeks are often in remission at one year are also consistent with a relation to these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/2,8-10\">",
"     2,8-10",
"    </a>",
"    ]. It has been suggested, for example, that mesangial proliferative glomerulonephritis is a more severe form of minimal change disease in which the initial injury is greater, leading to mesangial dysfunction and a slower rate of recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis, however, is not uniformly good. Ten to 30 percent of cases develop progressive renal insufficiency with signs of FSG on repeat renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has been tried in those patients with persistent nephrotic syndrome who are resistant to steroid treatment, particularly if they have a rising plasma creatinine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/2,9,12\">",
"     2,9,12",
"    </a>",
"    ]. One report, for example, treated 18 such patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and cyclophosphamide in full doses for three months with tapering over the next six months: 14 underwent complete remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/12\">",
"     12",
"    </a>",
"    ]. Nine of these patients relapsed after mean of six years; eight went into remission after a repeat course of therapy. Likewise, as in steroid resistant MCD and FSG, other agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, may be of value. Patients with the nephrotic syndrome and those who have failed or become resistant to steroids may benefit from alternative immunosuppressive agents. However, there are no reliable controlled studies to direct treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IGM NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with mesangial proliferative glomerulonephritis have prominent diffuse mesangial deposits of IgM and complement, along with electron dense deposits in the mesangium, and it has been suggested that this represents a separate disorder that has been called IgM nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/3,7,13\">",
"     3,7,13",
"    </a>",
"    ]. Other cases show IgM on immunofluorescence microscopy (often segmental rather than diffuse) but no mesangial deposits on electron microscopy; in this setting, the IgM may be nonspecifically deposited onto an abnormally permeable glomerular basement membrane or trapped in an area of glomerulosclerosis.",
"   </p>",
"   <p>",
"    Patients with IgM nephropathy are less likely to respond to immunosuppressive agents than those with minimal change disease. One summary of published studies, for example, revealed an approximately 1:1:1 distribution of patients who are steroid-responsive, steroid-dependent (requiring continuing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy to sustain a partial or complete remission of proteinuria), and steroid-resistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/7\">",
"     7",
"    </a>",
"    ]. Responses may be seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , but relapses and late resistance to therapy are not uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of 55 children with steroid-dependent or -resistant MCD identified twenty-three who had IgM deposits by immunofluorescence microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/5\">",
"     5",
"    </a>",
"    ]. Of these, 61 percent (14 of 23) had microscopic hematuria, 48 percent (11 of 23) were steroid-dependent and 48 percent (11 of 23) were steroid-resistant. Eighteen percent of those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (2 of 11 patients) obtained remission while 55 percent (6 of 11) were resistant to cyclophosphamide. Of those initially treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , 88 percent (7 of 8) obtained complete (4 of 8) or partial (3 of 8) remission. Positive immunofluorescence for IGM may be surrogate marker for the severity of MCD. In addition, these data suggest that children with MCD and IgM-positive immunofluorescence have a better response to cyclosporine than cyclophosphamide",
"   </p>",
"   <p>",
"    In the largest series to date, the probability of developing end-stage renal disease was approximately 23 percent at 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/14\">",
"     14",
"    </a>",
"    ]. This was more favorable than that observed in another relatively large series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/3\">",
"     3",
"    </a>",
"    ], in which the probability was approximately 20 and 36 percent at 5 and 10 years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/3\">",
"     3",
"    </a>",
"    ]. This difference was most likely related to a lower threshold for biopsy in the first series.",
"   </p>",
"   <p>",
"    It remains controversial, however, if IgM nephropathy is a separate disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Scattered (focal and segmental) IgM deposits can be found with roughly equal incidence in patients with minimal change disease, FSG, and mesangial proliferative glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/9\">",
"     9",
"    </a>",
"    ]. These observations have led to the suggestion that the IgM deposits are a secondary event and that the renal prognosis is best predicted by the findings on light microscopy, with those patients with minimal histologic changes having the best response to therapy and long-term outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the steroid response rate in IgM nephropathy with minimal change disease appears to be no better than 50 percent, which is well below the over 90 percent response rate in patients with idiopathic minimal change disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link\">",
"     \"Treatment of minimal change disease in adults\"",
"    </a>",
"    .) Thus, the presence of mesangial IgM deposits clearly signifies a worse prognosis, although the pathogenesis of the deposits and the possible relationship to FSG is unresolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     C1Q NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;C1q nephropathy refers to a disorder in which mesangial proliferation is associated with mesangial deposits on electron microscopy and prominent C1q deposits on immunofluorescence microscopy (",
"    <a class=\"graphic graphic_picture graphicRef80250 \" href=\"mobipreview.htm?27/46/28393\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. C1q nephropathy has been thought to be a subgroup of primary focal segmental glomerular sclerosis. However, many reports describe different symptoms, histopathologies, therapeutic responses and prognoses, suggesting that C1q nephropathy may be a combination of several disease groups rather than a single disease entity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/20\">",
"     20",
"    </a>",
"    ]. C1q nephropathy may be associated with either MCD, FSG, or proliferative glomerulonephritis. Criteria for the illness include predominant C1q deposits on immunofluorescence microscopy and no clinical evidence of systemic lupus erythematosus.",
"   </p>",
"   <p>",
"    The following are the results from three large single center series in which the clinical, histologic, and prognostic features of patients with C1q nephropathy were described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/17,21,22\">",
"     17,21,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among nearly 9000 renal biopsies reviewed from 1994 to 2002 from Columbia University in New York, nineteen were classified as C1q nephropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/17\">",
"       17",
"      </a>",
"      ]. Seventeen patients had FSG (six with collapsing and two with cellular forms) on renal biopsy, and two had minimal change disease. At a mean follow-up period of 27 months, 12 of 16 available patients (75 percent) had stable renal function, with 7 of 13 entering partial or complete remission (with or without immunosuppressive therapy). Two progressed to end-stage renal disease (both of whom had FSG).",
"     </li>",
"     <li>",
"      In one study of 4048 renal biopsies from Slovenia, 82 revealed C1q nephropathy, with 11, 27, and 20 also revealing FSG, no lesion by light microscopy, and proliferative glomerulonephritis, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/21\">",
"       21",
"      </a>",
"      ]. Of patients who had no lesion by light microscopy, 22 percent had asymptomatic hematuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mild to modest proteinuria; 63 percent had nephrotic syndrome; and 7 percent had a normal urinalysis. All patients with FSG presented with the nephrotic syndrome. Of those with proliferative glomerulonephritis, 75 percent presented with chronic kidney disease. Thirty-three percent of those who presented with FSG developed end-stage renal disease, whereas 77 percent of patients with a minimal change-like lesion had complete remission of nephrotic syndrome.",
"     </li>",
"     <li>",
"      In a third study, 61 of 16,860 biopsies examined between 1975 and 2004 revealed C1q nephropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41717/abstract/22\">",
"       22",
"      </a>",
"      ]. Of these, 46, 7, and 8 also displayed histologic evidence of MCD, proliferative glomerulonephritis, and FSG, respectively. Three patients with FSG developed end-stage renal disease 8 to 15 years after biopsy. Relapse of nephrotic syndrome was common among those with either MCD or FSG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, patients who have C1q nephropathy and FSG are more likely to progress to end-stage renal disease. Predominant presenting features in all studies also included nephrotic range proteinuria (41 to 79 percent), renal insufficiency (5 to 46 percent), and hematuria (22 to 69 percent).",
"   </p>",
"   <p>",
"    There are no randomized trials that have evaluated the treatment of C1q nephropathy. Therapy involves treatment of the underlying light microscopic lesion (eg, MCD or FSG). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=see_link\">",
"     \"Treatment of minimal change disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to minimal change disease (MCD), three disorders present with the nephrotic syndrome and initially show only minor changes on light microscopy. These include idiopathic mesangial proliferative glomerulonephritis, IgM nephropathy, and C1q nephropathy. All disorders are diagnosed by biopsy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic mesangial proliferative glomerulonephritis is characterized by mesangial proliferation and the absence of IgG or IgA immune deposits (though IgM deposits may be present). Patients may have isolated hematuria or nephrotic range proteinuria. Whereas the renal prognosis is good for patients with isolated hematuria, it is not as good for those with nephrotic syndrome as 10 to 30 percent may develop progressive renal insufficiency. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Idiopathic mesangial proliferative glomerulonephritis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"       \"Treatment of primary focal segmental glomerulosclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IgM deposits may be found in patients with MCD, focal segmental glomerulosclerosis (FSG), and mesangial proliferative glomerulonephritis. Some experts, however, believe that IgM nephropathy is a distinct entity characterized by mesangial proliferation and prominent mesangial deposits of IgM and complement. Others require the presence of electron dense deposits by electron microscopy as well as the finding of IgM deposition by immunofluorescence microscopy to define IgM nephropathy. The presence of IgM deposits in a patient with MCD signifies a poorer prognosis compared with MCD without deposits as fewer than 50 percent of such patients respond to steroids. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'IgM nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      C1q nephropathy is characterized by mesangial proliferation, mesangial deposits on electron microscopy, and prominent C1q deposits on immunofluorescence microscopy in a patient with no clinical and laboratory evidence of systemic lupus erythematosus. C1q nephropathy may be associated with MCD, FSG, or proliferative glomerulonephritis. The treatment of C1q nephropathy is the same as it is for MCD or FSG with no C1q deposits. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'C1q nephropathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/1\">",
"      Sagel I, Treser G, Ty A, et al. Occurrence and nature of glomerular lesions after group A streptococci infections in children. Ann Intern Med 1973; 79:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/2\">",
"      Brown EA, Upadhyaya K, Hayslett JP, et al. The clinical course of mesangial proliferative glomerulonephritis. Medicine (Baltimore) 1979; 58:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/3\">",
"      O'Donoghue DJ, Lawler W, Hunt LP, et al. IgM-associated primary diffuse mesangial proliferative glomerulonephritis: natural history and prognostic indicators. Q J Med 1991; 79:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/4\">",
"      Focal segmental glomerulosclerosis in children with idiopathic nephrotic syndrome. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int 1985; 27:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/5\">",
"      Swartz SJ, Eldin KW, Hicks MJ, Feig DI. Minimal change disease with IgM+ immunofluorescence: a subtype of nephrotic syndrome. Pediatr Nephrol 2009; 24:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/6\">",
"      Smith MC, Cooke JH, Zimmerman DM, et al. Asymptomatic glomerulonephritis after nonstreptococcal upper respiratory infections. Ann Intern Med 1979; 91:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/7\">",
"      Border WA. Distinguishing minimal-change disease from mesangial disorders. Kidney Int 1988; 34:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/8\">",
"      Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 1981; 20:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/9\">",
"      Childhood nephrotic syndrome associated with diffuse mesangial hypercellularity. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int 1983; 24:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/10\">",
"      Ji-Yun Y, Melvin T, Sibley R, Michael AF. No evidence for a specific role of IgM in mesangial proliferation of idiopathic nephrotic syndrome. Kidney Int 1984; 25:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/11\">",
"      Waldherr R, Gubler MC, Levy M, et al. The significance of pure diffuse mesangial proliferation in idiopathic nephrotic syndrome. Clin Nephrol 1978; 10:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/12\">",
"      Faedda R, Pirisi M, Satta A, et al. Immunosuppressive treatment of the nephrotic syndrome due to mesangial lesions. Clin Nephrol 1996; 46:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/13\">",
"      Cohen AH, Border WA, Glassock RJ. Nehprotic syndrome with glomerular mesangial IgM deposits. Lab Invest 1978; 38:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/14\">",
"      Myllym&auml;ki J, Saha H, Mustonen J, et al. IgM nephropathy: clinical picture and long-term prognosis. Am J Kidney Dis 2003; 41:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/15\">",
"      Jennette JC, Hipp CG. C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis 1985; 6:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/16\">",
"      Iskandar SS, Browning MC, Lorentz WB. C1q nephropathy: a pediatric clinicopathologic study. Am J Kidney Dis 1991; 18:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/17\">",
"      Markowitz GS, Schwimmer JA, Stokes MB, et al. C1q nephropathy: a variant of focal segmental glomerulosclerosis. Kidney Int 2003; 64:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/18\">",
"      Sharman A, Furness P, Feehally J. Distinguishing C1q nephropathy from lupus nephritis. Nephrol Dial Transplant 2004; 19:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/19\">",
"      Kersnik Levart T, Kenda RB, Avgustin Cavi�� M, et al. C1Q nephropathy in children. Pediatr Nephrol 2005; 20:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/20\">",
"      Mii A, Shimizu A, Masuda Y, et al. Current status and issues of C1q nephropathy. Clin Exp Nephrol 2009; 13:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/21\">",
"      Vizjak A, Ferluga D, Rozic M, et al. Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol 2008; 19:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41717/abstract/22\">",
"      Hisano S, Fukuma Y, Segawa Y, et al. Clinicopathologic correlation and outcome of C1q nephropathy. Clin J Am Soc Nephrol 2008; 3:1637.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3082 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-219.243.220.100-C5CC09C3EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41717=[""].join("\n");
var outline_f40_47_41717=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDIOPATHIC MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IGM NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      C1Q NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3082\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3082|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/46/28393\" title=\"picture 1\">",
"      SLE Mesangial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/9/31898?source=related_link\">",
"      Treatment of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_47_41718="Treatment of acute cellular rejection in liver transplantation";
var content_f40_47_41718=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute cellular rejection in liver transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41718/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41718/contributors\">",
"     Scott J Cotler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41718/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41718/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41718/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41718/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/47/41718/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cellular hepatic transplant rejection has decreased in incidence with the use of potent immunosuppressive agents but it still affects 15 to 25 percent of liver transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Most episodes occur within one month posttransplant, although acute cellular rejection may present later, often in association with inadequate immunosuppression or medication noncompliance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition to the type of immunosuppression, certain transplant related characteristics may influence the risk of rejection. As an example, patients who receive an organ from a living related donor may have a lower rate of acute cellular rejection compared to deceased liver transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The consequences of acute cellular rejection are variable. While it can predispose to steroid-resistant rejection and graft loss, most episodes do not have long-term adverse effects except in HCV positive patients (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Hepatitis C'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/5\">",
"     5",
"    </a>",
"    ]. Furthermore, acute cellular rejection identified by protocol liver biopsy in the absence of biochemical dysfunction often resolves without increasing immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/6\">",
"     6",
"    </a>",
"    ]. There is even a suggestion that such subclinical immune activation might be beneficial in inducing a degree of tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute cellular rejection is usually suspected by elevations in serum aminotransferases and alkaline phosphatase levels, which typically precede clinical symptoms of jaundice and fever. However, biochemical parameters are not sensitive or specific for detecting acute cellular rejection and do not correlate with its severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, the diagnosis should be confirmed by liver biopsy before initiating treatment for rejection. Histologic features include endothelitis, nonsuppurative cholangitis, and mixed mononuclear cell portal inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/28/37319?source=see_link\">",
"     \"Diagnosis of acute cellular rejection in liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;High dose corticosteroids are usually first line therapy for acute cellular rejection.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     Methylprednisolone",
"    </a>",
"    doses vary among centers, ranging from 500 mg to 1000 mg boluses given daily for one to three days. A gradual corticosteroid taper is provided at some centers following bolus methylprednisolone. In a randomized, controlled trial, 1000 mg of methylprednisolone followed by a six day taper from 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was more effective for the treatment of acute cellular rejection and associated with less infectious complications than giving 1000 mg of methylprednisolone on three consecutive days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 70 to 80 percent of episodes of acute cellular rejection resolve after a course of high dose corticosteroids, and a second course is effective in many of the remaining cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Biochemical and histologic improvement is generally observed within three to five days when corticosteroid therapy is successful. Some centers perform a follow-up liver biopsy at the completion of bolus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    therapy to document histologic recovery.",
"   </p>",
"   <p>",
"    The cumulative immunosuppressive effect of high dose corticosteroids increases susceptibility to infections, including oral candidiasis, cytomegalovirus (CMV), Aspergillus, Pneumocystis carinii, and bacterial pathogens. Other potential side effects include hyperglycemia, gastrointestinal hemorrhage, and mood changes. We use prophylactic proton pump inhibitors and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    and follow blood glucose levels during high dose corticosteroid therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of acute cellular rejection in patients with hepatitis C virus (HCV) infection requires special consideration. Treatment with corticosteroids or with T cell depletion is associated with acceleration of HCV progression and increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Furthermore, the biochemical and histologic features of acute cellular and HCV are similar, making it difficult to distinguish these disorders. As a result, many centers defer treatment of mild acute cellular rejection when it is not clearly the primary cause of histologic injury, given the tolerance of hepatic allografts to mild rejection and the negative consequences of treating rejection in patients with HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeated biopsies can be useful in assessing whether changes of mild acute cellular rejection progress and become the dominant histologic feature, prompting initiation of bolus corticosteroid therapy. An alternative approach to equivocal cases of acute cellular rejection in patients with HCV is to increase the calcineurin inhibitor dose or to start an additional agent such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/19\">",
"     19",
"    </a>",
"    ]. Further studies are needed to identify methods to better distinguish acute cellular rejection from HCV recurrence and to determine the impact of the various management options on outcomes. Hepatic gene expression profiling represents one means to differentiate between acute cellular rejection and HCV recurrence, although such technology is not yet sufficiently developed for clinical application [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     STEROID-RESISTANT REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten percent or less of patients with acute cellular rejection develop steroid-resistant rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/10\">",
"     10",
"    </a>",
"    ]. Agents including OKT3, thymoglobulin, anti-interleukin receptor antibodies, MMF,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    have been used as rescue agents to treat such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Muromonab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muromonab (OKT3) is a murine monoclonal antibody to the CD3 antigen-receptor complex present on mature T lymphocytes. Binding of OKT3 to the CD3 complex leads to clearance of circulating T lymphocytes by the reticuloendothelial system and interferes both with antigen recognition by the T cell receptor, and with T cell activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Persistent resolution of steroid-resistant rejection is achieved in up to 60 percent of patients treated with OKT3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients should be monitored carefully while receiving OKT3, especially after the first two to three doses. The toxicity of OKT3 is discussed in detail elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Thymoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymoglobulin is a polyclonal lymphocyte preparation that was shown to reverse steroid-resistant rejection in kidney transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/24\">",
"     24",
"    </a>",
"    ]. Although there are limited data in patients who have undergone liver transplantation, many centers use thymoglobulin to treat steroid-resistant liver allograft rejection to avoid the side effects of OKT3. We use thymoglobulin at our center in the rare cases when steroid-resistant rejection occurs. Thymoglobulin is administered at 1.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (based upon ideal body weight) for five days. The dose is titrated to achieve an absolute lymphocyte count &le;200 mm(3). WBC and platelet counts are followed for evidence of toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anti-Interleukin-2 receptor antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     Basiliximab",
"    </a>",
"    and daclizumab are monoclonal antibodies that bind to the IL-2 receptor on T cells. They block IL-2 mediated T cell proliferation, and thus inhibit the T cell response to alloantigens that produces allograft damage in acute cellular rejection. Anti-interleukin-2 receptor antibodies were effective as an induction agent in liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/25\">",
"     25",
"    </a>",
"    ]. When used for induction therapy, basiliximab is dosed at 20 mg on days 0 and 4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/25\">",
"     25",
"    </a>",
"    ], and daclizumab is dosed at 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on day 0 and 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on day 4 after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of steroid-resistant rejection with anti-interleukin-2 receptor antibodies has been reported in a small number of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. One series included 16 patients with steroid-resistant acute cellular rejection, most of whom also were started on MMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     Basiliximab",
"    </a>",
"    or daclizumab therapy was associated with resolution of steroid-resistant rejection in 75 percent of cases. In contrast, graft dysfunction persisted in nine patients with histologic evidence of chronic rejection. Five of the 25 patients treated in this series had significant infectious complications, including bacterial infections, pulmonary aspergillosis, and CMV reactivation, resulting in two deaths.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMF inhibits the synthesis of purines necessary for lymphocyte activation. It was developed to replace",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and has been used in liver and kidney transplantation as a primary immunosuppressive agent, and for the treatment of refractory rejection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of studies have evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil for treatment of refractory rejection in liver transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. In an illustrative series, MMF (2 to 3",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    was added to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in 47 patients with steroid-resistant acute cellular rejection, 12 of whom did not respond to OKT3&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/33\">",
"     33",
"    </a>",
"    ]. Liver enzymes normalized in 81 percent of patients. Another study evaluated the efficacy of the addition of high doses of MMF (3 g three times daily for the first month) for the treatment of steroid-resistant rejection in living donor liver transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/34\">",
"     34",
"    </a>",
"    ]. Forty-four of 54 (81 percent) patients responded to MMF and only ten required OKT3 for refractory rejection.",
"   </p>",
"   <p>",
"    The recommended dose of MMF is 2 g daily by mouth in two divided doses. Gastrointestinal disturbance is a common side effect. Initiating therapy at 500 mg twice daily and then titrating the dose upward may increase tolerability.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil does not cause significant nephrotoxicity or hepatotoxicity, and is associated with less bone marrow suppression than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    is structurally similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and binds to the FK binding protein 12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/35\">",
"     35",
"    </a>",
"    ]. Unlike tacrolimus, sirolimus blocks immune responses by inhibiting the mTOR signaling pathway, which regulates cell growth and proliferation. Sirolimus also inhibits IL-2 and IL-4 dependent proliferation of T and B cells.",
"   </p>",
"   <p>",
"    In open label and retrospective analyses, patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    as the primary immunosuppressive agent had relatively low rates of acute cellular rejection and steroid-resistant rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Sirolimus was associated with hepatic artery thrombosis in two large multicenter studies, leading to a \"black box\" warning regarding its use as an induction agent in liver transplantation. Reported side effects include impaired wound healing, cytopenia, dermatitis, interstitial pneumonitis, edema, pleural and pericardial effusions, joint pain, and oral aphthous ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Hyperlipidemia and nephrotoxicity occur more commonly when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is combined with sirolimus. On the positive side, sirolimus is not associated with nephrotoxicity or neurotoxicity when given alone. Sirolimus given in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    may cause less nephrotoxicity than the combination of sirolimus and cyclosporine. Sirolimus might have a benefit in patients with hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited data regarding treatment of steroid-resistant rejection with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . In one preliminary report, steroid-resistant rejection resolved in 8 of 14 patients (57 percent) who received sirolimus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is used as an immunosuppressive agent in most liver transplant recipients. However, in those receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , conversion from cyclosporine to tacrolimus can be effective in treating steroid-resistant acute cellular rejection and early chronic rejection. In one report, 9 of 16 (56 percent) patients converted to tacrolimus for OKT3-refractory rejection showed normalization of liver enzymes at an average of 60 days, and a one-year graft survival of 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/41\">",
"     41",
"    </a>",
"    ]. In another series, biochemical and histologic normalization occurred in 10 of 18 (56 percent) patients with steroid-resistant or OKT3-refractory rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RETRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 4 percent or less of liver transplant recipients develop severe ductopenic chronic rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/3\">",
"     3",
"    </a>",
"    ]. The risk of chronic ductopenic rejection appears to be increased in patients who have had repeated episodes of acute cellular rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41718/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who progress to chronic rejection should be considered for retransplantation. In such cases, reduction of immunosuppression should be considered in the preoperative period in an effort to reduce infectious complications associated with retransplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cellular rejection has decreased in incidence with the use of potent immunosuppressive agents but it still affects 15 to 25 percent of liver transplant recipients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of acute cellular rejection is usually suspected by elevations in serum aminotransferases and alkaline phosphatase levels, which typically precede clinical symptoms of jaundice and fever (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/28/37319?source=see_link\">",
"       \"Diagnosis of acute cellular rejection in liver transplantation\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      High dose corticosteroids are usually first line therapy for acute cellular rejection. Approximately 70 to 80 percent of episodes of acute cellular rejection resolve after a course of high dose corticosteroids, and a second course is effective in many of the remaining cases. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of acute cellular rejection in patients with hepatitis C virus (HCV) infection requires special consideration. Treatment with corticosteroids or with T cell depletion is associated with acceleration of HCV progression and increased mortality. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hepatitis C'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ten percent or less of patients with acute cellular rejection develop steroid-resistant rejection. Agents including OKT3, ATG, MMF, anti-interleukin receptor antibodies,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      have been used as rescue agents to treat such patients. Although the largest experience in treating steroid-resistant rejection is with OKT3, use of the other agents should be considered, particularly in patients with hepatitis C. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Steroid-resistant rejection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/1\">",
"      Maluf DG, Stravitz RT, Cotterell AH, et al. Adult living donor versus deceased donor liver transplantation: a 6-year single center experience. Am J Transplant 2005; 5:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/2\">",
"      Gruttadauria S, Vasta F, Mandal&agrave; L, et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Transplant Proc 2005; 37:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/3\">",
"      Wiesner RH, Menon KV. Late hepatic allograft dysfunction. Liver Transpl 2001; 7:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/4\">",
"      Liu LU, Bodian CA, Gondolesi GE, et al. Marked Differences in acute cellular rejection rates between living-donor and deceased-donor liver transplant recipients. Transplantation 2005; 80:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/5\">",
"      Seiler CA, Renner EL, Czerniak A, et al. Early acute cellular rejection: no effect on late hepatic allograft function in man. Transpl Int 1999; 12:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/6\">",
"      Bartlett AS, Ramadas R, Furness S, et al. The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systematic review. Liver Transpl 2002; 8:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/7\">",
"      Goddard S, Adams DH. Methylprednisolone therapy for acute rejection: too much of a good thing? Liver Transpl 2002; 8:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/8\">",
"      Abraham SC, Furth EE. Receiver operating characteristic analysis of serum chemical parameters as tests of liver transplant rejection and correlation with histology. Transplantation 1995; 59:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/9\">",
"      Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/10\">",
"      Volpin R, Angeli P, Galioto A, et al. Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl 2002; 8:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/11\">",
"      Adams DH, Neuberger JM. Patterns of graft rejection following liver transplantation. J Hepatol 1990; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/12\">",
"      Adams DH, Neuberger JM. Treatment of acute rejection. Semin Liver Dis 1992; 12:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/13\">",
"      Schluger LK, Sheiner PA, Thung SN, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/14\">",
"      Rosen HR, Shackleton CR, Higa L, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/15\">",
"      Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5:S107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/16\">",
"      Berenguer M, Prieto M, C&oacute;rdoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/17\">",
"      Burton JR Jr, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: The great conundrum. Liver Transpl 2006; 12:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/18\">",
"      Demetris AJ, Eghtesad B, Marcos A, et al. Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol 2004; 28:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/19\">",
"      Gedaly R, Clifford TM, McHugh PP, et al. Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey. Transpl Int 2008; 21:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/20\">",
"      Sreekumar R, Rasmussen DL, Wiesner RH, Charlton MR. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl 2002; 8:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/21\">",
"      Hooks MA, Wade CS, Millikan WJ Jr. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 1991; 11:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/22\">",
"      Schroeder TJ, First MR. Monoclonal antibodies in organ transplantation. Am J Kidney Dis 1994; 23:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/23\">",
"      Solomon H, Gonwa TA, Mor E, et al. OKT3 rescue for steroid-resistant rejection in adult liver transplantation. Transplantation 1993; 55:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/24\">",
"      Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/25\">",
"      Ramirez CB, Doria C, di Francesco F, et al. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months. J Surg Res 2007; 138:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/26\">",
"      Koch M, Niemeyer G, Patel I, et al. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002; 73:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/27\">",
"      Fernandes ML, Lee YM, Sutedja D, et al. Treatment of steroid-resistant acute liver transplant rejection with basiliximab. Transplant Proc 2005; 37:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/28\">",
"      Orr DW, Portmann BC, Knisely AS, et al. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation. Transplant Proc 2005; 37:4373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/29\">",
"      Klintmalm GB, Ascher NL, Busuttil RW, et al. RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993; 25:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/30\">",
"      Klupp J, Bechstein WO, Platz KP, et al. Mycophenolate mofetil added to immunosuppression after liver transplantation--first results. Transpl Int 1997; 10:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/31\">",
"      McDiarmid SV. Mycophenolate mofetil in liver transplantation. Clin Transplant 1996; 10:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/32\">",
"      Hebert MF, Ascher NL, Lake JR, et al. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/33\">",
"      Pfitzmann R, Klupp J, Langrehr JM, et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 2003; 76:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/34\">",
"      Akamatsu N, Sugawara Y, Tamura S, et al. Efficacy of mycofenolate mofetil for steroid-resistant acute rejection after living donor liver transplantation. World J Gastroenterol 2006; 12:4870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/35\">",
"      Mehrabi A, Fonouni H, Kashfi A, et al. The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant 2006; 20 Suppl 17:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/36\">",
"      Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003; 35:193S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/37\">",
"      Zaghla H, Selby RR, Chan LS, et al. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation. Aliment Pharmacol Ther 2006; 23:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/38\">",
"      Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc 2003; 35:209S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/39\">",
"      Montalbano M, Neff GW, Yamashiki N, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004; 78:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/40\">",
"      Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/41\">",
"      Gibbs JF, Husberg BS, Klintmalm GB, et al. Outcome analysis of FK 506 therapy for acute and chronic rejection. Transplant Proc 1993; 25:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/42\">",
"      Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation 1992; 53:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41718/abstract/43\">",
"      Soin AS, Rasmussen A, Jamieson NV, et al. CsA levels in the early posttransplant period--predictive of chronic rejection in liver transplantation? Transplantation 1995; 59:1119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4598 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41718=[""].join("\n");
var outline_f40_47_41718=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      STEROID-RESISTANT REJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Muromonab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Thymoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anti-Interleukin-2 receptor antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RETRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/28/37319?source=related_link\">",
"      Diagnosis of acute cellular rejection in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_47_41719="B-PLL spleen histology";
var content_f40_47_41719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histology of the spleen in B cell prolymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 513px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Low power view (original magnification x20) showing replacement of the white pulp and infiltration of the red pulp.",
"    <br/>",
"    (B) High power view (original magnification x100) of the white pulp showing the typical prolymphocyte morphology with abundant cytoplasm, round nuclei, and a central eosinophilic nucleolus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Dearden C. How I treat prolymphocytic leukemia. Blood 2012; 120:538. Copyright &copy; 2012 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41719=[""].join("\n");
var outline_f40_47_41719=null;
var title_f40_47_41720="Clinical manifestations, diagnosis, and staging of testicular germ cell tumors";
var content_f40_47_41720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41720/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41720/contributors\">",
"     Graeme S Steele, MBBCh, FCS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41720/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41720/contributors\">",
"     William K Oh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41720/contributors\">",
"     M Dror Michaelson, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41720/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41720/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41720/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41720/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/47/41720/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancer is the most common solid malignancy affecting males between the ages of 15 and 35, although it accounts for about 1 percent of all cancers in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/1\">",
"     1",
"    </a>",
"    ]. Germ cell tumors (GCTs) account for 95 percent of testicular cancers (",
"    <a class=\"graphic graphic_table graphicRef81626 \" href=\"mobipreview.htm?43/42/44715\">",
"     table 1",
"    </a>",
"    ). They may consist of one predominant histologic pattern, or represent a mix of multiple histologic types. For treatment purposes, two broad categories of testis tumors are recognized: pure seminoma (no nonseminomatous elements present), and all others, which together are termed nonseminomatous germ cell tumors (NSGCTs). In most series, the ratio of seminoma to NSGCT is about one.",
"   </p>",
"   <p>",
"    Testicular cancer has become one of the most curable of solid neoplasms because of remarkable treatment advances beginning in the late 1970s. Prior to that time, testicular cancer accounted for 11 percent of all cancer deaths in men between the ages of 25 to 34, and the five-year survival rate was 64 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/2\">",
"     2",
"    </a>",
"    ]. In 2011, about 350 deaths from testicular cancer are expected in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/1\">",
"     1",
"    </a>",
"    ]; the five-year survival rate is over 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and staging of testicular cancer will be presented here. Optimal therapy, which varies with the stage of disease, is discussed separately (see appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular tumors usually present as a nodule or painless swelling of one testicle, which may be noted incidentally by the patient or by his sexual partner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/4\">",
"     4",
"    </a>",
"    ]. Occasionally, a man with a previously small atrophic testis will note enlargement. Approximately 30 to 40 percent of patients complain of a dull ache or heavy sensation in the lower abdomen, perianal area, or scrotum, while acute pain is the presenting symptom in 10 percent.",
"   </p>",
"   <p>",
"    The presenting manifestations of testicular cancer are attributable to metastatic disease in approximately 10 percent of patients. Symptoms vary with the site of metastasis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A neck mass (supraclavicular lymph node metastasis)",
"     </li>",
"     <li>",
"      Cough or dyspnea (pulmonary metastasis)",
"     </li>",
"     <li>",
"      Anorexia, nausea, vomiting, or gastrointestinal hemorrhage (retroduodenal metastasis)",
"     </li>",
"     <li>",
"      Lumbar back pain (bulky retroperitoneal disease involving the psoas muscle or nerve roots)",
"     </li>",
"     <li>",
"      Bone pain (skeletal metastasis)",
"     </li>",
"     <li>",
"      Central or peripheral nervous system symptoms (cerebral, spinal cord, or peripheral root involvement)",
"     </li>",
"     <li>",
"      Unilateral or bilateral lower extremity swelling (iliac or caval venous obstruction or thrombosis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gynecomastia, which occurs in about 5 percent of men with testicular GCTs, is a systemic endocrine manifestation of these neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/5\">",
"     5",
"    </a>",
"    ]. It also occurs in 20 to 30 percent of patients with the less common (2 percent of testicular tumors) Leydig cell tumors of the testes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/6\">",
"     6",
"    </a>",
"    ]. These tumors are found in 6 to 10 year old boys who present with precocious puberty, and in 26 to 35 year old men who present with a testicular mass, gynecomastia, impotence, and loss of libido.",
"   </p>",
"   <p>",
"    Gynecomastia is usually associated with production of human chorionic gonadotropin (hCG) by foci of choriocarcinoma or trophoblastic cells in the tumor. However, the relationship between gynecomastia, testicular tumor morphology, and endocrine abnormalities remains incompletely defined. In individual patients, gynecomastia may or may not be associated with elevated serum concentrations of hCG, human chorionic somatomammotropin, prolactin, estrogens, or androgens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/9/6294?source=see_link\">",
"     \"Epidemiology and pathogenesis of gynecomastia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27384?source=see_link\">",
"     \"Causes and evaluation of gynecomastia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with marked overproduction of hCG can develop another endocrine complication, paraneoplastic hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/7\">",
"     7",
"    </a>",
"    ]. Thyroid stimulating hormone and hCG have a common alpha-subunit and a beta-subunit with considerable homology. As a result, hCG has weak thyroid-stimulating activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=see_link&amp;anchor=H994022#H994022\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'hCG and thyroid function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4103?source=see_link&amp;anchor=H8#H8\">",
"     \"Disorders that cause hyperthyroidism\", section on 'Trophoblastic disease and germ cell tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with testicular cancer also may develop a paraneoplastic limbic encephalitis. Most of these patients have anti-Ma2 (also called anti-Ta) antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/8\">",
"     8",
"    </a>",
"    ]. The Ma2 antigen is selectively expressed in the neuronal nucleoli of normal brain tissue and the testicular tumor of the patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=see_link\">",
"     \"Paraneoplastic and autoimmune encephalitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=see_link&amp;anchor=H3370761#H3370761\">",
"     \"Paraneoplastic and autoimmune encephalitis\", section on 'Ma2-associated encephalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Testicular examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination of the testes should begin with bimanual examination of the scrotal contents, starting with the normal contralateral testis. This permits the examiner to appreciate the relative size, contour, and consistency of the normal testis as a baseline for comparison of the suspected gonad. The testis should be carefully palpated between the thumb and first two fingers of the examining hand.",
"   </p>",
"   <p>",
"    The normal gonad is homogeneous in consistency, freely movable, and separable from the epididymis. Any firm, hard, or fixed area within the substance of the tunica albuginea should be considered suspicious until proved otherwise. Further evaluation of the affected side should be directed toward possible involvement of the spermatic cord, scrotal investments, or skin.",
"   </p>",
"   <p>",
"    Testicular tumors tend to remain ovoid, being limited by the tough investing tunica albuginea. However, spread to the epididymis or spermatic cord occurs in 10 to 15 percent of patients. In general, a seminoma tends to expand within the testis as a painless, rubbery enlargement, while an embryonal carcinoma or teratocarcinoma forms an irregular mass with indiscrete borders. However, this distinction is not always easily appreciated.",
"   </p>",
"   <p>",
"    A hydrocele may be present, and can make evaluation of a suspected testicular tumor more difficult. In such cases, ultrasonography of the scrotum is a rapid, reliable technique to exclude a hydrocele or epididymitis; it is indicated in any man with a suspected testicular tumor (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Scrotal ultrasound'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Physical examination should also include palpation of the abdomen for evidence of nodal disease or visceral involvement. Routine assessment of the supraclavicular lymph nodes may reveal adenopathy in men with advanced disease. Examination of the chest may disclose gynecomastia or raise suspicion for thoracic involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H137129371\">",
"    <span class=\"h3\">",
"     Cryptorchidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with a history of cryptorchidism and a prior orchiopexy are at increased risk for testicular cancer in both testes (greater in the undescended one), although the absolute risk is only 1 in 1000 to 1 in 2500. As such, testis self-examination is suggested. Because of the rarity of such tumors, routine scrotal ultrasound is not indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2457?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\", section on 'Cryptorchidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In any man with a solid, firm mass within the testis, testicular cancer must be the considered diagnosis until proven otherwise. Prompt diagnosis and treatment of testicular cancer provides the best opportunity for cure. Nevertheless, both patient and physician factors often contribute to a delay in diagnosis. Painless scrotal masses are sometimes ignored, while testicular cancers presenting with scrotal pain are often treated as epididymitis.",
"   </p>",
"   <p>",
"    The differential diagnosis of a testicular mass includes testicular torsion, epididymitis, or epididymoorchitis. Less common problems include hydrocele, varicocele, hernia, hematoma, spermatocele, or syphilitic gumma. In patients in whom the diagnosis is unclear or in whom a hydrocele precludes adequate examination, imaging studies are an important second step in determining the cause. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44360?source=see_link\">",
"     \"Evaluation of the acute scrotum in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic evaluation of men with suspected testicular cancer includes scrotal ultrasound followed by radiographic testing, measurement of serum tumor markers, radical inguinal orchiectomy, and, in some cases, retroperitoneal lymph node dissection. The results are used to determine the histologic type and extent of disease and to guide therapy. Testicular biopsy is not performed as part of the evaluation due to concern that it may result in tumor seeding into the scrotal sac or metastatic spread of tumor into the inguinal nodes. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Prognostic classification of advanced disease'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    In addition, since the vast majority of these patients are young men, consideration should be given to fertility issues and sperm cryopreservation during the initial diagnostic evaluation. If possible, a baseline sperm count and sperm banking should be performed prior to the radiographic diagnostic evaluation in order to avoid radiation exposure of the sperm (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Cryopreservation of sperm'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Scrotal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scrotal ultrasound can distinguish intrinsic from extrinsic testicular lesions with a high degree of accuracy, and can detect intratesticular lesions as small as 1 to 2 mm in diameter. In men with testicular masses, scrotal ultrasound has become an extension of the physical examination, but should never be considered a substitute for the latter.",
"   </p>",
"   <p>",
"    A cystic or fluid-filled mass is unlikely to represent malignancy. In comparison, seminomas appear as well-defined hypoechoic lesions without cystic areas, while nonseminomatous germ cell tumors (NSGCTs) are typically inhomogeneous with calcifications, cystic areas, and indistinct margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, this distinction is not always apparent; in one series, for example, the radiologist's interpretation of the type of tumor was correct in only 70 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/10\">",
"     10",
"    </a>",
"    ]. Even magnetic resonance imaging does not improve the specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another limitation is that, because the tunica albuginea is difficult to discern by ultrasonography, local tumor (T) staging has proved to be unreliable with this technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In the above report, tumor staging was accurate in 44 percent of seminomas and only 8 percent of nonseminomatous tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/10\">",
"     10",
"    </a>",
"    ]. For these reasons, scrotal ultrasound cannot replace radical inguinal orchiectomy for the determination of histology and stage.",
"   </p>",
"   <p>",
"    The widespread use of scrotal ultrasound in the evaluation of male infertility occasionally leads to the diagnosis of an incidental, nonpalpable testicular mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33481?source=see_link\">",
"     \"Evaluation of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the largest series, 46 asymptomatic lesions less than 10 mm were identified in 4418 men evaluated for infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/12\">",
"     12",
"    </a>",
"    ]. The majority of the men did not undergo surgery and were followed with active surveillance and serial ultrasound. Among the eight patients who either chose surgery or who had surgery because of progressive enlargement of the lesion, one seminoma and two Leydig cell tumors were identified. The remaining five patients had benign lesions. The authors concluded that ultrasound surveillance for small incidentally discovered testicular masses is a safe and appropriate alternative to surgery. For those men with an incidentally detected testicular mass (and normal serum tumor markers) who choose to undergo surgery, less radical surgery (ie, excisional biopsy) rather than orchiectomy is appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high-resolution computed tomography (CT) scan of the abdomen and pelvis and a chest x-ray are generally performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/4\">",
"     4",
"    </a>",
"    ]. Chest CT is recommended if the chest x-ray is abnormal, or if metastatic disease involving the thorax is strongly suspected.",
"   </p>",
"   <p>",
"    Regional metastases first appear in the retroperitoneal lymph nodes. Although CT is the imaging modality of choice to evaluate the retroperitoneum, false negative rates as high as 44 percent have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/16\">",
"     16",
"    </a>",
"    ]. Occult micrometastases are responsible for most of these false negatives, as evidenced by a retroperitoneal relapse rate of 20 to 25 percent in men with clinical stage I disease who do not undergo retroperitoneal lymph node dissection (RPLND) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of the staging CT scan is also dependent on the cutoff value used to define an abnormal node. Most institutions use a 10 mm cutoff to define pathologic adenopathy. Higher cutoffs (greater than 15 mm) yield higher false negative rates, while lower cutoffs (less than 5 mm) may result in some patients undergoing unnecessary therapeutic RPLND [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9272?source=see_link\">",
"     \"Retroperitoneal lymph node dissection in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H137129438\">",
"    <span class=\"h2\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) of the abdomen and pelvis, or scrotum usually adds little to the information obtained by CT scan and ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/11\">",
"     11",
"    </a>",
"    ]. CT or MRI of the brain are performed if brain metastases are suspected. Bone radionuclide scan is rarely indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     PET scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;PET scan is of limited utility in the initial staging of patients with testicular germ cell tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], because of the frequent occurrence of false negative results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The utility of PET as compared to CT as an initial staging modality for the retroperitoneum was studied in a German study of 70 men, all of whom underwent subsequent retroperitoneal lymph node dissection for clinical stage I or II NSGCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/21\">",
"       21",
"      </a>",
"      ]. In a preliminary report, correct staging was achieved in more patients by PET (55 of 70 versus 49 of 70 [78 versus 70 percent]). Although the positive predictive value was higher with PET (21 of 25 patients with a positive PET had viable tumor identified, compared to 22 of 33 with a positive CT), false negative results were a problem (only 34 of 45 patients with a negative PET scan had no tumor identified [negative predictive value 76 percent]), a value that was not significantly better than that achieved by CT (27 of 37 patients with a negative CT had no tumor identified [negative predictive value 73 percent]).",
"     </li>",
"     <li>",
"      Similar results were seen in a subsequent study in 111 patients with clinical stage I NSGCT patients with NSGCT, which used the negative results of PET to select patients for surveillance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/22\">",
"       22",
"      </a>",
"      ]. Of the 87 patients with a negative PET who were managed with surveillance, 33 (38 percent) relapsed within one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PET scanning is more commonly used for the evaluation of posttherapy residual masses than for initial diagnostic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/45/22230?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of stage II seminoma\", section on 'Post therapy residual masses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serum tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a man suspected of having a testicular cancer, blood should be obtained for a chemistry profile, complete blood count, and serum tumor markers. Three serum tumor markers have established roles in testicular cancer: alpha fetoprotein (AFP), the beta subunit of human chorionic gonadotropin (beta-hCG, since the alpha subunit is common to several pituitary hormones), and lactate dehydrogenase (LDH). Serum levels of AFP",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beta-hCG are elevated in 80 to 85 percent of men with NSGCTs, even when nonmetastatic. In contrast, serum beta-hCG is elevated in fewer than 20 percent of testicular seminomas, and AFP is not elevated in pure seminomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/58/38822?source=see_link\">",
"     \"Serum tumor markers in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neither serum beta-hCG nor AFP alone or in combination is sufficiently sensitive or specific to establish the diagnosis of testicular cancer in the absence of histologic confirmation. Marked elevations in these markers are rarely found in men except in GCTs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum beta-hCG concentrations above 10,000",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      occur only in GCTs, the rare patient with trophoblastic differentiation of a lung or gastric primary cancer, or, in women, pregnancy or gestational trophoblastic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12871?source=see_link\">",
"       \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24761?source=see_link\">",
"       \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum AFP concentrations above 10,000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      occur almost exclusively in GCTs and hepatocellular carcinoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=see_link\">",
"       \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations are especially pertinent for the patient with a suspected extragonadal GCT. Elevated serum tumor markers can be used to make the diagnosis if a biopsy is not feasible or will compromise a patient with compatible clinical features or if biopsy reveals poorly differentiated carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9096?source=see_link&amp;anchor=H1568145737#H1568145737\">",
"     \"Poorly differentiated cancer from an unknown primary site\", section on 'Extragonadal germ cell tumors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9096?source=see_link&amp;anchor=H2#H2\">",
"     \"Poorly differentiated cancer from an unknown primary site\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although serum tumor markers are helpful at the time of initial diagnosis of a testicular cancer and for prognostication, their main utility is for subsequent follow-up of disease status after primary treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/58/38822?source=see_link\">",
"     \"Serum tumor markers in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radical inguinal orchiectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A radical inguinal orchiectomy should be performed to permit histologic evaluation of the primary tumor and to provide local tumor control. Neither scrotal ultrasound, as mentioned above, nor serum tumor markers are sufficiently accurate to replace radical inguinal orchiectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/63/33782?source=see_link&amp;anchor=H7#H7\">",
"     \"Radical inguinal orchiectomy for testicular germ cell tumors\", section on 'Scrotal violation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Retroperitoneal lymph node dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retroperitoneal lymph node dissection is the only reliable method to identify nodal micrometastases given the high false negative rate with CT scan (see",
"    <a class=\"local\" href=\"#H8\">",
"     'CT scan'",
"    </a>",
"    above). It is also the gold standard for providing accurate pathologic staging of the retroperitoneum. Both the number and size of involved retroperitoneal lymph nodes have prognostic importance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9272?source=see_link\">",
"     \"Retroperitoneal lymph node dissection in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following radiographic evaluation of the retroperitoneum and radical inguinal orchiectomy, a subset of patients with low stage NSGCT (T1-3 N0-2 M0, see below) should be considered candidates for a surgical staging RPLND. In comparison, primary chemotherapy is the treatment of choice for patients with high volume stage II disease or stage III disease; in such patients, RPLND is reserved for those with residual postchemotherapy disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .) Surveillance is also an appropriate option for some men with clinical stage I testicular cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3334?source=see_link\">",
"     \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H607300785\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of clinical and radiographic evaluation are used to assign a clinical stage in order to estimate prognosis and guide therapy. Testicular cancer is staged using the joint comprehensive TNM staging system by the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/24\">",
"     24",
"    </a>",
"    ]. In the TNM system, assessments of primary tumor (T), lymph node (N) and distant metastasis (M) are combined with serum tumor marker values for beta-HCG, AFP, and LDH (S) to define stage groupings from I to III (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"mobipreview.htm?35/13/36061\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"mobipreview.htm?20/34/21037\">",
"     table 3",
"    </a>",
"    ). The TNM classification applies to both seminomas and nonseminomatous GCTs.",
"   </p>",
"   <p>",
"    Compared to NSGCTs, pure seminomas are more likely to be localized to the testis at presentation. Approximately 80 percent of men with seminomas present with stage I disease (limited to the testicle), while 15 percent have stage II disease (limited to retroperitoneal nodes). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22567?source=see_link\">",
"     \"Treatment of stage I seminoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the availability of serum tumor markers and the predictable metastatic pattern of testicular cancer, most experts do not require a confirmatory biopsy of suspected disease as part of the staging procedure. Biopsies of suspected disease should only be performed in unusual situations, such as in patients who present with imaging detected masses without elevated tumor markers or the presence of disease in atypical locations (eg, bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/25\">",
"     25",
"    </a>",
"    ]). If patients have evidence of advanced disease suggested by imaging",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated tumor markers, definitive treatment is recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSTIC CLASSIFICATION OF ADVANCED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men who present with advanced disease, numerous staging and prognostic systems have been proposed to separate different prognostic subgroups, based primarily on single institution experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. In 1997, consensus was reached on a uniform validated prognostic model by the International Germ Cell Cancer Collaborative Group (IGCCG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/31\">",
"     31",
"    </a>",
"    ]. The following risk groups were identified according to the type of tumor:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Good prognosis",
"    </span>",
"   </p>",
"   <p>",
"    For patients with seminoma:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Any primary site",
"     </li>",
"     <li>",
"      No nonpulmonary visceral metastases",
"     </li>",
"     <li>",
"      Normal serum AFP, any serum beta-hCG or LDH",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with NSGCT:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Testicular or retroperitoneal primary tumors",
"     </li>",
"     <li>",
"      No nonpulmonary visceral metastases",
"     </li>",
"     <li>",
"      Serum AFP less than 1000",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      beta-hCG less than 5000",
"      <span class=\"nowrap\">",
"       mIU/mL,",
"      </span>",
"      and LDH less than 1.5 times upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intermediate prognosis",
"    </span>",
"   </p>",
"   <p>",
"    For patients with seminoma:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Any primary site",
"     </li>",
"     <li>",
"      Nonpulmonary visceral metastases",
"     </li>",
"     <li>",
"      Normal serum AFP, any beta-hCG or LDH",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with NSGCT:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Testicular or retroperitoneal primary",
"     </li>",
"     <li>",
"      No nonpulmonary visceral metastases",
"     </li>",
"     <li>",
"      Any of the following: serum AFP 1,000 to 10,000",
"      <span class=\"nowrap\">",
"       ng/mL;",
"      </span>",
"      beta-hCG 5000 to 50,000",
"      <span class=\"nowrap\">",
"       mIU/mL;",
"      </span>",
"      LDH 1.5 to 10 times upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Poor prognosis",
"    </span>",
"   </p>",
"   <p>",
"    For patients with NSGCT only, any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mediastinal primary site",
"     </li>",
"     <li>",
"      Nonpulmonary visceral metastases",
"     </li>",
"     <li>",
"      Serum AFP &gt;10,000",
"      <span class=\"nowrap\">",
"       ng/mL;",
"      </span>",
"      serum beta-hCG &gt;50,000",
"      <span class=\"nowrap\">",
"       mIU/mL;",
"      </span>",
"      LDH more than 10 times upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The separate groups as defined by the IGCCG grouping have significantly different outcomes as illustrated by the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with good prognosis, comprising 60 percent of GCTs, had a five-year survival rate of 91 percent (range 89 to 93 percent). This group corresponds to the following AJCC groups: stage I to IIC, and stage",
"      <span class=\"nowrap\">",
"       IIIA/B",
"      </span>",
"      seminoma, or stage I to IIC, and IIIA NSGCT.",
"     </li>",
"     <li>",
"      Patients with intermediate prognosis, comprising 26 percent of GCTs, had a five year survival rate of 79 percent (range 75 to 83 percent). This group corresponds to the following AJCC groups: stage IIIC seminoma, or stage IIIB NSGCT.",
"     </li>",
"     <li>",
"      Patients with poor prognosis, comprising 14 percent of GCTs (all with NSGCT) had a five-year survival rate of 48 percent (range 42 to 54 percent). This group corresponds to AJCC stage IIIC NSGCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The selection of therapy for men with metastatic testicular cancer based upon risk stratification is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24852?source=see_link\">",
"     \"Risk stratification of metastatic testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CRYOPRESERVATION OF SPERM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Semen cryopreservation should be made available to all men diagnosed with testicular cancer prior to instituting therapy if they wish to preserve fertility. If possible, a baseline sperm count and sperm banking should be performed prior to the radiographic diagnostic evaluation in order to avoid radiation exposure of the sperm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13706?source=see_link&amp;anchor=H33#H33\">",
"     \"Effects of cytotoxic agents on gonadal function in adult men\", section on 'Prevention of gonadal toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a number of issues need to be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testicular tumors are associated with gonadal dysgenesis, and approximately 50 percent of men have some degree of underlying impairment of spermatogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/32-38\">",
"       32-38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13706?source=see_link&amp;anchor=H7#H7\">",
"       \"Effects of cytotoxic agents on gonadal function in adult men\", section on 'Testicular cancer'",
"      </a>",
"      .) Semen quality may further deteriorate following removal of the affected testis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/38\">",
"       38",
"      </a>",
"      ], although others have shown no impact of orchiectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/39\">",
"       39",
"      </a>",
"      ]. The cause of gonadal dysgenesis is unknown in these men; it as been suggested that common etiologic factors are responsible for both low semen quality and testicular cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Despite this abnormality, sperm from men with testicular cancer does not appear to be more sensitive to the effects of cryopreservation and thawing than normal donors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/36\">",
"       36",
"      </a>",
"      ]. Men with seminoma may have better sperm quality both before and after cryopreservation than those with NSGCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Newer assisted reproductive techniques and improvements in cryopreservation techniques may permit successful future pregnancy in 30 to 60 percent of men who undergo treatment for testicular cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41720/abstract/42-44\">",
"       42-44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3610?source=see_link\">",
"       \"Treatment of male infertility\"",
"      </a>",
"      .) Congenital abnormalities have not been noted in these children.",
"     </li>",
"     <li>",
"      Not all men are willing to undergo sperm testing or banking.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24645?source=see_link\">",
"       \"Patient information: Testicular cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular germ cell tumors (GCTs) are the most common malignancies affecting adult men between the ages 15 to 35 years. The availability of effective therapies and the development of highly sensitive assays for tumor markers have increased the cure rate for testicular GCTs to approximately 95 percent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of men with a testicular tumor present with a painless mass. Less commonly, local symptoms (such as pain or a heaviness in the lower abdomen), gynecomastia, or symptoms due to metastases may be the presenting manifestation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of a man with a suspected testicular tumor should include a physical examination of the scrotum, supplemented by ultrasound to differentiate tumor from a hydrocele or epididymitis. The initial evaluation should include measurement of serum tumor markers (beta-hCG, AFP, and LDH). Imaging studies should include chest x-ray as well as CT or MRI of the pelvis and abdomen to look for evidence of regional lymph node metastases. Prior to definitive treatment, the possible need for cryopreservation of sperm should also be considered. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Cryopreservation of sperm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radical inguinal orchiectomy is used both to provide the histologic diagnosis and local tumor control. Lesser surgical procedures, such as biopsy of the testicle, are generally contraindicated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radical inguinal orchiectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation should provide information regarding lymphatic spread, the presence or absence of metastases, and the levels of serum beta-hCG, AFP, and LDH. This information is used to define disease stage using the TNM classification. (See",
"      <a class=\"local\" href=\"#H607300785\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with metastatic testicular cancer, clinical features are used to stratify patients into good, intermediate, and poor subsets for both prognosis and to help determine treatment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prognostic classification of advanced disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/1\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/2\">",
"      Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8:1777.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LA, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2001, National Cancer Institute, Bethesda, MD, 2004 file://seer.cancer.gov/csr/1975_2007/index.html (Accessed on April 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/4\">",
"      Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/5\">",
"      Tseng A Jr, Horning SJ, Freiha FS, et al. Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications. Cancer 1985; 56:2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/6\">",
"      Gabrilove JL, Nicolis GL, Mitty HA, Sohval AR. Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature. Cancer 1975; 35:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/7\">",
"      Oosting SF, de Haas EC, Links TP, et al. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. Ann Oncol 2010; 21:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/8\">",
"      Voltz R, Gultekin SH, Rosenfeld MR, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999; 340:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/9\">",
"      Benson CB. The role of ultrasound in diagnosis and staging of testicular cancer. Semin Urol 1988; 6:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/10\">",
"      Marth D, Scheidegger J, Studer UE. Ultrasonography of testicular tumors. Urol Int 1990; 45:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/11\">",
"      Schultz-Lampel D, Bogaert G, Th&uuml;roff JW, et al. MRI for evaluation of scrotal pathology. Urol Res 1991; 19:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/12\">",
"      Toren PJ, Roberts M, Lecker I, et al. Small incidentally discovered testicular masses in infertile men--is active surveillance the new standard of care? J Urol 2010; 183:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/13\">",
"      Eifler JB Jr, King P, Schlegel PN. Incidental testicular lesions found during infertility evaluation are usually benign and may be managed conservatively. J Urol 2008; 180:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/14\">",
"      Powell TM, Tarter TH. Management of nonpalpable incidental testicular masses. J Urol 2006; 176:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/15\">",
"      Rolle L, Tamagnone A, Destefanis P, et al. Microsurgical \"testis-sparing\" surgery for nonpalpable hypoechoic testicular lesions. Urology 2006; 68:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/16\">",
"      Richie JP, Garnick MB, Finberg H. Computerized tomography: how accurate for abdominal staging of testis tumors? J Urol 1982; 127:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/17\">",
"      Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992; 10:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/18\">",
"      Gels ME, Hoekstra HJ, Sleijfer DT, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995; 13:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/19\">",
"      Nicolai N, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. J Urol 1995; 154:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/20\">",
"      Socinski MA, Stomper PC. Radiologic evaluation of nonseminomatous germ cell tumor of the testis. Semin Urol 1988; 6:203.",
"     </a>",
"    </li>",
"    <li>",
"     de Wit M, Hartmann M, Kotzerke J, et al. [18F]-FDG-PET in clinical stageI and II non-seminomatous germ cell tumors: first results of the german multicenter trial (abstract). J Clin Oncol 2005; 23:379s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/22\">",
"      Huddart RA, O'Doherty MJ, Padhani A, et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 2007; 25:3090.",
"     </a>",
"    </li>",
"    <li>",
"     Bower M, Rustin GJ. Serum tumor markers and their role in monitoring germ cell cancers of the testis. In: Textbook of Genitourinary Oncology, 2nd, Vogelzang NJ, Scardino PT, Shipley,WU, Coffey, DS (Eds), Lippincott, Williams and Wilkins, Philadelphia 2000. p.931.",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 5th, Fleming ID, Cooper JS, Henson DE, et al (Eds), Lippincott-Raven, Philadelphia 1997. p.225.",
"    </li>",
"    <li>",
"     Karpathakis A, Jamal-Hanjani M, Kwan A, et al. Testicular germ cell tumors with bony metastases: Diagnosis, management, and outcomes (a case series). J Clin Oncol 30, 2012 (suppl 5; abstr 343).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/26\">",
"      Birch R, Williams S, Cone A, et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 1986; 4:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/27\">",
"      Samuels ML, Johnson DE, Holoye PY. Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia. Cancer Chemother Rep 1975; 59:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/28\">",
"      Bosl GJ, Geller NL, Cirrincione C, et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983; 43:3403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/29\">",
"      Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995; 13:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/30\">",
"      Hoskin P, Dilly S, Easton D, et al. Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 1986; 4:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/31\">",
"      International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/32\">",
"      Foss&aring; SD, Kravdal O. Fertility in Norwegian testicular cancer patients. Br J Cancer 2000; 82:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/33\">",
"      Gordon W Jr, Siegmund K, Stanisic TH, et al. A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group. Int J Radiat Oncol Biol Phys 1997; 38:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/34\">",
"      Ohl DA, Sonksen J. What are the chances of infertility and should sperm be banked? Semin Urol Oncol 1996; 14:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/35\">",
"      Panidis D, Rousso D, Stergiopoulos K, et al. The effect of testicular seminoma in semen quality. Eur J Obstet Gynecol Reprod Biol 1999; 83:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/36\">",
"      Hallak J, Kolettis PN, Sekhon VS, et al. Sperm cryopreservation in patients with testicular cancer. Urology 1999; 54:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/37\">",
"      Carroll PR, Whitmore WF Jr, Herr HW, et al. Endocrine and exocrine profiles of men with testicular tumors before orchiectomy. J Urol 1987; 137:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/38\">",
"      Petersen PM, Skakkebaek NE, R&oslash;rth M, Giwercman A. Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. J Urol 1999; 161:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/39\">",
"      Sibert L, Rives N, Rey D, et al. Semen cryopreservation after orchidectomy in men with testicular cancer. BJU Int 1999; 84:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/40\">",
"      Jacobsen R, Bostofte E, Engholm G, et al. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ 2000; 321:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/41\">",
"      Agarwal A, Tolentino MV Jr, Sidhu RS, et al. Effect of cryopreservation on semen quality in patients with testicular cancer. Urology 1995; 46:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/42\">",
"      Hartmann JT, Albrecht C, Schmoll HJ, et al. Long-term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer 1999; 80:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/43\">",
"      Turek PJ, Lowther DN, Carroll PR. Fertility issues and their management in men with testis cancer. Urol Clin North Am 1998; 25:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41720/abstract/44\">",
"      Nalesnik JG, Sabanegh ES Jr, Eng TY, Buchholz TA. Fertility in men after treatment for stage 1 and 2A seminoma. Am J Clin Oncol 2004; 27:584.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2980 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-AF04787F30-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41720=[""].join("\n");
var outline_f40_47_41720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Testicular examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H137129371\">",
"      - Cryptorchidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Scrotal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H137129438\">",
"      MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PET scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serum tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radical inguinal orchiectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Retroperitoneal lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H607300785\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSTIC CLASSIFICATION OF ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Good prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intermediate prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Poor prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CRYOPRESERVATION OF SPERM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2980\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2980|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/42/44715\" title=\"table 1\">",
"      Testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/13/36061\" title=\"table 2\">",
"      TNM staging testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/34/21037\" title=\"table 3\">",
"      Stage group testicular CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3334?source=related_link\">",
"      Active surveillance following orchiectomy for stage I testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13706?source=related_link\">",
"      Effects of cytotoxic agents on gonadal function in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/9/6294?source=related_link\">",
"      Epidemiology and pathogenesis of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2457?source=related_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44360?source=related_link\">",
"      Evaluation of the acute scrotum in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12871?source=related_link\">",
"      Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24645?source=related_link\">",
"      Patient information: Testicular cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9096?source=related_link\">",
"      Poorly differentiated cancer from an unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/63/33782?source=related_link\">",
"      Radical inguinal orchiectomy for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9272?source=related_link\">",
"      Retroperitoneal lymph node dissection in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24852?source=related_link\">",
"      Risk stratification of metastatic testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22567?source=related_link\">",
"      Treatment of stage I seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/45/22230?source=related_link\">",
"      Treatment of stage II seminoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_47_41721="Care of the umbilicus and management of umbilical disorders";
var content_f40_47_41721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Care of the umbilicus and management of umbilical disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41721/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41721/contributors\">",
"     Debra L Palazzi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41721/contributors\">",
"     Mary L Brandt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41721/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41721/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41721/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41721/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41721/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/47/41721/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;At birth, the umbilical cord, which provided vascular flow between the fetus and placenta, is clamped and cut. Within the first week of life, the remnant umbilical cord stump separates from the neonate creating the umbilicus (commonly referred to as the navel).",
"   </p>",
"   <p>",
"    Infection, hernia, granulomas, and congenital anomalies can occur in the umbilicus and are more commonly seen in infancy.",
"   </p>",
"   <p>",
"    The care of the umbilical cord and clinical problems associated with the umbilicus will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Umbilical cord",
"    </span>",
"    &nbsp;&mdash;&nbsp;The umbilical cord contains two arteries and one vein, which are surrounded and supported by gelatinous tissue called Wharton's jelly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Thickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;At birth, the average diameter and circumference of the umbilical cord in a normal term infant is 1.5 and 3.6 cm, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Both thick and thin cords are associated with increased risk of significant pathology. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Newborn examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Length",
"    </span>",
"    &nbsp;&mdash;&nbsp;The umbilical cord lengthens through gestation from a mean of 32 cm at 20 weeks gestation to 60 cm at term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/3\">",
"     3",
"    </a>",
"    ]. Within each gestational age group, the length is highly variable. As an example, in term infants born between 40 and 41 weeks gestation, the umbilical length varies from 35 to 80 cm.",
"   </p>",
"   <p>",
"    Although the cord length has no effect on fetal blood flow, both long and short cords are associated with adverse effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With longer umbilical cords, there is an increased risk of cord knots, nuchal cords (umbilical cord coiled around the neck of the fetus at the time of birth), cord prolapse, thrombi, and fetal demise. Short umbilical cords (&lt;35 cm) have been associated with placental abruption and developmental abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40840?source=see_link&amp;anchor=H4#H4\">",
"       \"Gross examination of the placenta\", section on 'Umbilical cord'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Short cords with no coiling are associated with poor fetal growth and decreased activity, which can occur in fetuses with severe neural and musculoskeletal abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Coiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the umbilical vessels are longer than the cord itself, twisting and bending of the vessels within the cord is common. Coiling of the umbilical cord is thought to protect the blood supply from mechanical disruption.",
"   </p>",
"   <p>",
"    Although the mechanism of coiling is unknown, both excessive hypocoiling and hypercoiling are associated with adverse perinatal outcomes. This was illustrated in a review of 885 infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/6\">",
"     6",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with umbilical cord index (number of coils divided by the length of cord in cm) below the 10th percentile were more likely to be premature, have a trisomic genetic abnormality, or have a single umbilical artery. In addition, there was an increased risk of fetal death.",
"     </li>",
"     <li>",
"      Infants with umbilical cord index above the 90th percentile were more likely to have perinatal asphyxia, umbilical arterial pH below 7.05, trisomic genetic abnormality, single umbilical artery, or be small for gestational age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Umbilicus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The umbilicus is composed of three distinct anatomic areas (",
"    <a class=\"graphic graphic_figure graphicRef74008 \" href=\"mobipreview.htm?5/25/5524\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mamelon &mdash; Area of central depression",
"     </li>",
"     <li>",
"      Cicatrix &mdash; Dense scar, which marks the intersection of fetal intra- and extra-embryonic mesoderm",
"     </li>",
"     <li>",
"      Cushion &mdash; Slightly raised margin around the mamelon and cicatrix",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combination of these three features result in more than 60 reported normal anatomical variants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The umbilicus is located in the midline at the level of the iliac crest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/8\">",
"     8",
"    </a>",
"    ]. The umbilicus is lower than usual in patients with achondroplasia, displaced superiorly during pregnancy, and inferiorly by ascites (Tanyol's sign) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormal umbilical appearance or location may be a finding in a genetic disorder such as those illustrated by the following examples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Robinow's syndrome, a rare inherited disorder of short stature and macrocephaly with frontal bossing, the umbilicus is high, flat, and poorly epithelialized.",
"     </li>",
"     <li>",
"      In Axenfeld-Rieger syndrome, a rare genetic disorder that includes malformations of the anterior chamber of the eye and teeth, the umbilicus is broad and prominent with a large stalk and redundant skin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41463?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of glaucoma in infants and children\", section on 'Anterior segment dysgenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In Aarskog-Scott syndrome, a disorder of multiple limb and genital abnormalities with short stature, the umbilicus can be either flat with radiating branches of the cicatrix or a deep longitudinally oriented ovoid depression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An appreciation of the embryology of the umbilical cord helps in understanding the pathogenesis of congenital umbilical anomalies.",
"   </p>",
"   <p>",
"    In the fourth week of embryogenesis, the flat trilaminar embryonic disc folds and becomes a cylindrical C-shaped fetus, which narrows the opening of the yolk sac to the embryo (",
"    <a class=\"graphic graphic_figure graphicRef57342 \" href=\"mobipreview.htm?38/8/39046\">",
"     figure 2",
"    </a>",
"    ). This narrowed opening contains the umbilical vessels, the urachus, and the omphalomesenteric duct. The omphalomesenteric duct connects the yolk sac to the developing gut. At the same time, the allantois, a diverticulum of the caudal hindgut, forms and becomes the urachus. The urachus connects the developing genitourinary tract (bladder) to the umbilicus.",
"   </p>",
"   <p>",
"    In normal development, both the omphalomesenteric duct and urachus involute. After involution, no remnant of the omphalomesenteric duct persists but, in contrast, a remnant of the urachus persists and can be seen in some individuals extending from the bladder to the umbilicus in the preperitoneal midline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     UMBILICAL CORD AT BIRTH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Newborn examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;After delivery, the clamped umbilical cord of the newborn infant is inspected for its general appearance including the presence of discharge or a single umbilical artery.",
"   </p>",
"   <p>",
"    A thick cord may contain bowel, embryonic remnants (omphalomesenteric duct or urachal elements), or a vascular anomaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Thus, evaluation of infants with a thick cord should include histologic examination of the umbilical stump and consideration of ultrasonography to detect embryonic remnants or bowel involvement, and cystourography to detect urologic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/13\">",
"     13",
"    </a>",
"    ]. Thin cords less than 1 cm in circumference are associated with infants who are postdates or small for gestational age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Single umbilical artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single umbilical artery (SUA) is present in 0.2 to 0.6 percent of live births, occurring more frequently in small for gestational age and premature infants, and twins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In infants with SUA, there is an increased rate of chromosomal and other congenital anomalies. Multiple studies have shown that 20 to 30 percent of neonates with SUA had major structural anomalies, often involving multiple organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. The most commonly affected organs are the heart, gastrointestinal tract, and the central nervous system.",
"   </p>",
"   <p>",
"    SUA is an isolated finding in the remaining 70 to 80 percent of infants. In these neonates, there is an increased incidence of occult renal anomalies. This was illustrated in a meta-analysis of seven studies that included 204 infants who were screened for renal malformations either by ultrasonography or intravenous pyelography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/16\">",
"     16",
"    </a>",
"    ]. A renal anomaly was detected in 16 percent of these infants. However, the abnormality was persistent and considered clinically significant in only one-half (8 percent). Vesicoureteral reflux (VUR) of grade 2 or higher was the major renal finding and was found in 3 percent of the total study population.",
"   </p>",
"   <p>",
"    A subsequent prospective study of infants born over six years at a single English institution identified 137 of 33,057 live-born infants",
"    <span class=\"nowrap\">",
"     (4.1/1000)",
"    </span>",
"    with SUA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/18\">",
"     18",
"    </a>",
"    ]. Eight infants had major congenital anomalies (eg, complex heart disease, cloaca, anorectal, abnormal karyotypes, cystic adenomatoid malformation, and multiple anomalies), and three had minor anomalies (eg, preauricular skin tag, preaxial polydactyly, and syndactyly). Infants with SUA had a lower gestational age and were more likely to be small for gestational age than control infants with two umbilical arteries. In infants with isolated SUA, 117 of the 122 infants who underwent renal ultrasonography had normal scans. Two infants had significant renal abnormalities: a hypodysplastic kidney, which was already detected prenatally, and a single kidney. Renal anomalies were more common among infants with isolated SUA compared to the control cohort (4.1 versus 0.9 percent). There was no statistical difference in the risk of significant clinical renal abnormalities defined but the authors (1.6 versus 0.4 percent).",
"   </p>",
"   <p>",
"    Similar results were seen in a study of 65 infants with SUA from the Netherlands that reported a clinically insignificant renal abnormality in one of 57 cases of isolated SUA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Opinions differ on the value of screening these infants for renal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. However, based upon currently available data, we do",
"    <strong>",
"     not",
"    </strong>",
"    perform further imaging for healthy term infants with an isolated SUA, as there is a low likelihood of a renal or urological abnormality.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cord care",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developed countries, where aseptic care is routine in the clamping and cutting of the umbilical cord, it is unclear whether additional topical care is needed to prevent omphalitis. This was illustrated in a meta-analysis of 10 studies from developed countries that compared dry cord care to a number of different antiseptic topical agents including triple dye, alcohol,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9795?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/9/44180?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef76549 \" href=\"mobipreview.htm?12/26/12716\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/20\">",
"     20",
"    </a>",
"    ]. There was no difference between dry cord care and any of these agents in the incidence of death or omphalitis. Bacterial colonization by Staphylococcus aureus was reduced with the use of triple dye, silver",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/7/39029?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    , and chlorhexidine.",
"   </p>",
"   <p>",
"    In developing countries, where aseptic delivery care is not readily available, antiseptic topical care of the umbilicus reduces the risk of omphalitis and neonatal mortality. Community-based, cluster-randomized trials performed in Nepal, Pakistan and Bangladesh demonstrated using 4 percent",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/9/44180?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    compared with either dry or",
"    <span class=\"nowrap\">",
"     soap/water",
"    </span>",
"    for cord care reduced the incidence of omphalitis and neonatal mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inappropriate cord care also can increase umbilical infections. As an example, neonatal tetanus has been reported as a complication of inappropriate application of cow dung or bentonite clay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=see_link&amp;anchor=H13#H13\">",
"     \"Tetanus\", section on 'Neonatal tetanus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, the care of the umbilical cord in reducing the risk of infection is dependent upon the quality of care at delivery and postnatally. In a setting of low medical resources with a high risk of omphalitis, the use of antiseptic cord care is a beneficial and inexpensive option that reduces neonatal morbidity and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cord separation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cord separation normally occurs one week after birth. This was illustrated in a subsequent study of the previously mentioned Nepalese community-based trial that demonstrated a mean umbilical separation time of 4.2, 4.3, and 5.3 days in infants who received dry care,",
"    <span class=\"nowrap\">",
"     soap/water,",
"    </span>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/9/44180?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    umbilical cord care, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/25\">",
"     25",
"    </a>",
"    ]. Longer time periods to separation are associated with other antiseptic topical agents used in cord care including salicylate sugar powder (mean 5.6 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/26\">",
"     26",
"    </a>",
"    ], 70 percent alcohol (mean 16.9 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/26\">",
"     26",
"    </a>",
"    ], and triple dye (range 3 to 8 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Umbilical cord separation is initiated by thrombosis and contraction of the umbilical vessels followed by phagocyte-mediated tissue breakdown and epithelialization of the cord stump. Stump colonization by bacteria derived from the maternal genital tract or environment occurs soon after birth, and in some cases can cause umbilical infections. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Omphalitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Delayed separation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed cord separation does not have a specific definition, primarily because of the variation in normal cord separation. In general, any cord that persists after three weeks probably represents delayed cord separation. Delayed cord separation can be associated with underlying immunodeficiency, infection, or urachal abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/28\">",
"     28",
"    </a>",
"    ]. Neutrophil function should be evaluated in infants with delayed cord separation and signs of umbilical infection because infants with leukocyte adhesion defects often present with these findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22953?source=see_link&amp;anchor=H6#H6\">",
"     \"Leukocyte adhesion deficiency\", section on 'LAD I'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there are no data on the care of cords that fail to separate in the normal time frame of three weeks, these cords usually will separate without intervention eventually. Rubbing alcohol should not be applied to the cord as it may kill bacteria that assist in cord drying and separation. Drying of the cord may be helped by keeping the diaper folded below the cord, thereby exposing the cord to air. In some instances, after the cord has desiccated, it may be removed by a health care provider using a scissor or scalpel by dividing the desiccated tissue just distal to the normal skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OMPHALOMESENTERIC DUCT ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial or complete failure of involution of the omphalomesenteric duct can lead to a spectrum of anomalies in the newborn infant due to varying degrees and location of duct patency (",
"    <a class=\"graphic graphic_figure graphicRef62526 \" href=\"mobipreview.htm?34/30/35300\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete patency results in the omphalomesenteric duct directly connecting the umbilicus to the terminal ileum. This can lead to intestinal drainage from the umbilicus. These infants will often appear to have a \"stoma\" in the umbilicus after cord separation.",
"     </li>",
"     <li>",
"      Persistent tissue at the umbilicus with no intestinal connection results in an umbilical polyp. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Umbilical polyp'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Persistent tissue at the ileum, with no connection to the umbilicus results in Meckel's diverticulum. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29513?source=see_link&amp;anchor=H19#H19\">",
"       \"Diagnostic approach to lower gastrointestinal bleeding in children\", section on 'Meckel's diverticulum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patent midduct with closure at both the umbilical and ileal ends of the omphalomesenteric duct results in an omphalomesenteric duct cyst.",
"     </li>",
"     <li>",
"      Persistent fibrous cord between the umbilicus and the ileum; the intraabdominal fibrous band between the umbilicus and terminal ileum can lead to small bowel obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a case series of 217 children with omphalomesenteric duct anomalies, 85 (39 percent) were symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/29\">",
"     29",
"    </a>",
"    ]. The most common symptoms were rectal bleeding due to Meckel's diverticulum and intestinal obstruction; abdominal pain and bilious umbilical drainage were much less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/29\">",
"     29",
"    </a>",
"    ]. Among the 132 asymptomatic patients, Meckel's diverticulum was incidentally found at laparotomy.",
"   </p>",
"   <p>",
"    Because more than one omphalomesenteric duct anomaly can be present, radiologic evaluation should be performed in patients with an omphalomesenteric duct anomaly. This should include ultrasonography and possibly a Meckel scan (99m technetium pertechnetate, which has an affinity for gastric mucosa). If the results from ultrasonography are uncertain, computed tomography is performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29513?source=see_link&amp;anchor=H19#H19\">",
"     \"Diagnostic approach to lower gastrointestinal bleeding in children\", section on 'Meckel's diverticulum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment is surgical excision of the omphalomesenteric duct remnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     URACHAL ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urachus normally involutes, resulting in a fibrous cord between the umbilicus and the bladder. Disruption of this process can lead to a spectrum of rare anomalies (",
"    <a class=\"graphic graphic_figure graphicRef79324 \" href=\"mobipreview.htm?15/5/15446\">",
"     figure 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete patency results in a patent urachus with free communication between the bladder and the umbilicus. These children generally present with a persistently wet or draining umbilicus, and occasionally with a urinary tract infection.",
"     </li>",
"     <li>",
"      Persistent tissue at the umbilicus with no connection to the bladder results in an umbilical polyp. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Umbilical polyp'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Persistent tissue at the bladder with no connection to the umbilicus results in a bladder diverticulum. Bladder diverticulum can cause ureteral obstruction at the site of bladder insertion.",
"     </li>",
"     <li>",
"      Patent midduct with closure at both the umbilicus and the bladder results in a urachal cyst. The cyst can present as a mass, especially in older children and adults. The cyst may become infected and present with associated signs or symptoms of abdominal pain, erythema, or swelling, usually located below the umbilicus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some patients, the presentation of urachal anomalies is subtle with erythema of the umbilicus with or without drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/31\">",
"     31",
"    </a>",
"    ]. Pain or retraction of the umbilicus during micturition is a rare but specific finding in patients with urachal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a case series of 45 children with urachal anomalies, 19 presented with periumbilical discharge, 15 with umbilical cyst or mass, 10 with abdominal or periumbilical pain, and 1 with dysuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/33\">",
"     33",
"    </a>",
"    ]. Urachal abnormalities included urachal sinus in 22 children, urachal cyst in 16, and patent urachus in 7.",
"   </p>",
"   <p>",
"    Urachal anomalies may not be detected until adulthood. In one case series of 176 patients, which included 130 adult patients, the most common findings at presentation for affected adults were hematuria (49 percent), pain (27 percent), dysuria (12 percent), or the diagnosis was made incidentally during surgery for another disorder (18 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/34\">",
"     34",
"    </a>",
"    ]. In adults, half of the pathologic specimens demonstrated evidence of adenocarcinoma. In contrast, no child had evidence of malignancy.",
"   </p>",
"   <p>",
"    In a patient suspected of having a urachal anomaly, ultrasonography is useful in diagnosis of urachal cyst [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/35\">",
"     35",
"    </a>",
"    ], and a sinogram (radiocontrast injection into urachal opening) is diagnostic for patent urachus and urachal sinus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/33\">",
"     33",
"    </a>",
"    ]. Because of associated genitourinary abnormalities, a renal ultrasound and voiding cystourethrogram should be obtained in all patients with urachal anomalies.",
"   </p>",
"   <p>",
"    The treatment of urachal anomalies is surgical excision of the entire lesion including a cuff of the normal bladder. Complete excision is important to eliminate the risk of future urachal adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40409?source=see_link&amp;anchor=H13#H13\">",
"     \"Nonurothelial bladder cancer\", section on 'Urachal adenocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     UMBILICAL HERNIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fascial opening (umbilical ring) exists to allow passage of the umbilical vessels from the mother into the fetus. After birth, this fascial opening closes spontaneously with continued growth of the rectus abdominis muscles toward one another. Ultimately, complete closure occurs with fusion of the peritoneal and fascial layers within a small fibrous area of the umbilicus. Closure of the umbilical ring is complete in almost all children by 5 years of age, but may be slower in black children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although closure is complete in almost all children by five years of age, closure can continue in older children as manifested by lower rates of umbilical hernia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. This was illustrated in a cross-sectional study of 665 black children between 4 and 11 years of age that demonstrated the following rates of umbilical hernia based upon age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      4 to 5 years of age (n = 51) &mdash; 14 percent",
"     </li>",
"     <li>",
"      6 to 7 years of age (n = 142) &mdash; 4 percent",
"     </li>",
"     <li>",
"      8 to 9 years of age (n = 221) &mdash; 3 percent",
"     </li>",
"     <li>",
"      10 to 11 years of age (n = 251) &mdash; 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Umbilical herniation in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of abdominal hernias\", section on 'Umbilical hernia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spontaneous closure is less likely to occur in patients who have an opening that is greater than 1.5 cm, a significant amount of protruding skin, are older, or have an underlying predisposing condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/32,39\">",
"     32,39",
"    </a>",
"    ]. Umbilical hernias are frequently seen in patients with Ehlers-Danlos [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/40\">",
"     40",
"    </a>",
"    ], Beckwith-Wiedemann syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/39\">",
"     39",
"    </a>",
"    ], Down syndrome, mucopolysaccharidoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/41\">",
"     41",
"    </a>",
"    ], hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/42\">",
"     42",
"    </a>",
"    ], or trisomy 18. Increased intraabdominal pressure from ascites or peritoneal dialysis also can prevent closure of the umbilical ring resulting in herniation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the vast majority of pediatric patients with umbilical hernias are asymptomatic, in rare cases the hernia can interfere with feeding, especially in young infants with hernias that contain bowel.",
"   </p>",
"   <p>",
"    Umbilical hernias are detected during the newborn abdominal examination, particularly when there is increased intraabdominal pressure from crying. Umbilical hernias are easily reduced even if they are quite large, and the borders of the fascial defects can be palpated through the skin. The fascial defect, not the degree of protrusion, is most indicative of whether spontaneous closure will occur. It is important to differentiate umbilical hernias from the less common abdominal wall (also called ventral or supraumbilical) hernias that do not close spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children, umbilical hernias rarely become incarcerated (inability to be reduced by manipulation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/45\">",
"     45",
"    </a>",
"    ] or strangulated (vascular compromise of the contents of an incarcerated hernia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/46\">",
"     46",
"    </a>",
"    ], or even more rarely rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the natural course of the umbilical ring is eventual closure, most umbilical hernias will spontaneously resolve. In general, asymptomatic children with an umbilical ring that continues to decrease can be observed. Surgical intervention is required only in a minority of patients.",
"   </p>",
"   <p>",
"    Incarcerated umbilical hernia in children is an absolute indication for surgical repair to avoid strangulation. Children with large, proboscoid (trunk-like) hernias (",
"    <a class=\"graphic graphic_picture graphicRef63270 \" href=\"mobipreview.htm?19/29/19921\">",
"     picture 1",
"    </a>",
"    ) without any decrease in the size of the umbilical ring defect over the first two years of life, generally require surgery, because their hernias will fail to close spontaneously. Other relative indications for surgical repair include defects that cease decreasing in size, are symptomatic, or create significant behavioral problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     UMBILICAL MASSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilical masses in the neonate include umbilical granuloma, polyp, or ectopic tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Umbilical granuloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates, umbilical granuloma is a common abnormality and is the most common cause of an umbilical mass. It is a soft, moist, pink, pedunculated, friable lesion of granulation tissue that varies in size from 3 to 10 mm in length (",
"    <a class=\"graphic graphic_picture graphicRef58481 \" href=\"mobipreview.htm?37/24/38286\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Umbilical granuloma forms in the first few weeks of life from excess tissue that persists at the base of the umbilicus after cord separation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/47\">",
"     47",
"    </a>",
"    ]. Granuloma formation is more likely to occur when there is inflammation of the umbilical cord usually due to infection, which also delays cord separation.",
"   </p>",
"   <p>",
"    Umbilical granuloma is most often detected after the cord has separated because of persistent drainage of serous or serosanguinous fluid or moisture around the umbilicus.",
"   </p>",
"   <p>",
"    The most common treatment for umbilical granuloma is topical 75 percent",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/46/20194?source=see_link\">",
"     silver nitrate",
"    </a>",
"    , usually applied by a wooden applicator with premounted silver nitrate. The lesion is treated once or twice a week for several weeks, but generally only a few applications are required for successful treatment. Caution should be exercised in applying silver nitrate because it can cause chemical burns or staining of the surrounding skin.",
"   </p>",
"   <p>",
"    In cases that fail to respond to topical",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/46/20194?source=see_link\">",
"     silver nitrate",
"    </a>",
"    , ligation can be performed in the office without discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/48\">",
"     48",
"    </a>",
"    ]. Before ligation, the umbilicus should be carefully examined to rule out other causes of umbilical masses, such as umbilical polyp. Failure of the granuloma to resolve with ligation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    silver nitrate should also increase the suspicion that the lesion is actually an umbilical polyp.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Umbilical polyp",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilical polyps are firm masses comprised of intestinal epithelium or uroepithelium, which are omphalomesenteric ductal or urachal embryologic remnants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Umbilical polyps are rare and often larger than granulomas, do not respond to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/46/20194?source=see_link\">",
"     silver nitrate",
"    </a>",
"    therapy, and require surgical excision.",
"   </p>",
"   <p>",
"    If there is any question of whether an umbilical mass in a neonate is a polyp or granuloma, histopathologic evaluation of the lesion should be performed. If a polyp is diagnosed, further evaluation for associated embryologic anomalies (eg, Meckel's diverticulum) should be performed. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Omphalomesenteric duct anomalies'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Urachal anomalies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Ectopic tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic tissue in the umbilical cord is a rare lesion that presents as a solid mass. Ectopic tissue can include pancreas, which most likely arises from growth of pluripotent cells derived from the omphalomesenteric duct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/32,51\">",
"     32,51",
"    </a>",
"    ], or liver, which probably results from mechanical entrapment as the umbilical ring closes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/32,52\">",
"     32,52",
"    </a>",
"    ]. Surgical excision is required for its removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Older children and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilical masses in older children and adults are uncommon. Both benign and malignant umbilical tumors have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign lesions include hamartomas, pyogenic granulomas, nevi, inclusion cysts, hemangiomas, dermatofibromas, neurofibromas, granular cell tumors, desmoid tumors, and lipomas.",
"     </li>",
"     <li>",
"      Primary malignancies are rare and include melanoma, urachal adenocarcinoma, squamous cell carcinoma, and basal cell carcinoma.",
"     </li>",
"     <li>",
"      Metastatic lesions have been reported from many primary sources (eg, stomach, pancreas, endometrium, ovary, cervix, colon, small bowel, gallbladder, prostate, lung, and breast). Metastatic lesions to the umbilicus are called \"Sister Mary Josephs node\", named after the nun who worked with Dr. William Mayo, the surgeon who developed the surgical approach to umbilical hernia repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other umbilical lesions include omphalitis, which result from lint accumulation in the umbilicus that become \"ossified\". These lesions are often hard and black, and thus can be misdiagnosed as a melanoma. In addition, keloid formation within or near the umbilicus can occur and mimic a primary tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OTHER ABNORMALITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Appendicoumbilical fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appendicoumbilical fistula is rare and appears to occur in two settling: during development with entrapment of the appendix in the closing umbilical ring; and after a perforated appendicitis. The presenting manifestation is drainage of stool from the umbilicus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Enteric fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteric fistula to the umbilicus has been reported in patients with Crohn's disease or following surgery for tuberculous peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/8,54\">",
"     8,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24693?source=see_link\">",
"     \"Clinical manifestations of Crohn's disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     UMBILICAL INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilical infections, which can progress to systemic infections, occur primarily in the newborn because of the following predisposing factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediately following birth, the umbilicus becomes colonized with a diverse flora of microorganisms. Staphylococcal species and other gram-positive cocci are present within hours, and enteric organisms follow shortly thereafter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/55-57\">",
"       55-57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Devitalized tissues of the umbilical cord stump provide an excellent growth medium for bacteria.",
"     </li>",
"     <li>",
"      The thrombosed blood vessels within the umbilical cord stump provide an entry for microorganisms into the bloodstream of the neonates potentially leading to sepsis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Omphalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Omphalitis is an infection of the umbilicus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surrounding tissues. It is predominantly a disease of the neonate and is characterized by purulent discharge from the umbilical cord stump with surrounding induration, erythema, and tenderness (",
"    <a class=\"graphic graphic_picture graphicRef63960 graphicRef71634 \" href=\"mobipreview.htm?26/17/26898\">",
"     picture 3A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50750 \" href=\"mobipreview.htm?36/28/37327\">",
"     picture 4",
"    </a>",
"    ). Umbilical stump bleeding may occur with omphalitis as a result of delayed obliteration of the umbilical vessels.",
"   </p>",
"   <p>",
"    Omphalitis is rare in developed countries with a reported incidence of 0.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/58\">",
"     58",
"    </a>",
"    ]. However, in the developing world, the estimated incidence is as high as 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the newborn, risk factors for the development of omphalitis include low birth-weight, prolonged labor, prolonged rupture of membranes or maternal infection, non-sterile delivery, umbilical catheterization, and home birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Improper cord care also increases the risk of omphalitis, such as cultural application of cow dung. Abnormalities of the immune system, such as defects in leukocyte adhesion, neutrophil or natural killer lymphocyte function, and interferon production, can contribute to the development of omphalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/60,62\">",
"     60,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic signs, including lethargy, fever, irritability, and poor feeding are suggestive of more severe infection or complication. The most common complication of omphalitis is sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/61\">",
"     61",
"    </a>",
"    ]. Other complications include septic umbilical arteritis, portal vein thrombosis, liver abscess, peritonitis, intestinal gangrene, small bowel evisceration, necrotizing fasciitis, and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/12,55\">",
"     12,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among infants with omphalitis, mortality rate is estimated between 7 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/63\">",
"     63",
"    </a>",
"    ]. Male sex, prematurity, septic delivery (including unplanned home delivery), and abnormal temperature are reported risk factors for poor prognosis in infants with omphalitis. However, data are limited and firm conclusions cannot be drawn regarding the role of these factors in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/63\">",
"     63",
"    </a>",
"    ]. Although rare, the development of necrotizing fasciitis is associated with a higher mortality rate. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Necrotizing fasciitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Omphalitis is a polymicrobial infection. Historically, the predominant pathogens included Staphylococcus aureus, Streptococcus pyogenes, and gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. However, with the routine use of antistaphylococcal cord care regimens, gram-negative infections of the umbilicus have increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/61,66\">",
"     61,66",
"    </a>",
"    ]. In addition, anaerobic bacteria such as Bacteroides fragilis, Clostridium perfringens, and Clostridium tetani can contribute to umbilical infections, especially in infants born to mothers with chorioamnionitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/67\">",
"     67",
"    </a>",
"    ]. In these infants, foul-smelling umbilical drainage is a typical finding.",
"   </p>",
"   <p>",
"    Whenever possible, cultures of the discharge should be obtained prior to the start of antibiotic therapy. Blood and cerebrospinal fluid cultures should also be obtained in infants with systemic signs (eg, fever) as they are more likely to be septic or develop meningitis.",
"   </p>",
"   <p>",
"    Antibiotic treatment of omphalitis is required and is directed against gram-positive and gram-negative organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/61\">",
"     61",
"    </a>",
"    ]. In the neonate, parenterally administered antistaphylococcal penicillin and aminoglycoside agents are administered to decrease the risk of significant complications, such as sepsis and necrotizing fasciitis. In communities with a high prevalence of methicillin-resistant S. aureus,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be used in place of an antistaphylococcal penicillin.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     Clindamycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    also has been suggested in the treatment of infants with omphalitis for anaerobic coverage, especially those with foul smelling discharge or born to mothers with amnionitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/47,67\">",
"     47,67",
"    </a>",
"    ]. We typically administer a 10-day course of intravenous antibiotics in neonatal patients, which can be modified dependent upon the patient's clinical response and whether complications develop.",
"   </p>",
"   <p>",
"    In older patients, similar antibiotic coverage can be administered orally, and is modified based on culture results and clinical improvement.",
"   </p>",
"   <p>",
"    Mild discharge from the umbilical stump in the absence of inflammatory signs may be a normal occurrence, even when accompanied by some odor. Some clinicians treat infants with minimal symptoms with topical applications such as alcohol,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/63/33779?source=see_link\">",
"     bacitracin",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/18/43300?source=see_link\">",
"     mupirocin",
"    </a>",
"    . However, there is no evidence of efficacy of this practice or on the efficacy of the administration of oral antibiotics in these infants.",
"   </p>",
"   <p>",
"    In the developing world, antiseptic topical care of the umbilicus stump reduces the risk of omphalitis and neonatal mortality. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Cord care'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Necrotizing fasciitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal necrotizing fasciitis is a rare complication of omphalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/47\">",
"     47",
"    </a>",
"    ]. It is a polymicrobial infection of the skin, subcutaneous fat, and superficial and deep fascia. It is characterized by rapid spread of infection and inflammation, and signs of systemic toxicity. Infants presenting with fasciitis have a high incidence of bacteremia, shock, and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/47,61\">",
"     47,61",
"    </a>",
"    ]. Reported mortality rates are as high as 60 to 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/32,68\">",
"     32,68",
"    </a>",
"    ]. Prompt aggressive surgery, broad-spectrum antibiotics, and supportive care are critical in the management of necrotizing fasciitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41721/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Funisitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Funisitis is inflammation of the umbilical cord that occurs with chorioamnionitis (in response to intraamniotic infection). Funisitis involves only the external surface of the cord and Wharton's jelly and does not involve the umbilical vessels. The inflammatory cells seen migrating through the fetal vessels in the cord are evidence of a fetal response to an external pathologic factor that is maternal in origin.",
"   </p>",
"   <p>",
"    Funisitis does not involve the umbilical stump. Necrotizing funisitis occurs with long-standing infection and is characterized by inflammatory debris and calcification of umbilical cord tissues. Infants with funisitis can be born healthy, but should be treated with broad-spectrum antibiotics (similar to the regimen used for omphalitis) for a minimum of seven days of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=see_link\">",
"     \"Histopathology of placental disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4089?source=see_link\">",
"     \"Placental infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Infected umbilical piercing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infected umbilical piercings are characterized by purulent discharge from the pierced skin with surrounding induration, erythema, and tenderness.",
"   </p>",
"   <p>",
"    Local wound care and topical antibiotics usually are sufficient for resolution of local infection in older children, and it is usually not necessary to remove the device. When infection persists or occurs in a child younger than 1 year of age, oral antibiotics aimed at treating S. aureus and S. pyogenes are recommended. Neonates with an infected umbilicus require an evaluation for sepsis and intravenous antibiotics. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Omphalitis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10282?source=see_link\">",
"     \"Body piercing in adolescents and young adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/22/43361?source=see_link\">",
"       \"Patient information: Meckel&rsquo;s diverticulum (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At delivery, the clamped umbilical cord is inspected to detect any alterations of the normal characteristics (thickness, length, and coiling) of the cord, which can be associated with an increase risk of significant pathology in the newborn infant. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Umbilical cord'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the newborn, the most common cause of umbilical drainage is umbilical granuloma. Other causes of umbilical drainage include omphalitis and umbilical anomalies, such as omphalomesenteric duct and urachal abnormalities. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Newborn examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Umbilical granuloma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Other abnormalities'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Omphalitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A single umbilical artery (SUA) is seen in 0.2 to 0.6 percent of live births, of whom 20 to 30 percent will have other major structural anomalies. Although infants with an isolated finding of SUA have an increased risk of occult renal anomalies, these are generally not clinically significant. As a result, in patients with isolated SUA, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      to perform a screening renal ultrasonography (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Single umbilical artery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the neonate, umbilical cord care is directed toward reducing the risk of umbilical infection and is dependent upon the quality of care at delivery and postnatally. In developing countries where there is an increased risk for omphalitis, we recommend antiseptic topical cord care (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/9/44180?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cord care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Umbilical cord separation usually occurs within the first week of life. Delayed cord separation is associated with underlying immunodeficiency, infection, or urachal anomaly. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cord separation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Umbilical hernias are commonly found in children, generally easily reducible, and usually resolve without intervention over the first five years of life. Surgical repair is required in those patients with incarcerated hernia. We suggest surgical repair for patients with large defects (&gt;1.5 cm in diameter) that fail to decrease in size or are symptomatic. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Umbilical granuloma is the most common umbilical mass. It is usually detected after cord separation because of persistent drainage. Topical",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/46/20194?source=see_link\">",
"       silver nitrate",
"      </a>",
"      is most commonly used to treat this lesion. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Umbilical granuloma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Failed embryologic closure of the omphalomesenteric duct results in a range of anomalies including completely patent duct, umbilical polyp, Meckel's diverticulum, omphalomesenteric duct cyst, or intraabdominal fibrous band. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Embryology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Omphalomesenteric duct anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Failed embryologic closure of the urachus results in a range of anomalies including patent urachus, umbilical polyp, bladder diverticulum, or urachal cyst. &nbsp;(See",
"      <a class=\"local\" href=\"#H8\">",
"       'Embryology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Urachal anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Omphalitis, a polymicrobial infection of the umbilicus and surrounding tissue, occurs predominately in the neonate. Complications include sepsis and necrotizing fasciitis, which has a high mortality rate. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Omphalitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Necrotizing fasciitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotic treatment of omphalitis is required and is directed against gram-positive and gram-negative organisms. We suggest initial parenteral administration of antistaphylococcal and aminoglycoside agents as opposed to topical or oral antibiotic therapy in infants with omphalitis to reduce the risk of severe complications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In communities with a high prevalence of methicillin-resistant S. aureus,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      is typically used as an alternative to an antistaphylococcal penicillin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Omphalitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/1\">",
"      Moinian M, Meyer WW, Lind J. Diameters of umbilical cord vessels and the weight of the cord in relation to clamping time. Am J Obstet Gynecol 1969; 105:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/2\">",
"      Patel D, Dawson M, Kalyanam P, et al. Umbilical cord circumference at birth. Am J Dis Child 1989; 143:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/3\">",
"      Naeye RL. Umbilical cord length: clinical significance. J Pediatr 1985; 107:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/4\">",
"      Ananth CV, Oyelese Y, Yeo L, et al. Placental abruption in the United States, 1979 through 2001: temporal trends and potential determinants. Am J Obstet Gynecol 2005; 192:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/5\">",
"      Gilbert-Barness E, Drut RM, Drut R, et al. Developmental abnormalities resulting in short umbilical cord. Birth Defects Orig Artic Ser 1993; 29:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/6\">",
"      de Laat MW, Franx A, Bots ML, et al. Umbilical coiling index in normal and complicated pregnancies. Obstet Gynecol 2006; 107:1049.",
"     </a>",
"    </li>",
"    <li>",
"     Cullen T. Embryology, Anatomy, and Diseases of the Umbilicus Together with Diseases of the Urachus, WB Saunders, Philadephia 1916.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/8\">",
"      Coetzee T. Clinical anatomy of the umbilicus. S Afr Med J 1980; 57:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/9\">",
"      Friedman JM. Umbilical dysmorphology. The importance of contemplating the belly button. Clin Genet 1985; 28:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/10\">",
"      Wildhaber BE, Antonelli E, Pfister RE. The giant umbilical cord. Arch Dis Child Fetal Neonatal Ed 2005; 90:F535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/11\">",
"      Iwasaki I, Yu TJ, Itahashi K, et al. Isolated well-formed intestinal tissue in the umbilical cord. A variant of cyst of omphalomesenteric duct. Acta Pathol Jpn 1986; 36:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/12\">",
"      Ameh EA, Nmadu PT. Major complications of omphalitis in neonates and infants. Pediatr Surg Int 2002; 18:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/13\">",
"      Ueno T, Hashimoto H, Yokoyama H, et al. Urachal anomalies: ultrasonography and management. J Pediatr Surg 2003; 38:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/14\">",
"      Bourke WG, Clarke TA, Mathews TG, et al. Isolated single umbilical artery--the case for routine renal screening. Arch Dis Child 1993; 68:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/15\">",
"      Gornall AS, Kurinczuk JJ, Konje JC. Antenatal detection of a single umbilical artery: does it matter? Prenat Diagn 2003; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/16\">",
"      Thummala MR, Raju TN, Langenberg P. Isolated single umbilical artery anomaly and the risk for congenital malformations: a meta-analysis. J Pediatr Surg 1998; 33:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/17\">",
"      Chow JS, Benson CB, Doubilet PM. Frequency and nature of structural anomalies in fetuses with single umbilical arteries. J Ultrasound Med 1998; 17:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/18\">",
"      Deshpande SA, Jog S, Watson H, Gornall A. Do babies with isolated single umbilical artery need routine postnatal renal ultrasonography? Arch Dis Child Fetal Neonatal Ed 2009; 94:F265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/19\">",
"      de Boom ML, Kist-van Holthe JE, Sramek A, et al. Is screening for renal anomalies warranted in neonates with isolated single umbilical artery? Neonatology 2010; 97:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/20\">",
"      Zupan J, Garner P, Omari AA. Topical umbilical cord care at birth. Cochrane Database Syst Rev 2004; :CD001057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/21\">",
"      Mullany LC, Darmstadt GL, Khatry SK, et al. Topical applications of chlorhexidine to the umbilical cord for prevention of omphalitis and neonatal mortality in southern Nepal: a community-based, cluster-randomised trial. Lancet 2006; 367:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/22\">",
"      Soofi S, Cousens S, Imdad A, et al. Topical application of chlorhexidine to neonatal umbilical cords for prevention of omphalitis and neonatal mortality in a rural district of Pakistan: a community-based, cluster-randomised trial. Lancet 2012; 379:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/23\">",
"      Arifeen SE, Mullany LC, Shah R, et al. The effect of cord cleansing with chlorhexidine on neonatal mortality in rural Bangladesh: a community-based, cluster-randomised trial. Lancet 2012; 379:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Neonatal tetanus--Montana, 1998. MMWR Morb Mortal Wkly Rep 1998; 47:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/25\">",
"      Mullany LC, Darmstadt GL, Khatry SK, et al. Impact of umbilical cord cleansing with 4.0% chlorhexidine on time to cord separation among newborns in southern Nepal: a cluster-randomized, community-based trial. Pediatrics 2006; 118:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/26\">",
"      Pezzati M, Biagioli EC, Martelli E, et al. Umbilical cord care: the effect of eight different cord-care regimens on cord separation time and other outcomes. Biol Neonate 2002; 81:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/27\">",
"      Wilson CB, Ochs HD, Almquist J, et al. When is umbilical cord separation delayed? J Pediatr 1985; 107:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/28\">",
"      Razvi S, Murphy R, Shlasko E, Cunningham-Rundles C. Delayed separation of the umbilical cord attributable to urachal anomalies. Pediatrics 2001; 108:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/29\">",
"      Vane DW, West KW, Grosfeld JL. Vitelline duct anomalies. Experience with 217 childhood cases. Arch Surg 1987; 122:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/30\">",
"      Crankson SJ, Ahmed GS, Palkar V. Patent omphalomesenteric duct of the vermiform appendix in a neonate: congenital appendicoumbilical fistula. Pediatr Surg Int 1998; 14:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/31\">",
"      Rowe PC, Gearhart JP. Retraction of the umbilicus during voiding as an initial sign of a urachal anomaly. Pediatrics 1993; 91:153.",
"     </a>",
"    </li>",
"    <li>",
"     Cilley R. Disorders of the umbilicus. In: Pediatric Surgery, Grosfeld J, O'Neill J, Coran A, Fonkalsrud E (Eds), Mosby Inc., Philadelphia 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/33\">",
"      Cilento BG Jr, Bauer SB, Retik AB, et al. Urachal anomalies: defining the best diagnostic modality. Urology 1998; 52:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/34\">",
"      Ashley RA, Inman BA, Routh JC, et al. Urachal anomalies: a longitudinal study of urachal remnants in children and adults. J Urol 2007; 178:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/35\">",
"      Widni EE, H&ouml;llwarth ME, Haxhija EQ. The impact of preoperative ultrasound on correct diagnosis of urachal remnants in children. J Pediatr Surg 2010; 45:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/36\">",
"      Walker SH. The natural history of umbilical hernia. A six-year follow up of 314 Negro children with this defect. Clin Pediatr (Phila) 1967; 6:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/37\">",
"      Hall DE, Roberts KB, Charney E. Umbilical hernia: what happens after age 5 years? J Pediatr 1981; 98:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/38\">",
"      Meier DE, OlaOlorun DA, Omodele RA, et al. Incidence of umbilical hernia in African children: redefinition of \"normal\" and reevaluation of indications for repair. World J Surg 2001; 25:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/39\">",
"      Katz DA. Evaluation and management of inguinal and umbilical hernias. Pediatr Ann 2001; 30:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/40\">",
"      Colige A, Sieron AL, Li SW, et al. Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene. Am J Hum Genet 1999; 65:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/41\">",
"      Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol 1983; 25:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/42\">",
"      LaFranchi SH, Murphey WH, Foley TP Jr, et al. Neonatal hypothyroidism detected by the Northwest Regional Screening Program. Pediatrics 1979; 63:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/43\">",
"      Tank ES, Hatch DA. Hernias complicating chronic ambulatory peritoneal dialysis in children. J Pediatr Surg 1986; 21:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/44\">",
"      Blumberg NA. Infantile umbilical hernia. Surg Gynecol Obstet 1980; 150:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/45\">",
"      Papagrigoriadis S, Browse DJ, Howard ER. Incarceration of umbilical hernias in children: a rare but important complication. Pediatr Surg Int 1998; 14:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/46\">",
"      Okada T, Yoshida H, Iwai J, et al. Strangulated umbilical hernia in a child: report of a case. Surg Today 2001; 31:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/47\">",
"      Pomeranz A. Anomalies, abnormalities, and care of the umbilicus. Pediatr Clin North Am 2004; 51:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/48\">",
"      Sheth SS, Malpani A. The management of umbilical granulomas with cryocautery. Am J Dis Child 1990; 144:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/49\">",
"      Larralde de Luna M, Cicioni V, Herrera A, et al. Umbilical polyps. Pediatr Dermatol 1987; 4:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/50\">",
"      O��uzkurt P, Kotilo��lu E, Tanyel FC, Hi&ccedil;s&ouml;nmez A. Umbilical polyp originating from urachal remnants. Turk J Pediatr 1996; 38:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/51\">",
"      Avolio L, Cerritello A, Verga L. Heterotopic pancreatic tissue at umbilicus. Eur J Pediatr Surg 1998; 8:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/52\">",
"      Ito F, Ando H, Watanabe Y, et al. An accessory lobe of the liver disturbing closure of the umbilical ring. Pediatr Surg Int 1999; 15:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/53\">",
"      Skinner MA, Grosfeld JL. Inguinal and umbilical hernia repair in infants and children. Surg Clin North Am 1993; 73:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/54\">",
"      Veloso FT, Cardoso V, Fraga J, et al. Spontaneous umbilical fistula in Crohn's disease. J Clin Gastroenterol 1989; 11:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/55\">",
"      Cushing AH. Omphalitis: a review. Pediatr Infect Dis 1985; 4:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/56\">",
"      Rotimi VO, Duerden BI. The development of the bacterial flora in normal neonates. J Med Microbiol 1981; 14:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/57\">",
"      Harnden A, Lennon D. Serious suppurative group A streptococcal infections in previously well children. Pediatr Infect Dis J 1988; 7:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/58\">",
"      McKenna H, Johnson D. Bacteria in neonatal omphalitis. Pathology 1977; 9:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/59\">",
"      Sawardekar KP. Changing spectrum of neonatal omphalitis. Pediatr Infect Dis J 2004; 23:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/60\">",
"      Davies EG, Isaacs D, Levinsky RJ. Defective immune interferon production and natural killer activity associated with poor neutrophil mobility and delayed umbilical cord separation. Clin Exp Immunol 1982; 50:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/61\">",
"      Mason WH, Andrews R, Ross LA, Wright HT Jr. Omphalitis in the newborn infant. Pediatr Infect Dis J 1989; 8:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/62\">",
"      Hayward AR, Harvey BA, Leonard J, et al. Delayed separation of the umbilical cord, widespread infections, and defective neutrophil mobility. Lancet 1979; 1:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/63\">",
"      G&uuml;ven&ccedil; H, Ayg&uuml;n AD, Ya��ar F, et al. Omphalitis in term and preterm appropriate for gestational age and small for gestational age infants. J Trop Pediatr 1997; 43:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/64\">",
"      Chamberlain, JW. Omphalitis in the newborn. J Pediatr 1936; 9:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/65\">",
"      Brook, I. Bacteriology of neonatal omphalitis. J Infect 1982; 5:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/66\">",
"      Faridi MM, Rattan A, Ahmad SH. Omphalitis neonatorum. J Indian Med Assoc 1993; 91:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/67\">",
"      Brook I. Cutaneous and subcutaneous infections in newborns due to anaerobic bacteria. J Perinat Med 2002; 30:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41721/abstract/68\">",
"      Hsieh WS, Yang PH, Chao HC, Lai JY. Neonatal necrotizing fasciitis: a report of three cases and review of the literature. Pediatrics 1999; 103:e53.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5009 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41721=[""].join("\n");
var outline_f40_47_41721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Umbilical cord",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Thickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Length",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Coiling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Umbilicus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      UMBILICAL CORD AT BIRTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Newborn examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Single umbilical artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cord care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cord separation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Delayed separation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OMPHALOMESENTERIC DUCT ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      URACHAL ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      UMBILICAL HERNIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      UMBILICAL MASSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Umbilical granuloma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Umbilical polyp",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Ectopic tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Older children and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OTHER ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Appendicoumbilical fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Enteric fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      UMBILICAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Omphalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Necrotizing fasciitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Funisitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Infected umbilical piercing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5009\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5009|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/25/5524\" title=\"figure 1\">",
"      Normal anatomy umbilicus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/8/39046\" title=\"figure 2\">",
"      Fetal development weeks 3-5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/30/35300\" title=\"figure 3\">",
"      Omphalomesenteric anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/5/15446\" title=\"figure 4\">",
"      Anomalies of the urachus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5009|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/29/19921\" title=\"picture 1\">",
"      Proboscoid hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/24/38286\" title=\"picture 2\">",
"      Umbilical granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/60/33742\" title=\"picture 3A\">",
"      Omphalitis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/1/40991\" title=\"picture 3B\">",
"      Omphalitis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/28/37327\" title=\"picture 4\">",
"      Omphalitis shoelace",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5009|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/26/12716\" title=\"table 1\">",
"      Antiseptics umbilical cord",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/2/10282?source=related_link\">",
"      Body piercing in adolescents and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24693?source=related_link\">",
"      Clinical manifestations of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29513?source=related_link\">",
"      Diagnostic approach to lower gastrointestinal bleeding in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40840?source=related_link\">",
"      Gross examination of the placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=related_link\">",
"      Histopathology of placental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22953?source=related_link\">",
"      Leukocyte adhesion deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40409?source=related_link\">",
"      Nonurothelial bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/22/43361?source=related_link\">",
"      Patient information: Meckel&rsquo;s diverticulum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4089?source=related_link\">",
"      Placental infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_47_41722="Overview of the management of Crohn's disease in children and adolescents";
var content_f40_47_41722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of Crohn's disease in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41722/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41722/contributors\">",
"     Athos Bousvaros, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41722/contributors\">",
"     Alan Leichtner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41722/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41722/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41722/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/47/41722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/47/41722/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/47/41722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five principal components of a treatment program caring for the child with Crohn's disease (CD):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medications",
"     </li>",
"     <li>",
"      Surgery",
"     </li>",
"     <li>",
"      Nutritional rehabilitation",
"     </li>",
"     <li>",
"      Psychiatric support",
"     </li>",
"     <li>",
"      Colorectal cancer screening for older patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, treatment involves a multidisciplinary effort that includes the primary pediatrician, pediatric gastroenterologist, adjunctive pediatric subspecialists (rheumatologist, ophthalmologist, dermatologist, and endocrinologist), surgeon, nutritionist, psychiatrist, gastrointestinal nurse specialist, and social worker.",
"   </p>",
"   <p>",
"    This review primarily focuses on the medical therapy, while the other areas are discussed only briefly. An overview of the clinical manifestations of CD in children and adolescents is presented separately. The diagnosis of CD and differentiation from ulcerative colitis also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24693?source=see_link\">",
"     \"Clinical manifestations of Crohn's disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=see_link\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of appropriate medical therapy depends upon an understanding of the location of the disease, its severity, and the precise complication the patient is experiencing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Location is important because some drugs work only on one section of the bowel. As an example, the enteric-coated steroid",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"       budesonide",
"      </a>",
"      is designed to be effective only in the treatment of disease involving the ileum and ascending colon, while aminosalicylate enemas are effective only in the rectum and left colon.",
"     </li>",
"     <li>",
"      Severity is important because patients with mild disease may respond to weaker agents with a more favorable side effect profile (ie, aminosalicylates or antibiotics).",
"     </li>",
"     <li>",
"      Knowing the exact complications the patient is experiencing also is essential. Perianal fistulae require antibiotic treatment or immunosuppression, intraabdominal abscesses or intestinal strictures generally require surgery, and short",
"      <span class=\"nowrap\">",
"       stature/growth",
"      </span>",
"      failure requires intensive nutritional therapy and the use of steroid sparing agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of the ill patient with active Crohn's disease (CD) typically involves an induction regimen that includes a potent therapy with a more rapid action of onset and the potential for development of more side effects (",
"    <a class=\"graphic graphic_algorithm graphicRef64031 \" href=\"mobipreview.htm?34/41/35486\">",
"     algorithm 1",
"    </a>",
"    ). Once a remission is induced, the patient can be transitioned to a maintenance regimen, typically involving medications with a slower onset of action and fewer side effects (",
"    <a class=\"graphic graphic_table graphicRef65046 \" href=\"mobipreview.htm?28/16/28928\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Approximately 30 percent of children with CD are refractory to or dependent on steroids despite concomitant use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/47/15095?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (also known as 6-mercaptopurine; 6-MP) or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/1\">",
"     1",
"    </a>",
"    ]; a few others are intolerant of thiopurines. These patients may require conversion from thiopurine to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    maintenance therapy, or treatment with a biologic agent such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    . In some cases, surgical resection of a diseased segment of bowel may result in dramatic improvement in disease activity, and avoid the risks of additional immunosuppression (",
"    <a class=\"graphic graphic_algorithm graphicRef75566 \" href=\"mobipreview.htm?40/51/41776\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Refractory'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Specific recommendations based on the severity and location of a patient's disease and his or her response to treatment are discussed below. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Choice of treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Assessment of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of therapy usually is assessed by the clinician's assessment of control of clinical disease activity and supporting laboratory data. However, for clinical trials, a pediatric Crohn's disease activity index (PCDAI) similar to the adult version has been developed. The PCDAI permits the calculation of a numerical score ranging from 0 to 100 based upon a child's well-being, degree of abdominal pain, bowel movements, weight gain, linear growth, physical examination, hematocrit, sedimentation rate, and serum albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A score of 0 to 10 denotes inactive disease, 11 to 30 mild disease activity, and over 30 moderate to severe disease activity. A decrease in PCDAI of &ge;12.5 reflects a clinical response (improvement from",
"    <span class=\"nowrap\">",
"     moderate/severe",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     mild/inactive",
"    </span>",
"    disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/4\">",
"     4",
"    </a>",
"    ]. Another tool used in clinical studies of children with inflammatory bowel disease (IBD) is the IMPACT-35 quality of life scale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our program, we see stable patients approximately every three to four months, consistent with guidelines from the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/7\">",
"     7",
"    </a>",
"    ]. During these visits, we inquire about fatigue, anorexia, growth failure, abdominal pain, diarrhea, extraintestinal symptoms, school attendance, and psychological stress. We measure weight and height and review the interval height velocity. Screening and assessing children for growth failure is an essential component of medical care, and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2794?source=see_link\">",
"     \"Growth failure and poor weight gain in children with inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We examine the patient for signs of abdominal, perianal, dermatologic, and rheumatologic illness. The laboratory assessment usually includes a complete blood count, serum albumin, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and liver aminotransferases (alanine aminotransferase, ALT; and aspartate aminotransferase, AST). There is some evidence that fecal calprotectin levels are correlated with disease activity and can be a useful adjunct to the clinical and laboratory evaluation of the patient, if this test is available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=see_link&amp;anchor=H184210643#H184210643\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\", section on 'Laboratory features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional testing depends on the clinical course of the patient. In some patients, particularly those with active disease or on prolonged glucocorticoid therapy, we measure vitamin D and vitamin B12 levels and assess skeletal health using bone densitometry periodically (",
"    <a class=\"graphic graphic_table graphicRef66288 \" href=\"mobipreview.htm?0/33/541\">",
"     table 2",
"    </a>",
"    ). If ALT and AST are elevated, we check gamma glutamyl transpeptidase (GGTP) to assess for the unusual complication of primary sclerosing cholangitis (PSC); some providers monitor GGTP routinely, along with ALT and AST.",
"   </p>",
"   <p>",
"    If the clinical assessment suggests persistent disease activity, repeat radiographic and endoscopic assessment should be considered. For patients presenting with a flare of colitis, we screen for bacterial causes of colitis, with stool cultures and testing for C. difficile toxin; for those with refractory colitis, we also evaluate for infection with cytomegalovirus (CMV). Indications for and selection among the endoscopic and imaging options is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=see_link&amp;anchor=H20369433#H20369433\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with extensive colitis, we begin surveillance colonoscopy approximately 7 to 10 years after the diagnosis of IBD. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Surveillance for cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For Crohn&rsquo;s disease (CD) affecting the ileum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colon, a variety of medications are available (",
"    <a class=\"graphic graphic_table graphicRef65046 \" href=\"mobipreview.htm?28/16/28928\">",
"     table 1",
"    </a>",
"    ). The choice of medication typically depends on disease location, severity, and response. The properties of the medications are discussed in this section. An algorithmic approach to treatment is discussed later in this topic review. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Choice of treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practice varies with regard to the use of glucocorticoids (corticosteroids) as initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/8\">",
"     8",
"    </a>",
"    ]. In the United States, glucocorticoids remain the primary initial medical treatment for the acute therapy of moderate to severe Crohn's disease (CD). In contrast, in other countries such as Canada and the United Kingdom, patients with small bowel involvement are often treated with an elemental (eg, Vivonex) or polymeric diet (eg, Ensure) rather than glucocorticoids for induction of remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Exclusive enteral nutrition'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    are superior to placebo at induction of remission in children with CD. The efficacy of budesonide is limited to the ileum and ascending colon. Budesonide is probably less effective than prednisone, but also has fewer side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10321478\">",
"    <span class=\"h3\">",
"     Methylprednisolone",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with severe disease at presentation, glucocorticoids are often given intravenously initially (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose every 12 hours, up to a maximum of 30 mg every 12 hours), then transitioned to oral forms if the patient demonstrates a good clinical response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with active mucosal inflammation,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    given orally at a dose of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum 60 mg daily) brings rapid improvement in most patients. Once remission is achieved, glucocorticoids can be tapered. Although glucocorticoids are effective for inducing remission in most patients, many become glucocorticoid-dependent or require surgery. This was illustrated in a review that described the natural history of CD from 1970 to 1993, a period when glucocorticoids were the most effective available medical therapy for CD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/10\">",
"     10",
"    </a>",
"    ]. Although 80 percent of patients were in remission after 30 days, after 12 months, 28 percent were still glucocorticoid-dependent and 38 percent had undergone surgery.",
"   </p>",
"   <p>",
"    Like other glucocorticoids,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    also are associated with many long-term side effects, including growth failure, osteopenia, hirsutism, diabetes, psychosis, cataracts, and altered body shape and image. Furthermore, they are not effective for maintaining remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, prednisone or prednisolone should serve as a short-term induction therapy and as a bridge to a more effective maintenance therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Budesonide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteric-coated",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    , designed for release in the ileum and cecum, is an alternative to oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    . Budesonide has local effects on the bowel but has a high first-pass hepatic metabolism; thus, systemic effect is decreased. The efficacy of budesonide is limited to the ileum and ascending colon (right colon).",
"   </p>",
"   <p>",
"    The initial starting dose for an adolescent or adult is 9",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    tapered by 3 mg increments. There are few data on the optimal dosing in children. The adult dose of 9",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    has been used in clinical trials in children six years and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A retrospective study of 62 children used oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    in doses of 0.45",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (maximum dose 9",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for the treatment of mild to moderate CD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in adults suggest that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    was slightly less effective than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    in inducing remission in active disease, but was associated with fewer side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/40/10886?source=see_link\">",
"     \"Budesonide in the treatment of Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar conclusions were reached in a controlled trial in children, which included 48 patients who were randomly assigned to receive",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/12\">",
"     12",
"    </a>",
"    ]. The proportion of patients achieving remission at two months was lower in the budesonide group, but the difference was not statistically significant (55 versus 71 percent). However, patients in the budesonide group had significantly fewer side effects (eg, moon face, acne) and less adrenal suppression. Studies by another group showed that the response rate to budesonide for induction is approximately 48 percent, compared to 77 percent for",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    , and that prednisone is effective rescue therapy in approximately 75 percent of patients who do not respond to budesonide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the slightly lower efficacy,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    offers the advantage of less toxicity. However, patients treated long-term with budesonide still may experience growth failure, either because of direct suppression of linear growth or an inability to fully control disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/16\">",
"     16",
"    </a>",
"    ]. Although no large studies have been done in children, budesonide has not been consistently effective for maintaining remission in adults. As a result (and because of the potential for development of side effects with long-term use), budesonide, like conventional glucocorticoids, should be used only for short-term therapy (ideally four months or less).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Aminosalicylates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminosalicylate medications are well tolerated by patients. They are typically used for maintenance rather than treatment of CD, as their benefits are small compared with glucocorticoids. However, in children who present with mild CD, they may be useful as initial therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef64031 \" href=\"mobipreview.htm?34/41/35486\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The term aminosalicylates encompasses a wide variety of medications, each with a 5-aminosalicylate (5-ASA) moiety. The 5-ASA is readily absorbed throughout the small intestine; therefore, the parent compound generally must be modified for site-specific use in CD. The family of 5-ASA medications includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/43/21173?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      , in which the 5-ASA is conjugated to sulfapyridine",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/5/27734?source=see_link\">",
"       Mesalamine",
"      </a>",
"      , in which the 5-ASA moiety is coated either with ethylcellulose (Pentasa) or an acrylic-based resin, Eudragit (Asacol, Claversal [Europe]), or is uncoated (Rowasa suppositories, enemas; Canasa suppositories)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/17/16659?source=see_link\">",
"       Olsalazine",
"      </a>",
"      (Dipentum), in which two 5-ASA molecules are conjugated by an azo bond",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/14/37092?source=see_link\">",
"       Balsalazide",
"      </a>",
"      (Colazal), in which the 5-ASA moiety is conjugated to a 4-aminobenzoyl-beta-alanine carrier",
"     </li>",
"     <li>",
"      Once a day formulations of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/5/27734?source=see_link\">",
"       mesalamine",
"      </a>",
"      are available. These use formulations (Multi-matrix System [MMX] marketed in the United States as Lialda, or delayed release granules, marketed as Apriso) that are designed to release mesalamine in the colon.",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20344?source=see_link\">",
"       \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these systems are designed to deliver the 5-ASA moiety to the colon, where the 5-ASA inhibits synthesis of proinflammatory prostaglandins and leukotrienes. However, because of their specific enteric coating, timed-release Pentasa and pH-sensitive release Asacol also may deliver medication to the proximal and distal small intestine, respectively, making these 5-ASA preparations potentially useful in the treatment of diffuse small bowel CD and Crohn ileocolitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17962?source=see_link\">",
"     \"Investigational therapies in the medical management of Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although these medications have proven efficacy in the treatment of mild to moderate ulcerative colitis, their role as induction and maintenance agents in CD remains controversial. In adults, at least two 5-ASA agents (Pentasa and Asacol) were slightly superior to placebo (remission rate 40 percent for ASA versus 30 percent for placebo) in inducing remission in active CD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High doses of Pentasa (4",
"    <span class=\"nowrap\">",
"     grams/day,",
"    </span>",
"    16 pills a day) or Asacol (at least 3.2",
"    <span class=\"nowrap\">",
"     grams/day,",
"    </span>",
"    8 pills a day) must be used to achieve these modest effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/18\">",
"     18",
"    </a>",
"    ]. Similarly,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/5/27734?source=see_link\">",
"     mesalamine",
"    </a>",
"    has a slight benefit (risk difference for relapse 5 to 10 percent over placebo) in preventing relapses of CD in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/19\">",
"     19",
"    </a>",
"    ]. No pediatric studies have evaluated the efficacy of these medications, and given these modest effects and the large sample size needed to show efficacy, it is unlikely that pediatric studies will be performed.",
"   </p>",
"   <p>",
"    The choice among the aminosalicylates depends in part upon individual physician preference, although some relevant differences exist in their delivery systems.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/43/21173?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/17/16659?source=see_link\">",
"     olsalazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/14/37092?source=see_link\">",
"     balsalazide",
"    </a>",
"    are designed to release 5-ASA in the colon. Patients with Crohn ileitis who do not have colonic involvement should be treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/5/27734?source=see_link\">",
"     mesalamine",
"    </a>",
"    (Pentasa or Asacol) rather than sulfasalazine, because sulfasalazine is not designed for ileal release.",
"   </p>",
"   <p>",
"    Most aminosalicylates can be started in their full doses. However,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/43/21173?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    should be started gradually, according to the patient's tolerance, and the dose is increased to 50 to 75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum dose of 4 to 6",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    Because sulfasalazine competitively inhibits folate absorption, patients should be treated simultaneously with folate (1",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Sulfasalazine and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/17/16659?source=see_link\">",
"     olsalazine",
"    </a>",
"    can be compounded into a suspension for young children to drink. It is recommended that other aminosalicylates be swallowed whole; however, capsules of Pentasa may be opened and administered by sprinkling the granules on soft food.",
"   </p>",
"   <p>",
"    As a class of agents, aminosalicylates generally are well tolerated. Approximately 20 percent of patients will have dose-limiting side effects with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/43/21173?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , with the most common adverse reactions being headaches, photosensitivity, and skin rash. Studies in adults have highlighted concerns about an association with renal disease, including interstitial nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/20\">",
"     20",
"    </a>",
"    ]. Other side effects seen with sulfasalazine include a hypersensitivity reaction (manifested by fever, skin rash, and adenopathy), hepatitis, pancreatitis, leukopenia, and decreased sperm count. Other aminosalicylates also may have side effects (eg, rash, pancreatitis, proteinuria, pneumonitis, pericarditis), but these are infrequent. Nevertheless, monitoring of patients on aminosalicylates should include complete blood counts (suggested frequency at least twice a year) and urinalysis (suggested frequency at least annually). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mercaptopurine and azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thiopurine drugs",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA) and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/47/15095?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (also known as 6-mercaptopurine, 6-MP) have been used in the treatment of glucocorticoid-refractory CD since the 1970s. In the liver, these medications are converted to 6-thioguanine nucleotides, which inhibit lymphocyte proliferation by impairing DNA synthesis.",
"   </p>",
"   <p>",
"    Approximately 70 to 80 percent of patients with corticosteroid-dependent CD will enter a remission if treated with 6-MP or AZA, but the medication may take two to four months to achieve its maximal effect. Thus,",
"    <span class=\"nowrap\">",
"     6-MP/AZA",
"    </span>",
"    are better suited as maintenance rather than induction agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Dose and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because AZA is metabolized into 6-MP, the drugs are equally effective and differ only in their dosing. In children, standard doses for AZA are 1.5 to 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally (maximum dose 200 mg per day). 6-MP is generally given at doses between 1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally (maximum 150 mg per day). Some patients may benefit from doses above this range (eg, 6-MP 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), if appropriately monitored for toxicity. As an example, one observational report suggests that younger children (&lt;6 years) may require doses at the higher end of this range or above (median AZA-equivalent 3.1",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    to achieve clinical remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/21\">",
"     21",
"    </a>",
"    ]. All children treated with these drugs should be monitored closely for signs of toxicity, as discussed below.",
"   </p>",
"   <p>",
"    Because of genetic variation in metabolism of thiopurines, the optimal dose of these drugs varies. To determine a safe starting dose, we suggest evaluating patients for the thiopurine methyltransferase genotype (TPMT genotype) or phenotype (TPMT activity) prior to beginning treatment with 6-MP or AZA. TPMT is an enzyme that is essential in the metabolism of thiopurines. Approximately 90 percent of patients are homozygous for the allele TPMT 1 (ie, TPMT",
"    <span class=\"nowrap\">",
"     1/1",
"    </span>",
"    genotype), and have normal or rapid metabolism of thiopurines. In contrast, 10 percent of patients have reduced TPMT activity (eg, TPMT",
"    <span class=\"nowrap\">",
"     1/3a",
"    </span>",
"    genotype), and metabolize thiopurines more slowly. These patients typically respond to much lower doses of the medication (eg, 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of 6-MP). Approximately 1 in 300 patients has absent TPMT activity (eg, TPMT",
"    <span class=\"nowrap\">",
"     3a/3a",
"    </span>",
"    genotype) and does not metabolize the medication. These patients are at high risk for pancytopenia and should not be treated with thiopurines.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     6-MP/AZA",
"    </span>",
"    are well tolerated by children. Unlike glucocorticoids, they have no external cosmetic side effects. However, toxicities of these drugs include myelosuppression, infections, pancreatitis, elevated aminotransferases, and possibly an increased risk of developing lymphoma, which can be associated with infection with Epstein-Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/7,22,23\">",
"     7,22,23",
"    </a>",
"    ]. Patients who develop acute EBV infection during treatment with",
"    <span class=\"nowrap\">",
"     6-MP/AZA",
"    </span>",
"    should be carefully evaluated, and immunosuppressive therapy should be suspended, if possible. The risk of lymphoma related to treatment with",
"    <span class=\"nowrap\">",
"     6-MP/AZA",
"    </span>",
"    in patients with CD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/5/21592?source=see_link&amp;anchor=H190342717#H190342717\">",
"     \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\", section on 'Neoplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of these issues, patients treated with 6-MP or AZA require frequent monitoring. In our practice, we monitor with a complete blood count and aminotransferase levels (ALT and AST) before treatment, and again at 2, 4, 8, and 12 weeks after initiating therapy. If patients are stable, we monitor every three months thereafter, and two to three weeks after a change in dose. If significant leukopenia (WCB count &lt;3000) is detected, thiopurine treatment should be interrupted",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the dose reduced.",
"   </p>",
"   <p>",
"    Monitoring of blood levels of 6-thioguanine (6-TG) (the active metabolite) and 6-methylmercaptopurine (6-MMP) also can be helpful in assessing drug metabolism and compliance and in optimizing drug dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, genotyping and metabolite testing does not substitute for conventional laboratory monitoring for toxicity, with periodic measurements of a complete blood count and aminotransferases as described below. Metabolite monitoring is discussed in detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44566?source=see_link\">",
"     \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Early use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authorities have suggested that 6-MP should be used as part of the initial treatment strategy for children newly diagnosed with CD. This strategy was evaluated in a study involving 55 children (mean age 13) newly diagnosed with moderate to severe CD who were randomly assigned to receive",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    plus either 6-MP (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) as maintenance therapy or placebo (no maintenance therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/26\">",
"     26",
"    </a>",
"    ]. The duration of steroid use and the cumulative steroid dose was decreased significantly in the group randomized to 6-MP. Furthermore, although the rate of remission achieved in both groups was similar (89 percent), relapses were observed less often in the group receiving 6-MP (9 versus 47 percent) during the 18 months of study follow-up. These findings led the investigators to suggest that 6-MP should be added as part of the initial treatment regimen for children with newly diagnosed moderate to severe CD. This study has led to more widespread use of thiopurines in the early stages of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While early thiopurine usage clearly reduces the likelihood of relapse (at least in the first 18 months), the treatment also carries a small risk of complications, including leukopenia, opportunistic infections, and pancreatitis. In addition, there is also a slight increased risk of lymphoma associated with thiopurine therapy. Thus, when contemplating early treatment with thiopurines, the provider and family should carefully review the benefits and risks and consider individual factors including the extent and severity of the patient's CD. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     Infliximab",
"    </a>",
"    is a chimeric monoclonal antibody directed against the cytokine tumor-necrosis factor alpha. It was approved by the US Food and Drug Administration (FDA) in May 2006 for the treatment of moderate to severe CD in children who have had an inadequate response to conventional therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/28\">",
"     28",
"    </a>",
"    ]. The pharmacology, efficacy, and safety of infliximab are discussed in detail separately. Data particularly relevant to its use in children are discussed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     Infliximab",
"    </a>",
"    is effective in treating patients whose disease is resistant to steroids and 6-MP, and also can close perianal fistulas refractory to therapy with antibiotics and 6-MP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Initial studies in children suggest efficacy comparable to that achieved in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the initial studies of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    in adults, a single dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    infliximab resulted in clinical response in significantly more patients than placebo (81 versus 17 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/29\">",
"     29",
"    </a>",
"    ]. However, only 24 percent of patients were in remission three months after treatment. Thus, repeated doses are usually necessary, a strategy supported in long-term studies in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients who do not respond to the 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose can sometimes respond to increasing the infliximab dose (maximal dose up to 10",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or to increasing the frequency of infusions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a multicenter open-label trial in 112 pediatric patients, 88 percent of subjects responded to 10 weeks of treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    and 59 percent achieved clinical remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/37\">",
"     37",
"    </a>",
"    ]. Among the responders, there were superior sustained remission rates in children receiving infusions every eight weeks as compared to infusions every 12 weeks (56 versus 24 percent of patients were still in remission at 56 weeks). In a subpopulation of 23 patients with perianal disease, the perianal symptoms resolved in 70 percent, and remained in remission through 54 weeks of maintenance therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/38\">",
"     38",
"    </a>",
"    ]. Seven percent of the subjects developed serious infections (pneumonia, or Crohn-associated abscess, sepsis, or enterocolitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/37\">",
"     37",
"    </a>",
"    ]. Eighteen percent had an infusion reaction, but these usually did not require discontinuation of infliximab therapy.",
"   </p>",
"   <p>",
"    Currently used regimens involve the administration of three initial doses (zero, two, and six weeks) and follow-up infusions at two-month intervals if the patient responds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     Infliximab",
"    </a>",
"    is generally well tolerated, but as experience with the drug increases, concerns have been raised about the possibility of some rare but serious adverse effects.",
"   </p>",
"   <p>",
"    The most common adverse effect of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    is an infusion reaction, which occurs in 15 to 35 percent of patients (approximately 5 percent of infusions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/36,39-41\">",
"     36,39-41",
"    </a>",
"    ]. Infusion reactions can present with acute symptoms (chest tightness, shortness of breath, rash, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood pressure instability), or delayed symptoms (fever, arthritis, and rash occurring 2 to 14 days after an infusion). Some infusion reactions are caused by antibodies to infliximab, and the probability of developing antibodies is reduced if patients are premedicated with intravenous (IV)",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , through the use of scheduled infusions rather than \"on-demand\" infusions, and by concomitant treatment with thiopurines or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many infusion reactions are mild and can be managed by IV glucocorticoids,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/29/34256?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , and a decrease in infusion rate. In a patient with a history of infusion reaction, subsequent infusions are typically managed by giving glucocorticoids orally for several days and an IV dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    immediately prior to the infusion. Test doses of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    (usually 0.1 mg over 15 minutes, followed by 1 mg) are given and, if tolerated, the treatment infusion is performed. Alternatively, a patient with a history of a reaction can be converted from infliximab to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/53/20311?source=see_link\">",
"     adalimumab",
"    </a>",
"    (a humanized tumor necrosis factor [TNF] antagonist that is effective in adult patients who are intolerant of infliximab).",
"   </p>",
"   <p>",
"    A small number of cases of hepatosplenic T cell lymphoma (HSTCL) have been reported complicating",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    therapy of children and young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. All patients were taking concomitant immunosuppressive drugs, so these reports are not sufficient to establish that infliximab has a primary role in the development of this cancer. However, because studies in adults have demonstrated an increased risk of lymphoproliferative disease (LPD) in association with treatment with TNF inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/48\">",
"     48",
"    </a>",
"    ], a direct association with infliximab alone or in combination with other immunosuppressive agents is biologically plausible. Because HSTCL is otherwise extremely rare (approximately 100 cases have been reported in the literature), it is unlikely that these cases are due to chance alone. Although most reported cases of HSTCL occurred in patients treated with a combination of medicines known to suppress the immune system, including the TNF blockers, AZA,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    6-MP, there have been cases reported in patients receiving AZA or 6-MP alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The true long-term risks of lymphoma and other malignancies in children receiving TNF inhibitors and other immunomodulators are unknown. Most available data suggest a mildly increased risk of malignancy in patients receiving these medications, but the actual risk remains low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, it is difficult to ascertain whether a malignancy risk is related to the underlying CD, to the TNF inhibitors,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to the other immunomodulators that are often used prior to or in combination with TNF inhibitors. We and most other experts believe that in children with moderate to severe CD that is refractory to conventional treatment, the established benefit of TNF inhibitors and other immunomodulators exceeds the risk of a slight increase in lymphoma. However, these potential benefits and risks should be explained in detail to the family.",
"   </p>",
"   <p>",
"    Citing concerns about possible increased risks for lymphoma and other malignancies, the FDA performed a",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/ucm250913.htm\">",
"     Safety Review of TNF inhibitors",
"    </a>",
"    and strengthened the warnings in the prescribing information. The FDA specifically recommended that discussions with patients and families include the risks and potential benefits of TNF inhibitors, as well as the risks and benefits of alternative treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concerns about HSTCL and the potential association with combination thiopurine and biologic therapy are complex issues when considering treatment for individuals with IBD. On the one hand, a large trial in adults&nbsp;comparing AZA monotherapy,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    monotherapy, and combination AZA and infliximab therapy demonstrated improved remission rates in patients taking the combination treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/52\">",
"     52",
"    </a>",
"    ].&nbsp;On the other hand, for the past several years, pediatric gastroenterologists have tended to&nbsp;utilize infliximab monotherapy because of the fears about&nbsp;lymphoma.&nbsp;Malignancy risks of TNF inhibitors are discussed in more detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other serious complications with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    therapy have been reported, including liver failure, miliary tuberculosis (TB), other opportunistic infections, autoimmune disease, and demyelinating disease. In 2008, the FDA issued a warning about the risk for pulmonary and disseminated histoplasmosis, coccidiomycosis, blastomycosis, and other invasive fungal infections in patients undergoing treatment with infliximab or other TNF inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/53\">",
"     53",
"    </a>",
"    ]. The warning is based on case reports of patients in whom histoplasmosis infection was not promptly recognized, and some of these patients died. Typical signs and symptoms of histoplasmosis and other invasive fungal infections include fever, malaise, weight loss, sweats, cough, dyspnea, pulmonary infiltrates on X-ray, or serious systemic illness including shock. Infliximab may also induce psoriasis in children and adults with IBD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies are currently examining the utility of using",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    and other immunomodulators early in the course of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/55\">",
"     55",
"    </a>",
"    ]. This has been called a \"top-down\" approach, and has shown some promise when 6-MP is used in children. The safety and efficacy of top-down approaches to CD have not been established in adults or children. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Early use'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15465691\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative risks and benefits of monotherapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    or other biologic agents versus combination therapy (ie, infliximab with 6-MP,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    [MTX]) remain unclear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potential risks &ndash; The main concern about combination therapy is that it might increase the risk of lymphoma as compared with monotherapy. Since large studies of IBD patients suggest that thiopurines confer a slight increase in lymphoma risk, it is logical to infer that thiopurine discontinuation might reduce that risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/51,56\">",
"       51,56",
"      </a>",
"      ]. However, because the overall risk of lymphoma in this population is small, any increased risk conferred by combination therapy is probably also very small, albeit poorly defined.",
"     </li>",
"     <li>",
"      Potential benefits &ndash; Combination therapy reduces the rate of antibody formation and improves remission rates as compared to monotherapy, based on evidence from large studies in adults with moderate or severe CD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/52\">",
"       52",
"      </a>",
"      ]. How the patient&rsquo;s age and disease severity affect this potential benefit is unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because the risks and benefits of combination therapy versus",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    monotherapy are poorly understood, there is considerable variation in clinical practice among IBD specialists. Practice ranges from avoiding combination therapy altogether, to continuing combination therapy indefinitely. At our institution, we follow the protocol used in some studies: Patients failing thiopurines or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    and starting infliximab are typically kept on combination therapy for 6 to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/57\">",
"     57",
"    </a>",
"    ].&nbsp;Then, if a patient is in remission, we either continue combination therapy (thiopurine with infliximab, or MTX with infliximab), or discontinue the thiopurine or MTX and continue with infliximab alone. To make this decision, we have a detailed discussion with the patient and family about the risks and benefits of combination therapy versus monotherapy, acknowledging the limited information available. In most cases, we suggest continuing combination therapy indefinitely, if the family is comfortable with this plan. For such patients, we usually use MTX with infliximab, or sometimes a thiopurine with infliximab. &nbsp;",
"   </p>",
"   <p>",
"    Data from adult studies and other considerations regarding concomitant immunosuppressive agents are discussed in more detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44105?source=see_link&amp;anchor=H12#H12\">",
"     \"Infliximab in Crohn's disease\", section on 'Use of immunosuppressive agents in combination with infliximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23124329\">",
"    <span class=\"h2\">",
"     Adalimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/53/20311?source=see_link\">",
"     adalimumab",
"    </a>",
"    is an antibody directed against TNF. In patients who do not respond to infliximab, or who develop infusion reactions to this compound, adalimumab has been utilized successfully [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. In a retrospective series of 115 children and adolescents treated with adalimumab, 70 percent had a clinical response at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/62\">",
"     62",
"    </a>",
"    ]. Most of these subjects had failed a prior trial of infliximab because of loss of response, infusion reaction, or intolerance. The IMAgINE 1 trial evaluated two double-blind maintenance dosing regimens of adalimumab in 188 pediatric patients with moderate to severe CD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/63\">",
"     63",
"    </a>",
"    ]. Subjects were enrolled only if they had failed treatment with an oral glucocorticoids or immunomodulator (a thiopurine or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    ), and had responded to an open-label induction with adalimumab; about 40 percent of patients had been previously treated with infliximab but had become unresponsive or had adverse reactions to that drug. After 26 weeks of maintenance therapy with adalimumab, 33.5 percent of patients remained in clinical remission, and there was no significant difference between the two dosing regimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29559?source=see_link\">",
"     \"Adalimumab for treatment of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intramuscular or subcutaneous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) given once a week is moderately effective in inducing and maintaining remission in adult patients with steroid-refractory or steroid-dependent CD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is less published experience in the use of MTX in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/31\">",
"     31",
"    </a>",
"    ]. In an uncontrolled multicenter study of 42 children who had failed treatment with thiopurines, 80 percent of patients responded to or entered remission with MTX treatment; 26 percent had sustained remission for at least 24 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/67\">",
"     67",
"    </a>",
"    ]. Smaller open-label studies demonstrated similar results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MTX typically is given in children at a dose of 15",
"    <span class=\"nowrap\">",
"     mg/M",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per week (up to a maximum of 25 mg per week, which is the dose used for adults) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/9,68,70\">",
"     9,68,70",
"    </a>",
"    ]. On occasion, slightly higher doses are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/67\">",
"     67",
"    </a>",
"    ]. We suggest giving the drug subcutaneously for three to six months to ensure absorption. Patients who successfully enter remission may be switched to oral MTX, although this practice is supported by only a few small clinical studies, so the efficacy of oral as compared to subcutaneous dosing has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7673?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunomodulator therapy in Crohn's disease\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Side effects include myelosuppression, oral ulcers, infection, pulmonary abnormalities, and hepatitis. Therefore, we recommend monitoring of the complete blood count and aminotransferases as with thiopurine therapy. Because",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation may reduce the likelihood of oral ulcers, we routinely give 1 mg daily. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link&amp;anchor=H7#H7\">",
"     \"Major side effects of low-dose methotrexate\", section on 'Role of folate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics typically are used to treat infectious complications of IBD (abdominal or perianal abscess), but they also have a limited role in the treatment of mild active CD, especially perianal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/9\">",
"     9",
"    </a>",
"    ]. Agents such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    have efficacy comparable to aminosalicylates in the treatment of mild active CD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/72\">",
"     72",
"    </a>",
"    ]. The primary side effects of metronidazole are metallic taste, a disulfiram reaction if taken with alcohol, peripheral neuropathy with long-term use, and risk for birth defects in pregnant women. Ciprofloxacin is generally well tolerated; reported side effects include stomach upset, allergic reactions, increased risk for Clostridium difficile (C. difficile) infection, and tendonitis or tendon rupture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/34/20008?source=see_link\">",
"     \"Antibiotics for treatment of inflammatory bowel diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of therapies including",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    , mycophenolic acid (MPA), and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/42/42664?source=see_link\">",
"     thalidomide",
"    </a>",
"    have been used for patients not responding to any of the above agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/31\">",
"     31",
"    </a>",
"    ]. Most of the available information about these therapies comes from studies in adults, and treatment decisions in pediatric patients are made on a case-by-case basis. Given the potential toxicities of these potent immunosuppressive agents, they should be used only after other conventional medical therapies have failed, and if the patient is not a good surgical candidate.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    , a monoclonal antibody, is an effective induction agent for CD in adults and children. In a randomized study of Natalizumab in children with CD, there was a clinical response in 55 percent and remission in 29 percent at 10 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/73\">",
"     73",
"    </a>",
"    ]. However, there are important safety concerns that limit its use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3429?source=see_link\">",
"     \"Natalizumab for treatment of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    was effective in randomized trials in adults with refractory CD, but the renal toxicity of this agent limits its long-term use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    has been effective in the acute treatment of fistulizing disease in adults, but the effect is highly variable and it is probably not helpful in maintaining remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7673?source=see_link&amp;anchor=H18#H18\">",
"     \"Immunomodulator therapy in Crohn's disease\", section on 'Tacrolimus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7673?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunomodulator therapy in Crohn's disease\", section on 'Cyclosporine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/42/42664?source=see_link\">",
"     Thalidomide",
"    </a>",
"    , an inhibitor of both tumor necrosis factor and angiogenesis, has been used off-label to treat refractory IBD for more than a decade. Published case series and our own clinical experience suggest that it is an effective agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Toxicities include neuropathy, leukopenia, and profound birth defects in the offspring of women who took thalidomide during pregnancy. For this reason, thalidomide is tightly monitored and regulated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17962?source=see_link&amp;anchor=H4393221#H4393221\">",
"     \"Investigational therapies in the medical management of Crohn's disease\", section on 'Thalidomide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients also may seek advice from practitioners of alternative medicine. In a survey of more than 200 children with CD from three different IBD centers in the United States, more than 40 percent were using therapies not prescribed by their clinician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/79\">",
"     79",
"    </a>",
"    ]. The clinician should inquire about the use of herbs and dietary supplements since some of these complementary therapies may have gastrointestinal side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/79\">",
"     79",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Infection risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with immunomodulators",
"    <span class=\"nowrap\">",
"     (6-MP/AZA",
"    </span>",
"    and MTX) or biologics (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    ) confers an increased risk of bacterial, fungal, and viral infection. The risks are not fully established, and likely vary with choice of drug and dose; the known risks are discussed briefly below and in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To minimize risk of serious infection, we suggest that children treated with these drugs (especially",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    and other TNF-alpha inhibitors) undergo pretreatment screening for tuberculosis (TB), using Mantoux (PPD) skin testing. Testing for TB in children who have been vaccinated with bacillus Calmette-Gu&eacute;rin (BCG), and management of patients who are thought to be anergic, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13143?source=see_link\">",
"     \"Latent tuberculosis infection in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\", section on 'Negative tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt review of a child's immunization status as soon as CD is diagnosed will minimize potential conflicts between immunizations and initiation of immunosuppressive medications. Immunization with inactivated vaccines should be brought up to date and rigorously maintained during treatment, including influenza, meningococcus, and pneumococcus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/7,80\">",
"     7,80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"     \"Standard immunizations for children and adolescents\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, patients are considered immunosuppressed if they are undergoing treatment with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      (&gt;20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for adults),",
"      <span class=\"nowrap\">",
"       6-MP/AZA,",
"      </span>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"       infliximab",
"      </a>",
"      or other immunomodulators or biologicals, or have significant protein-calorie malnutrition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/81\">",
"       81",
"      </a>",
"      ]. Patients are considered immunosuppressed for about three months after completing treatment with any of these agents.",
"     </li>",
"     <li>",
"      Children with CD should receive the pneumococcal conjugate vaccine (PCV), which is recommended for all children. They should also be given the",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/12/4294?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV), because they are considered to be at increased risk for invasive pneumococcal disease if they are treated with immunosuppressive medication. When possible, the PPSV should be given prior to initiation of immunosuppressive therapy; patients on combination therapy (TNF-alpha inhibitors and immunomodulators) have impaired vaccine response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/82\">",
"       82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link\">",
"       \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=see_link&amp;anchor=H5#H5\">",
"       \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who have been immunized for measles or varicella, or have a history of the disease, we suggest checking titers prior to treatment with immunomodulators or biologics. If titers are low, we re-immunize patients at least six weeks before beginning immunosuppressive treatment.",
"     </li>",
"     <li>",
"      In patients who have not been immunized for varicella and do not have a history of the disease, the patient should be immunized if immunosuppressive therapy is not planned within six weeks. There is controversy over the issue of whether varicella immunization should be considered for children who require more urgent immunosuppressive therapy to control CD; no guidelines sufficiently address this issue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/80,81,83,84\">",
"       80,81,83,84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of administering other live vaccines, including polio, rubella, and yellow fever, to patients on immunomodulator or biologic therapy has not been established [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/80,84\">",
"       80,84",
"      </a>",
"      ]. Nonetheless, most experts avoid live viral vaccines during treatment or if treatment is planned within 4 to 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/81\">",
"       81",
"      </a>",
"      ]. Family and household contacts of immunosuppressed patients can be safely immunized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Indications and efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery in Crohn's disease (CD) is reserved primarily for patients who do not respond to medications, or who develop complications (abscess, fistula, or stricture) that can be treated only surgically. In a review of 204 children with CD from 1968 to 1994 (a period before widespread use of 6-",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/47/15095?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    [6-MP] and other immunomodulators), 46 percent of patients with CD required surgery for complications of growth retardation, bowel perforation, internal fistula, or hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/85\">",
"     85",
"    </a>",
"    ]. The median duration from diagnosis to first surgery was 2.8 years. In a series of 854 children with CD in North America, the risk for CD-related bowel surgery was 1.4 percent at one year after diagnosis, and 13.8 percent at five years after diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/86\">",
"     86",
"    </a>",
"    ]. Early initiation of immunomodulator therapy did not influence the risk of bowel surgery. Thus, although treatment of CD primarily is medical, many patients will require surgery at some point during their clinical course. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery can be particularly effective in patients with a limited region of disease (eg, terminal ileal or ileocecal disease). The benefits of surgery include rapid improvement in an ill patient, and catch-up of growth and puberty in a child or adolescent. Surgery usually involves resection of the diseased bowel segment and primary end-to-end anastomosis. In some patients with multiple small bowel strictures, strictureplasty (widening of the strictured area in a manner similar to pyloroplasty) may reduce the need for bowel resection. In patients with extensive Crohn colitis, full colonic resection and end-ileostomy may be unavoidable.",
"   </p>",
"   <p>",
"    The aim of surgery is to resect as little bowel as possible since CD recurs in approximately 40 to 50 percent of patients within two to five years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/809?source=see_link\">",
"     \"Medical prophylaxis of postoperative Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Preventing postoperative recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient undergoes surgery and the diseased bowel is resected, medical therapy delays the onset of postoperative recurrence. There is considerable debate about the best regimen for postoperative recurrence prophylaxis in CD patients that have undergone a limited resection. Aminosalicylates and antibiotics somewhat reduce the postoperative recurrence rate (from 40 percent untreated to about 30 percent if treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/5/27734?source=see_link\">",
"     mesalamine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. However, some studies suggest that 6-MP may be the most effective agent for prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/87,90,91\">",
"     87,90,91",
"    </a>",
"    ]. Endoscopic surveillance of the anastomotic area 6 to 12 months after recurrence may identify a preclinical endoscopic recurrence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/809?source=see_link\">",
"     \"Medical prophylaxis of postoperative Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     NUTRITIONAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional therapy has three distinct applications in the treatment of Crohn's disease (CD):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exclusive enteral nutrition &ndash; Providing all nutritional needs through a liquid formula (total enteral nutrition or primary nutritional therapy) can promote mucosal healing in a patient with active disease and suppress intestinal inflammation, possibly by altering the gut microflora [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/92-94\">",
"       92-94",
"      </a>",
"      ]. In this context, nutritional therapy is used as an alternative or supplement to anti-inflammatory medications. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Exclusive enteral nutrition'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Supplemental enteral nutrition &ndash; Enteral nutrition can also be used as a supplement to increase energy and nutrient intake and promote growth in a patient with growth failure while the patient continues to take food orally. Supplemental enteral nutrition may also maintain remission by suppressing intestinal inflammation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2794?source=see_link\">",
"       \"Growth failure and poor weight gain in children with inflammatory bowel disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H27\">",
"       'Supplemental enteral nutrition'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Micronutrient deficiencies &ndash; Children with CD are at risk for micronutrient deficiencies due to inadequate food intake and malabsorption. Optimal care includes routine monitoring for these deficiencies and replacement as needed (",
"      <a class=\"graphic graphic_table graphicRef66288 \" href=\"mobipreview.htm?0/33/541\">",
"       table 2",
"      </a>",
"      ). Assurance of adequate intake of calcium and vitamin D are particularly important to minimize risks of osteopenia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/6/43113?source=see_link\">",
"       \"Nutrient deficiencies in inflammatory bowel disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H31\">",
"       'Micronutrient deficiencies'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H32\">",
"       'Bone mineral density'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Exclusive enteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exclusive enteral nutrition (EEN) requires that the patient stop eating and receive all dietary energy as elemental",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polymeric formula taken by mouth, nasogastric (NG) tube, or gastrostomy. In most centers, the duration of a course of EEN is six to eight weeks. A daily volume of formula is calculated based on estimated energy requirements and adjusted based on serial measurements of weight and height. The method and evidence base for EEN are reviewed in guidelines from the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/95\">",
"     95",
"    </a>",
"    ] and the British Society for Pediatric Gastroenterology, Hepatology, and Nutrition (BSPGHAN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/9\">",
"     9",
"    </a>",
"    ]. The NASPGHAN guidelines include",
"    <a class=\"external\" href=\"file://www.naspghan.org/user-assets/Documents/pdf/PositionPapers/Use_of_Enteral_Nutrition_for_the_Control_of.29[1].pdf\">",
"     practical considerations for implementation of EEN",
"    </a>",
"    , including calculation of energy needs and methods of nasogastric tube feeding.",
"   </p>",
"   <p>",
"    Primary nutritional therapy with EEN appears to suppress inflammation and promote mucosal healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/9,95-99\">",
"     9,95-99",
"    </a>",
"    ]. Moreover, small randomized trials suggest that primary nutritional therapy improves growth as compared to glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/100-102\">",
"     100-102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This form of nutritional therapy appears to be useful for inducing remission, but probably is less effective than glucocorticoids. The largest meta-analysis of randomized trials found that glucocorticoids induced remission more frequently than EEN (pooled OR 0.33) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/103\">",
"     103",
"    </a>",
"    ]. Subgroup analyses showed no significant differences in effectiveness between formulas of different protein composition (elemental versus polymeric). These findings are consistent with an earlier meta-analysis of eight studies conducted prior to 1995, in which the remission rate ranged from 50 to 80 percent after four weeks of EEN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/104\">",
"     104",
"    </a>",
"    ]. One of the included studies found that EEN induced mucosal healing more often than glucocorticoids, while the two treatments were equally effective in inducing remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/96\">",
"     96",
"    </a>",
"    ]. One report suggests that EEN may be less effective in CD that is limited to the colon, as compared to ileocolic CD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently, EEN is used far less often than glucocorticoids in the United States for treatment of CD. Providers who rarely use EEN generally cite concerns about adherence, due to the limited palatability of most formulas and the desire of most North American children to avoid use of a nasogastric tube [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/106\">",
"     106",
"    </a>",
"    ]. As compared to the United States, EEN is used somewhat more frequently in Canada, and much more frequently in Western Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/9,106-108\">",
"     9,106-108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consistent with the guidelines cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/7,9,95\">",
"     7,9,95",
"    </a>",
"    ], we suggest that treatment with EEN be routinely offered as an alternative to glucocorticoids for induction of remission in children with CD. EEN may be particularly appropriate for patients with growth failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those who are steroid-dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/109\">",
"     109",
"    </a>",
"    ]. This suggestion is based on knowledge of the established adverse effects of glucocorticoids, particularly on bone density, and on the evidence that EEN is moderately effective for inducing remission and mucosal healing. For patients with severe disease, EEN might be used in combination with glucocorticoids or other medical treatments for induction of remission. &nbsp;",
"   </p>",
"   <p>",
"    Little evidence is available to guide maintenance treatment for children in whom EEN successfully induces remission. Options include transition to maintenance medical therapy (eg, 5-aminosalicylic acid [ASA] or 6-",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/47/15095?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    [6-MP])",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tapering to partial enteral nutrition. In one case series, 28 children were transitioned to nocturnal enteral feeds and resumed eating by mouth during the day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/110\">",
"     110",
"    </a>",
"    ]. These children were less likely to relapse during the subsequent 12 months, as compared to a group of children who opted not to use nocturnal feedings (43 percent versus 79 percent relapse, p &lt;0.02). Other authors report using partial enteral nutrition intermittently as a maintenance regimen (70 percent of energy needs for one in four months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of EEN on quality of life and psychological well-being are not well studied. One study found that treatment with EEN was associated with improvements on a standardized measure of quality of life, and that this was closely correlated with disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Supplemental enteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral nutrition also has been used to maintain remission, in which case it is generally used as a supplement to a regular diet (partial enteral nutrition). Although supplemental therapy is less effective than EEN in inducing remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/97\">",
"     97",
"    </a>",
"    ], limited data suggest that it can be helpful in maintaining remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/110,111,113\">",
"     110,111,113",
"    </a>",
"    ]. However, the efficacy of this approach has not been established, and many children are unwilling to continue enteral nutrition long-term.",
"   </p>",
"   <p>",
"    Supplemental enteral nutrition also is used to enhance linear growth and nutritional status in children with growth failure. The indications and implementation of this approach are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2794?source=see_link\">",
"     \"Growth failure and poor weight gain in children with inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Other dietary changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic and biological research suggests a possible role for several dietary factors in the pathogenesis of inflammatory bowel disease (IBD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/114\">",
"     114",
"    </a>",
"    ]. However, although a variety of dietary changes and supplements have been explored as adjuncts to treatment, none have been shown to be beneficial in maintaining remission. Thus, there is currently no good evidence for specific dietary regimens other than to eat a healthy, diverse diet.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fat, fiber, and carbohydrates &ndash; Observational evidence in humans and experimental evidence in animals suggest that dietary fats and carbohydrates may affect intestinal inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/114\">",
"       114",
"      </a>",
"      ]. Soluble fiber is fermented into short chain fatty acids in the colon, which in turn are thought to reduce colonic inflammation. However, the same fermentation process may produce gas and diarrhea, causing increased symptoms. Diets with variable fiber content and carbohydrate composition have been studied in single-blind randomized trials in adults. Neither diets low in sugar and increased in fiber content [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/115,116\">",
"       115,116",
"      </a>",
"      ], nor diets with reduced fiber content (\"low residue\"), altered the clinical course of the subjects as compared to a control group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/117\">",
"       117",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fish oil &ndash; Fish oil and other sources of n-3 fatty acids have antiinflammatory effects in animal models of IBD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/118\">",
"       118",
"      </a>",
"      ]. The effect of adding n-3 fatty acids to the diet of patients with CD was studied in a few randomized trials. The largest study did not show an effect of fish oil on extending remission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/119\">",
"       119",
"      </a>",
"      ]. However, a second trial of good methodologic quality reported a lower relapse rate among patients with inactive CD treated with fish oil [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/120\">",
"       120",
"      </a>",
"      ]. Because the results of these and other trials were inconsistent, a systematic review of the available literature concluded that there is insufficient evidence to draw conclusions about the effects of n-3 fatty acids on the clinical outcomes of CD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been a number of elimination diets popularized via the internet to treat inflammatory bowel disease, including the specific carbohydrate diet and the Maker&rsquo;s diet (which focuses on organic and unrefined foods).&nbsp;While there are anecdotal reports of patients responding to such diets, there are no convincing data from clinical trials demonstrating the efficacy of these interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/122\">",
"     122",
"    </a>",
"    ].&nbsp;Nevertheless, many patients are interested in trying such interventions to see if they might help.&nbsp;In such cases, counseling by a registered dietician may be helpful to make sure the patient is receiving adequate calories and micronutrients.",
"   </p>",
"   <p>",
"    A few other dietary changes may be appropriate in specific clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactose intolerance &ndash; Lactose intolerance is more prevalent in patients with CD, particularly those with small bowel disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/123\">",
"       123",
"      </a>",
"      ]. These individuals, like other patients with lactose intolerance, may get symptomatic relief from reducing dietary lactose. Thus, for patients with symptoms consistent with lactose intolerance, a trial of a lactose-reduced diet is reasonable. In this case, care should be taken to ensure that adequate dietary calcium and vitamin D are provided.",
"     </li>",
"     <li>",
"      Strictures &ndash; For other patients with CD and strictures, a low-residue diet may be an appropriate step to avoid bowel obstruction. However, it should be recognized that such dietary changes are unlikely to be relevant except in unusual cases where a stricture is nearly obstructive, and these patients are likely to need other intervention to avoid this complication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/124\">",
"       124",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Monitoring nutritional status",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Growth failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth failure is common in children with CD. Exacerbations of CD may lead to the acute onset of anorexia, weight loss, and dehydration. More commonly in children, a chronic low-grade anorexia may result in poor weight gain and decreased height velocity, which may lead to permanent stunting. Growth failure in children with CD can be reversed if the disease is controlled medically, use of glucocorticoids is minimized, and sufficient dietary energy and nutrients are provided to give the prepubertal child substrate for adequate weight gain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2794?source=see_link\">",
"     \"Growth failure and poor weight gain in children with inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All children with IBD should have regular measurements of body weight, height, and pubertal status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/7,64,113\">",
"     7,64,113",
"    </a>",
"    ]. Body mass index (BMI) should be calculated. Changes in BMI and height percentiles should be monitored over time by plotting on a standard chart. In our practice, we perform these measurements at least every four months for patients with quiescent disease, and more frequently for those with active disease or evidence of growth failure (",
"    <a class=\"graphic graphic_table graphicRef61093 \" href=\"mobipreview.htm?3/50/3885\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Micronutrient deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for monitoring nutritional status in children and adults vary between publications. Some authors recommend that healthy children with CD should be screened annually for micronutrient deficiencies, or more frequently if there is active disease (",
"    <a class=\"graphic graphic_table graphicRef66288 \" href=\"mobipreview.htm?0/33/541\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/7\">",
"     7",
"    </a>",
"    ]. Low levels of vitamins A, D and E, and of zinc,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. Vitamin B12 deficiency is especially common in patients who undergo ileal resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/6/43113?source=see_link\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced bone mineral density is present in approximately 30 percent of children and adolescents with CD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/127\">",
"     127",
"    </a>",
"    ]. It may be associated with vitamin D deficiency, calcium malabsorption, pubertal delay, or glucocorticoids therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/128\">",
"     128",
"    </a>",
"    ]. There are no widely accepted standards for monitoring bone health in children with IBD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2794?source=see_link&amp;anchor=H17#H17\">",
"     \"Growth failure and poor weight gain in children with inflammatory bowel disease\", section on 'Bone disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30569?source=see_link\">",
"     \"Metabolic bone disease in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children and adolescents, it is unclear whether modest decreases in bone density predict fracture risk. Thus, we suggest that prevention and treatment focus on minimizing risk factors for bone disease, by intensive counseling to optimize nutrition, addressing pubertal delay, and minimizing use of glucocorticoids. The recommended intake of vitamin D and calcium are the same as those for healthy children: vitamin D is 600 IU for all ages, calcium is 1300 mg daily for adolescents 9 to 18 years, and 1000 mg daily for children four to eight years of age. Many children require supplements to meet these goals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/6/43113?source=see_link&amp;anchor=H9#H9\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\", section on 'Vitamin D'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/6/43113?source=see_link&amp;anchor=H19#H19\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\", section on 'Calcium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the lack of data on bisphosphonate use in children, this therapy is not recommended at the present time, except perhaps in unusual circumstances such as vertebral fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2794?source=see_link&amp;anchor=H17#H17\">",
"     \"Growth failure and poor weight gain in children with inflammatory bowel disease\", section on 'Bone disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PSYCHOLOGICAL SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the chronic relapsing nature of this illness and its profound effects on body appearance and image, it is not surprising that many children will require psychological support. The short stature and pubertal delay often render children much smaller than their classmates. The presence of surgical scars, nasogastric tubes, or ostomies also may lead to a sense of feeling different. Many of these patients are taking more than 10 pills a day, and may develop \"medication fatigue.\" Conflicts may arise from their parents over appetite and eating, especially if parents do not recognize that the disease is causing a child's anorexia. Finally, children and parents may develop a fear of the future, particularly for patients with severe disease. Problems reported include excessive absenteeism and reduced school functioning, embarrassment during athletic activities, teasing by classmates, and increased fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/7,129,130\">",
"     7,129,130",
"    </a>",
"    ]. In another study, 25 percent of adolescents with inflammatory bowel disease (IBD) had clinically significant depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inflammatory bowel disease in a child also has important effects on the family&rsquo;s emotional stress and quality of life. One study of families with adolescent children with IBD found that adolescent depressive symptoms had the most important impact on the parent&rsquo;s level of distress, independent of disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/132\">",
"     132",
"    </a>",
"    ]. Most of the parent respondents in this study were mothers. A separate study interviewed both parents, and also found that the mother&rsquo;s distress was closely linked to the adolescent&rsquo;s emotional adjustment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/133\">",
"     133",
"    </a>",
"    ]. By contrast, the fathers&rsquo; distress was more closely associated with the adolescent&rsquo;s disease activity. &nbsp;",
"   </p>",
"   <p>",
"    Given these issues, psychological counseling may be beneficial for children with IBD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their parents. Unfortunately, many teenagers are either \"too busy\" or reluctant to go to such counseling. Thus, the pediatrician and gastroenterologist should address some of the above issues honestly and openly during clinic visits. In addition, parents and children may benefit from joining a support group, such as the Crohn's and Colitis Foundation of America (CCFA,",
"    <a class=\"external\" href=\"file://www.ccfa.org/\">",
"     www.ccfa.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6397339\">",
"    <span class=\"h1\">",
"     TRANSITION TO ADULT HEALTH CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Designing a healthy transition to adult care is an essential goal for the pediatric clinician caring for a child with inflammatory bowel disease (IBD). The process extends throughout adolescence, and includes each of the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Throughout adolescence, the pediatric provider",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      discusses and shapes the patient and family&rsquo;s expectations for the transition",
"     </li>",
"     <li>",
"      cultivates the patients&rsquo; knowledge and self-management skills, including adherence to the medication regimen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the patient is developmentally ready (and ideally when he or she is medically stable), there is a deliberate transfer of care to an adult provider, with organized transfer of medical information between providers.",
"     </li>",
"     <li>",
"      The accepting provider helps to educate the transitioning patient about any differences in protocols or procedures, and provides additional time and support during the transition process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines have been developed to facilitate an organized transition process for adolescents and young adults with IBD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/134,135\">",
"     134,135",
"    </a>",
"    ], with an approximate timeline for each step [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SURVEILLANCE FOR CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like patients with ulcerative colitis, patients with extensive Crohn colitis have an increased risk for developing colon cancer. While there are limited data upon which to make meaningful recommendations, children with Crohn colitis probably should undergo colonoscopy for cancer screening beginning 7 to 10 years after the diagnosis of their Crohn's disease (CD), depending on the extent of the colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/7\">",
"     7",
"    </a>",
"    ]. The frequency of the screening should be determined by the findings on the initial colonoscopy, but ranges from every one to three years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of small bowel cancer in CD is also higher than in the general population; however, because of the rarity of these tumors, the number of patients with CD with this complication is small. Increases in incidence of squamous cell carcinoma of the anus, duodenal neoplasia, and lymphoma all have been reported in CD, although the strength of these associations is unclear. Several population-based studies on the incidence of lymphoma in adults with inflammatory bowel disease (IBD) have found relative risks ranging from 0.4 to 2.4. Considering the data in aggregate, they do not support an increased risk of developing lymphoma in patients with IBD compared to the general population. However, whether the risk is increased in patients with IBD treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA) or 6-",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/47/15095?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (6-MP) remains unclear. At present, no guidelines exist for monitoring these complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     CHOICE OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion provides the basis for our approach to treatment. The following sections will briefly summarize our suggestions for the treatment in a variety of commonly encountered clinical settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Ileocolic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For Crohn&rsquo;s disease (CD) affecting the ileum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colon, the type of drug chosen typically depends on disease severity and response (",
"    <a class=\"graphic graphic_algorithm graphicRef64031 \" href=\"mobipreview.htm?34/41/35486\">",
"     algorithm 1",
"    </a>",
"    ): &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Mild",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with mild disease and minimal complications, we generally make an initial attempt to induce remission using aminosalicylates, with or without antibiotics, although there are little data to support the use of antibiotics except in the setting of perianal fistulas. Induction of remission with glucocorticoids or with exclusive enteral nutrition (EEN) therapy is a reasonable alternative. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Aminosalicylates'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Antibiotics'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H26\">",
"     'Exclusive enteral nutrition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Once remission is induced, the patient is transitioned to maintenance therapy with aminosalicylates alone or a thiopurine (6-",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/47/15095?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    [6-MP] or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    [AZA]). Aminosalicylates are less effective but have lower toxicity as compared with thiopurines. As a result, we generally attempt maintenance with aminosalicylates before considering thiopurine therapy for patients with mild disease. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Aminosalicylates'",
"    </a>",
"    above.) By contrast, patients with recurrent flares requiring glucocorticoid treatment (eg, two or more flares in a 12-month period) are likely to benefit from thiopurine therapy, to reduce glucocorticoid use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/47/41722/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Mercaptopurine and azathioprine'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Moderate or severe",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with more severe disease, aggressive treatment with glucocorticoids will typically be required to induce remission (",
"    <a class=\"graphic graphic_algorithm graphicRef64031 \" href=\"mobipreview.htm?34/41/35486\">",
"     algorithm 1",
"    </a>",
"    ). EEN is an appropriate alternative to glucocorticoids, especially for patients with growth failure; this approach is frequently used as an induction regimen in the United Kingdom and in parts of Europe and Canada. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Exclusive enteral nutrition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If remission is successfully induced by glucocorticoids, patients are transitioned to either aminosalicylates or to a thiopurine for maintenance treatment. Although aminosalicylates are attractive because of low toxicity, it is unclear if these drugs are superior to placebo in preventing relapse. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Aminosalicylates'",
"    </a>",
"    above.) As a result, thiopurines are increasingly used for maintenance therapy. Occasional courses of glucocorticoids may be needed to re-induce remission during a flare.",
"   </p>",
"   <p>",
"    Prior to beginning thiopurine treatment, the following steps should be taken:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be evaluated for thiopurine methyltransferase genotype (TPMT genotype) or phenotype (TPMT activity), to determine a safe starting dose. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Mercaptopurine and azathioprine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunization with inactivated vaccines should be brought up to date and rigorously maintained during treatment, including influenza, meningococcus, and pneumococcus. In addition to the standard pneumococcal conjugate vaccine, they should also be given the",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/12/4294?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV), because they are considered to be at high risk for invasive pneumococcal disease if they are treated with immunosuppressive medication. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Immunizations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Refractory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients will become refractory to or dependent on steroids despite treatment with thiopurines; a few others are intolerant of thiopurines. In this case, treatment options include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    , or occasionally surgical resection of a discrete diseased segment of the bowel (",
"    <a class=\"graphic graphic_algorithm graphicRef75566 \" href=\"mobipreview.htm?40/51/41776\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Before beginning treatment with immunosuppressing medications (especially",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    and other tumor necrosis factor-alpha [TNF-A] inhibitors), patients should be evaluated for tuberculosis (TB) risk factors and tested for latent infection. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Infection risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Other disease locations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above general guidelines for medication choice by disease severity and response to treatment, some medication choices are influenced by disease location.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Oral lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    syrup may be helpful. For lesions on the lips, consider 0.1 percent",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/45/40656?source=see_link\">",
"     triamcinolone",
"    </a>",
"    applied to the lips. Evaluate for systemic disease and treat accordingly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Gastroduodenal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is induced with glucocorticoids for other enteric disease locations. However, because aminosalicylates are ineffective in the stomach, patients with medically significant gastroduodenal disease should be treated with 6-MP for maintenance therapy. Acid blockade for gastritis or esophagitis with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/23/24952?source=see_link\">",
"     omeprazole",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/53/2904?source=see_link\">",
"     lansoprazole",
"    </a>",
"    may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Active ileitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If disease appears to involve the ileum, treatment is similar to that outlined above, except that the choice of aminosalicylate should be a timed-release or pH-sensitive release form of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/5/27734?source=see_link\">",
"     mesalamine",
"    </a>",
"    (Pentasa or Asacol) and not one of the other aminosalicylate that is released only in the colon. Medical failures are good surgical candidates if the disease is limited to the ileum. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Aminosalicylates'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Perineal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drain any perianal abscesses surgically if needed. Provide antibiotics (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ) as initial therapy, followed by 6-MP if perineum does not heal. If disease remains refractory, consider",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    , which may be particularly valuable for patients with enterocutaneous fistulas. Topical",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ointment also may be helpful. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Infliximab'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8241845\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For Crohn&rsquo;s disease (CD) affecting the ileum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      colon, a variety of drugs are available (",
"      <a class=\"graphic graphic_table graphicRef65046 \" href=\"mobipreview.htm?28/16/28928\">",
"       table 1",
"      </a>",
"      ). The type of drug chosen for induction typically depends on disease severity and response (",
"      <a class=\"graphic graphic_algorithm graphicRef64031 \" href=\"mobipreview.htm?34/41/35486\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with mild disease, we suggest an initial attempt to induce remission using aminosalicylates with or without antibiotics, rather than initial treatment with glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Mild'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with moderate or severe disease, we suggest induction of remission with either glucocorticoids or exclusive enteral nutrition, rather than aminosalicylates (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). As compared to standard glucocorticoids,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"       budesonide",
"      </a>",
"      has fewer side effects but also is somewhat less effective. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Moderate or severe'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that treatment with exclusive enteral nutrition (EEN) be routinely offered as an alternative to glucocorticoids for induction of remission in children with CD (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). EEN may be particularly appropriate for patients with growth failure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those who are steroid-dependent. This suggestion is based on the established adverse effects of glucocorticoids, particularly on bone density, and on the evidence that EEN is moderately effective for inducing remission and mucosal healing. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Exclusive enteral nutrition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The choice of maintenance therapy depends on the patient&rsquo;s disease severity and initial response. The main options for maintenance therapy are aminosalicylates and thiopurines. If aminosalicylates are effective in eliminating symptoms and avoiding frequent relapses, they are generally preferable to thiopurines, because of lower toxicity. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Mild'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Aminosalicylates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with recurrent and frequent relapses, we suggest thiopurines or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"       methotrexate",
"      </a>",
"      rather than frequent courses of glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Before beginning treatment with thiopurines, patients should be evaluated for the thiopurine methyltransferase genotype (TPMT genotype) or phenotype (TPMT activity) to determine a safe starting dose. Patients treated with these drugs require close monitoring during therapy. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Moderate or severe'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Mercaptopurine and azathioprine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Methotrexate'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      For patients who are refractory to or dependent on steroids despite treatment with thiopurines, or those who are intolerant of thiopurines, treatment options include",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/51/21303?source=see_link\">",
"       infliximab",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/32/13833?source=see_link\">",
"       methotrexate",
"      </a>",
"      , or occasionally surgical resection of a discrete diseased segment of the bowel (",
"      <a class=\"graphic graphic_algorithm graphicRef75566 \" href=\"mobipreview.htm?40/51/41776\">",
"       algorithm 2",
"      </a>",
"      ). Before beginning treatment with immunosuppressing medications (especially infliximab and other tumor necrosis factor--alpha [TNF-A] inhibitors), patients should be evaluated for tuberculosis (TB) risk factors and tested for latent infection. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Refractory'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Infliximab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An alternative approach is to initiate therapy with thiopurines early in the course of disease, rather than using these agents only in patients who fail other interventions. This is sometimes termed a &ldquo;top down&rdquo; approach. While early thiopurine usage reduces the likelihood of relapse in the short term, the treatment also carries a small risk of complications. There are insufficient data to determine the overall risks and benefits of this approach. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Early use'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Growth failure is common in CD. Screening and monitoring patients for growth failure is important to optimize nutrition and is an essential component of care (",
"      <a class=\"graphic graphic_table graphicRef61093 \" href=\"mobipreview.htm?3/50/3885\">",
"       table 3",
"      </a>",
"      ); disturbances in these parameters are also sensitive indicators of occult CD activity. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Monitoring nutritional status'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/1\">",
"      Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006; 4:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/2\">",
"      Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/3\">",
"      Otley A, Loonen H, Parekh N, et al. Assessing activity of pediatric Crohn's disease: which index to use? Gastroenterology 1999; 116:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/4\">",
"      Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005; 41:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/5\">",
"      Otley A, Smith C, Nicholas D, et al. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 35:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/6\">",
"      Perrin JM, Kuhlthau K, Chughtai A, et al. Measuring quality of life in pediatric patients with inflammatory bowel disease: psychometric and clinical characteristics. J Pediatr Gastroenterol Nutr 2008; 46:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/7\">",
"      Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/8\">",
"      Kappelman MD, Bousvaros A, Hyams J, et al. Intercenter variation in initial management of children with Crohn's disease. Inflamm Bowel Dis 2007; 13:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/9\">",
"      Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United kingdom. J Pediatr Gastroenterol Nutr 2010; 50 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/10\">",
"      Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/11\">",
"      Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2003; :CD000301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/12\">",
"      Escher JC, European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004; 16:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/13\">",
"      Levine A, Kori M, Dinari G, et al. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial. Inflamm Bowel Dis 2009; 15:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/14\">",
"      Levine A, Broide E, Stein M, et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr 2002; 140:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/15\">",
"      Levine A, Weizman Z, Broide E, et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003; 36:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/16\">",
"      Kundhal P, Zachos M, Holmes JL, Griffiths AM. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr 2001; 33:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/17\">",
"      Leichtner AM. Aminosalicylates for the treatment of inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1995; 21:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/18\">",
"      Gisbert JP, Gomoll&oacute;n F, Mat&eacute; J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 2002; 47:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/19\">",
"      Camm&agrave; C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/20\">",
"      Muller AF, Stevens PE, McIntyre AS, et al. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther 2005; 21:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/21\">",
"      Grossman AB, Noble AJ, Mamula P, Baldassano RN. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm Bowel Dis 2008; 14:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/22\">",
"      Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/23\">",
"      Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/24\">",
"      Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/25\">",
"      Benkov K, Lu Y, Patel A, et al. Role of Thiopurine Metabolite Testing and Thiopurine Methyltransferase Determination in Pediatric IBD. J Pediatr Gastroenterol Nutr 2013; 56:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/26\">",
"      Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/27\">",
"      Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Drugs@FDA www.accessdata.fda.gov/scripts/cder/drugsatfda (Accessed on August 30, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/29\">",
"      Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/30\">",
"      Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/31\">",
"      Faubion WA Jr, Bousvaros A. Medical therapy for refractory pediatric Crohn's disease. Clin Gastroenterol Hepatol 2006; 4:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/32\">",
"      Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000; 137:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/33\">",
"      Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000; 95:3189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/34\">",
"      Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003; 98:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/35\">",
"      de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004; 39:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/36\">",
"      Lamireau T, C&eacute;zard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004; 10:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/37\">",
"      Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/38\">",
"      Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr 2009; 49:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/39\">",
"      Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95:3469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/40\">",
"      Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005; 11:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/41\">",
"      Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr 2007; 96:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/42\">",
"      Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/43\">",
"      Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/44\">",
"      Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/45\">",
"      Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/46\">",
"      Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005; 40:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/47\">",
"      Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009; 48:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/48\">",
"      Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration Safety Communication 4/14/11. Available at: file://www.fda.gov/Drugs/DrugSafety/ucm250913.htm (Accessed on November 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/50\">",
"      Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk 2010; 10:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/51\">",
"      Ashworth LA, Billett A, Mitchell P, et al. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis 2012; 18:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/52\">",
"      Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration MedWatch www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124185.htm (Accessed on August 05, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/54\">",
"      Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 52:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/55\">",
"      Hommes D, Baert F, van Assche G, et al. Management of recent onset Crohn's disease: a controlled, randomized trial comparing step-up and top-down therapy. Gastroenterology 2007; 129:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/56\">",
"      Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther 2010; 32:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/57\">",
"      Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/58\">",
"      Wyneski MJ, Green A, Kay M, et al. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 2008; 47:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/59\">",
"      Noe JD, Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/60\">",
"      Rosenbach Y, Hartman C, Shapiro R, et al. Adalimumab treatment in children with refractory Crohn's disease. Dig Dis Sci 2010; 55:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/61\">",
"      Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol 2009; 104:2566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/62\">",
"      Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009; 104:3042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/63\">",
"      Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012; 143:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/64\">",
"      Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/65\">",
"      Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/66\">",
"      Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/67\">",
"      Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis 2006; 12:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/68\">",
"      Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998; 132:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/69\">",
"      Weiss B, Lerner A, Shapiro R, et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr 2009; 48:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/70\">",
"      Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol 2007; 102:2804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/71\">",
"      Stephens MC, Baldassano RN, York A, et al. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2005; 40:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/72\">",
"      Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/73\">",
"      Hyams JS, Wilson DC, Thomas A, et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr 2007; 44:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/74\">",
"      Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000; 137:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/75\">",
"      Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/76\">",
"      Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/77\">",
"      Bousvaros A, Mueller B. Thalidomide in gastrointestinal disorders. Drugs 2001; 61:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/78\">",
"      Felipez LM, Gokhale R, Tierney MP, Kirschner BS. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. J Pediatr Gastroenterol Nutr 2012; 54:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/79\">",
"      Heuschkel R, Afzal N, Wuerth A, et al. Complementary medicine use in children and young adults with inflammatory bowel disease. Am J Gastroenterol 2002; 97:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/80\">",
"      Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/81\">",
"      Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010; 105:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/82\">",
"      Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/83\">",
"      Lu Y, Bousvaros A. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr 2010; 50:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/84\">",
"      Lu Y, Jacobson D, Bousvaros A. Immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/85\">",
"      Patel HI, Leichtner AM, Colodny AH, Shamberger RC. Surgery for Crohn's disease in infants and children. J Pediatr Surg 1997; 32:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/86\">",
"      Schaefer ME, Machan JT, Kawatu D, et al. Factors that determine risk for surgery in pediatric patients with Crohn's disease. Clin Gastroenterol Hepatol 2010; 8:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/87\">",
"      D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/88\">",
"      McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995; 109:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/89\">",
"      Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/90\">",
"      Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/91\">",
"      Mamula P, Baldassano RN. Postsurgical recurrences in Crohn's disease: why, when and how to prevent them. J Pediatr Gastroenterol Nutr 2000; 30:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/92\">",
"      Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/93\">",
"      Day AS, Whitten KE, Sidler M, Lemberg DA. Systematic review: nutritional therapy in paediatric Crohn's disease. Aliment Pharmacol Ther 2008; 27:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/94\">",
"      Tjellstr&ouml;m B, H&ouml;gberg L, Stenhammar L, et al. Effect of exclusive enteral nutrition on gut microflora function in children with Crohn's disease. Scand J Gastroenterol 2012; 47:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/95\">",
"      Critch J, Day AS, Otley A, et al. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012; 54:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/96\">",
"      Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006; 4:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/97\">",
"      Johnson T, Macdonald S, Hill SM, et al. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut 2006; 55:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/98\">",
"      Knight C, El-Matary W, Spray C, Sandhu BK. Long-term outcome of nutritional therapy in paediatric Crohn's disease. Clin Nutr 2005; 24:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/99\">",
"      Wilson D, Thomas A, Croft N, et al. Systematic Review of the Evidence Base for the Medical Treatment of Paediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/100\">",
"      Sanderson IR, Udeen S, Davies PS, et al. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987; 62:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/101\">",
"      Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1993; 17:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/102\">",
"      Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev 2005; :CD003873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/103\">",
"      Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007; :CD000542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/104\">",
"      Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995; 108:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/105\">",
"      Afzal NA, Davies S, Paintin M, et al. Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig Dis Sci 2005; 50:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/106\">",
"      Stewart M, Day AS, Otley A. Physician attitudes and practices of enteral nutrition as primary treatment of paediatric Crohn disease in North America. J Pediatr Gastroenterol Nutr 2011; 52:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/107\">",
"      Levine A, Milo T, Buller H, Markowitz J. Consensus and controversy in the management of pediatric Crohn disease: an international survey. J Pediatr Gastroenterol Nutr 2003; 36:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/108\">",
"      Akobeng AK. Crohn's disease: current treatment options. Arch Dis Child 2008; 93:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/109\">",
"      Mayberry JF, Lobo A, Ford AC, Thomas A. NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people. Aliment Pharmacol Ther 2013; 37:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/110\">",
"      Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996; 38:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/111\">",
"      Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988; 94:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/112\">",
"      Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther 2004; 20:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/113\">",
"      Verma S, Kirkwood B, Brown S, Giaffer MH. Oral nutritional supplementation is effective in the maintenance of remission in Crohn's disease. Dig Liver Dis 2000; 32:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/114\">",
"      Razack R, Seidner DL. Nutrition in inflammatory bowel disease. Curr Opin Gastroenterol 2007; 23:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/115\">",
"      Ritchie JK, Wadsworth J, Lennard-Jones JE, Rogers E. Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn's disease. Br Med J (Clin Res Ed) 1987; 295:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/116\">",
"      Brandes JW, Lorenz-Meyer H. [Sugar free diet: a new perspective in the treatment of Crohn disease? Randomized, control study]. Z Gastroenterol 1981; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/117\">",
"      Levenstein S, Prantera C, Luzi C, D'Ubaldi A. Low residue or normal diet in Crohn's disease: a prospective controlled study in Italian patients. Gut 1985; 26:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/118\">",
"      Zhang P, Kim W, Zhou L, et al. Dietary fish oil inhibits antigen-specific murine Th1 cell development by suppression of clonal expansion. J Nutr 2006; 136:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/119\">",
"      Lorenz-Meyer H, Bauer P, Nicolay C, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand J Gastroenterol 1996; 31:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/120\">",
"      Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996; 334:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/121\">",
"      MacLean CH, Mojica WA, Newberry SJ, et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr 2005; 82:611.",
"     </a>",
"    </li>",
"    <li>",
"     Crohn's and Colitis Foundation of America, \"The specific carbohydrate diet: Does it work?\" Available at: file://www.ccfa.org/resources/specific-carbohydrate-diet.html (Accessed on January 16, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/123\">",
"      Mishkin B, Yalovsky M, Mishkin S. Increased prevalence of lactose malabsorption in Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin. Am J Gastroenterol 1997; 92:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/124\">",
"      Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/125\">",
"      Kleinman RE, Baldassano RN, Caplan A, et al. Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology And Nutrition. J Pediatr Gastroenterol Nutr 2004; 39:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/126\">",
"      Bousvaros A, Zurakowski D, Duggan C, et al. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J Pediatr Gastroenterol Nutr 1998; 26:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/127\">",
"      Herzog D, Bishop N, Glorieux F, Seidman EG. Interpretation of bone mineral density values in pediatric Crohn's disease. Inflamm Bowel Dis 1998; 4:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/128\">",
"      Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998; 114:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/129\">",
"      Rabbett H, Elbadri A, Thwaites R, et al. Quality of life in children with Crohn's disease. J Pediatr Gastroenterol Nutr 1996; 23:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/130\">",
"      Mackner LM, Bickmeier RM, Crandall WV. Academic achievement, attendance, and school-related quality of life in pediatric inflammatory bowel disease. J Dev Behav Pediatr 2012; 33:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/131\">",
"      Szigethy E, Levy-Warren A, Whitton S, et al. Depressive symptoms and inflammatory bowel disease in children and adolescents: a cross-sectional study. J Pediatr Gastroenterol Nutr 2004; 39:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/132\">",
"      Herzer M, Denson LA, Baldassano RN, Hommel KA. Patient and parent psychosocial factors associated with health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 52:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/133\">",
"      Kunz JH, Greenley RN, Howard M. Maternal, paternal, and family health-related quality of life in the context of pediatric inflammatory bowel disease. Qual Life Res 2011; 20:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/134\">",
"      Leung Y, Heyman MB, Mahadevan U. Transitioning the adolescent inflammatory bowel disease patient: guidelines for the adult and pediatric gastroenterologist. Inflamm Bowel Dis 2011; 17:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/135\">",
"      Baldassano R, Ferry G, Griffiths A, et al. Transition of the patient with inflammatory bowel disease from pediatric to adult care: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2002; 34:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/47/41722/abstract/136\">",
"      Hait E, Arnold JH, Fishman LN. Educate, communicate, anticipate-practical recommendations for transitioning adolescents with IBD to adult health care. Inflamm Bowel Dis 2006; 12:70.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5866 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-94E968098A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41722=[""].join("\n");
var outline_f40_47_41722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8241845\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Assessment of response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10321478\">",
"      - Methylprednisolone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Prednisone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Budesonide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Aminosalicylates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mercaptopurine and azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Dose and monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Early use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Infliximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15465691\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23124329\">",
"      Adalimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Infection risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Preventing postoperative recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      NUTRITIONAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Exclusive enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Supplemental enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Other dietary changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Monitoring nutritional status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Growth failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Micronutrient deficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PSYCHOLOGICAL SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6397339\">",
"      TRANSITION TO ADULT HEALTH CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SURVEILLANCE FOR CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      CHOICE OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Ileocolic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Mild",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Moderate or severe",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Refractory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Other disease locations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Oral lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Gastroduodenal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Active ileitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Perineal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8241845\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5866\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5866|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?34/41/35486\" title=\"algorithm 1\">",
"      Algorithm ileocolonic Crohns child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?40/51/41776\" title=\"algorithm 2\">",
"      Algorithm refractory Crohns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5866|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/16/28928\" title=\"table 1\">",
"      Drugs Crohns children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/33/541\" title=\"table 2\">",
"      Nutrition labs IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/50/3885\" title=\"table 3\">",
"      IBD nutr monitor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44566?source=related_link\">",
"      6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29559?source=related_link\">",
"      Adalimumab for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/34/20008?source=related_link\">",
"      Antibiotics for treatment of inflammatory bowel diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/5/21592?source=related_link\">",
"      Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/40/10886?source=related_link\">",
"      Budesonide in the treatment of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24693?source=related_link\">",
"      Clinical manifestations of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2794?source=related_link\">",
"      Growth failure and poor weight gain in children with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17962?source=related_link\">",
"      Investigational therapies in the medical management of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13143?source=related_link\">",
"      Latent tuberculosis infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/809?source=related_link\">",
"      Medical prophylaxis of postoperative Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30569?source=related_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3429?source=related_link\">",
"      Natalizumab for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/6/43113?source=related_link\">",
"      Nutrient deficiencies in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25273?source=related_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_47_41723="Classification of acute extremity ischemia";
var content_f40_47_41723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of acute extremity ischemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Viable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Threatened",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nonviable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left_single\">",
"        Pain",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left_single\">",
"        Capillary",
"refill",
"       </td>",
"       <td>",
"        Intact",
"       </td>",
"       <td>",
"        Delayed",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left_single\">",
"        Motor",
"deficit",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Partial",
"       </td>",
"       <td>",
"        Complete",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left_single\">",
"        Sensory",
"deficit",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Partial",
"       </td>",
"       <td>",
"        Complete",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left_single\">",
"        Arterial",
"Doppler",
"       </td>",
"       <td>",
"        Audible",
"       </td>",
"       <td>",
"        Inaudible",
"       </td>",
"       <td>",
"        Inaudible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left_single\">",
"        Venous",
"Doppler",
"       </td>",
"       <td>",
"        Audible",
"       </td>",
"       <td>",
"        Audible",
"       </td>",
"       <td>",
"        Inaudible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left_single\">",
"        Treatment",
"       </td>",
"       <td>",
"        Urgent work-up",
"       </td>",
"       <td>",
"        Emergency surgery",
"       </td>",
"       <td>",
"        Amputation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Rutherford RB, Semin Vasc Surg 1992; 5:4.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41723=[""].join("\n");
var outline_f40_47_41723=null;
var title_f40_47_41724="Chemo agents and mucositis";
var content_f40_47_41724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy agents associated with mucositis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"9\">",
"        Alkylating agents",
"       </td>",
"       <td>",
"        Busulfan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carboplatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mechlorethamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melphalan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Procarbazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiotepa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Anthracyclines",
"       </td>",
"       <td>",
"        Daunorubicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxorubicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epirubicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idarubicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitoxantrone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"11\">",
"        &nbsp;",
"        <br/>",
"        Antimetabolites",
"       </td>",
"       <td>",
"        6-Mercaptopurine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-Thioguanine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capecitabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytarabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fludarabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluorouracil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gemcitabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydroxyurea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pemetrexed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pralatrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Antitumor antibiotics",
"       </td>",
"       <td>",
"        Dactinomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Taxanes",
"       </td>",
"       <td>",
"        Docetaxel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paclitaxel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Topoisomerase inhibitors",
"       </td>",
"       <td>",
"        Etoposide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irinotecan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teniposide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topotecan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"9\">",
"        &nbsp;",
"        <br/>",
"        Molecularly targeted agents",
"       </td>",
"       <td>",
"        Cabozantinib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cetuximab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erlotinib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Everolimus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Panitumumab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regorafenib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sorafenib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sunitinib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Temsirolimus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41724=[""].join("\n");
var outline_f40_47_41724=null;
var title_f40_47_41725="Variation serum testosterone";
var content_f40_47_41725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Variation in serum total testosterone concentrations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 303px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serum total testosterone concentrations have a diurnal variation in young men (blue dashed line); concentrations are highest at 8 AM and lowest around 8 PM. In contrast, older men have little variation throughout the day (red line). To convert serum testosterone values to nmol/L multiply by 3.47.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bremner WJ, Vitiello V, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men.&nbsp;J Clin Endocrinol Metab 1983; 56:1278.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41725=[""].join("\n");
var outline_f40_47_41725=null;
var title_f40_47_41726="Stage of engagment in HIV care";
var content_f40_47_41726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Number of individuals in different stages of engagment in HIV care",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 370px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The spectrum of engagement in HIV care in the United States spanning from HIV acquisition to full engagement in care, receipt of antiretroviral therapy, and achievement of complete viral suppression. Only an estimated 19 percent of HIV-infected individuals in the United States have an undetectable HIV load.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793. By permission of Infectious Diseases Society of America. Copyright &copy; 2012 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41726=[""].join("\n");
var outline_f40_47_41726=null;
var title_f40_47_41727="Spinous process fracture";
var content_f40_47_41727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spinous process (clay shoveler's) fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 480px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The spinous process fracture, also called the clay shoveler's fracture, is an avulsion fracture of the tip of the spinous process, most commonly involving C7.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Amilcare Gentili, MD. Copyright &copy; Amilcare Gentili, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_47_41727=[""].join("\n");
var outline_f40_47_41727=null;
